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Abstract 
 
In reference to recent studies highlighting the importance of Thymosin beta 4 (Tβ4) during 
embryonic development and its therapeutic potential, an inducible cardiac-specific 
knockdown of Tβ4 was established to investigate the outcomes of loss of function in adult 
mammalian hearts. Tβ4shRNAflox/MerCreMer mice were generated with the aim of 
depleting cardiac Tβ4 expression by RNA interference in a tamoxifen-dependent fashion. In 
vivo, in vitro and ex vivo approaches showed that tamoxifen treatment of 
Tβ4shRNAflox/MerCreMer mice does not result in significant down-regulation of Tβ4 mRNA 
or protein in the heart. Interestingly, higher levels of Tβ4 were identified in cardiac fibroblasts 
compared to cardiomyocytes. The above analyses suggest that an inducible knockout of 
Tβ4 would be a more direct, more reliable and more effective means to study loss of function 
in the adult mammalian heart. 
In the course of the study, an adverse cardiac phenotype was observed in tamoxifen-treated 
MerCreMer-positive animals, consisting of perivascular and interstitial fibrosis, decreased 
cardiac function, a marked inflammatory response and increased expression of factors 
involved in cardiac remodelling and hypertrophy. This was not related to MerCreMer gene 
copy number (homo/heterozygosity) but found to be associated with tamoxifen dose, mode 
of delivery and genetic background. A thorough analysis of related literature revealed that a 
number of recent publications have failed to include tamoxifen-treated αMHC/MerCreMer 
controls and some of the presented data may be affected by Cre toxicity. In conclusion, 
αMHC/MerCreMer mice should be included as controls in the analysis of future studies or 
alternative inducible systems considered. 
Recent analyses revealed that IGF-1Ea overexpression in the heart improves the outcome 
of myocardial infarction in mice. This process has been described on the molecular level but 
a comprehensive analysis of the subcellular structure of αMHC/IGF-1Ea hearts had not 
previously been performed. A detailed transmission electron microscope analysis of 
αMHC/IGF-1Ea hearts revealed previously not described large electron-dense structures 
inside αMHC/IGF-1Ea cardiomyocytes. The structures resembled large 
autophagolysosomes although markers of autophagy were neither found to be associated 
with the structures nor upregulated in the hearts of αMHC/IGF-1Ea mice. Intriguingly 
lysosomes were identified in the proximity of the structures potentially implying a role in 
turnover of intracellular material. These results provide further insights into the diverse roles 
of IGF-1Ea in the heart. 
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Chapter 1 -  Introduction 
 
1.1 The mammalian heart 
The four chambered mammalian heart is a sophisticated midline organ which circulates 
blood through the lungs and the organs in two serial vascular circuits. The pulmonary circuit 
facilitates the removal of waste products, such as carbon dioxide (CO2), re-oxygenation of 
the blood and exchange of heat at the blood air barrier in the alveoli. The systemic 
circulation is required for oxygen (O2), nutrient/waste and water transport and also to 
regulate the body temperature. The vasculature also functions as a transport route for cells 
and signalling molecules. 
Despite playing a central role in distributing nutrients and oxygen throughout the body, the 
adult mammalian heart itself cannot regenerate when blood supply via the coronary arteries 
fails and the myocardium is damaged. However, two recent reports have challenged this 
central dogma of cardiac research. Zebrafish hearts retain a substantial regenerative 
capacity throughout adult life involving factors that are also known to exist in mammals (Lien 
et al. 2006). While this regenerative capacity is not observed in adult mammalian hearts, 
Porrello et. al recently demonstrated that in the early post-natal days, mice can indeed 
regenerate significant proportions of lost myocardium (Porrello et al. 2011). These studies 
bear promise that by identifying the correct factors involved in the regenerative process, a 
dormant regenerative program could be re-activated in damaged adult mammalian 
myocardium. The loss of cardiac tissue is the consequence of disrupted blood supply by 
arterial occlusion or injury which leads to hypoxia or anoxia and the build-up of toxic waste 
products which over time inevitably results in death of the cells in the affected area. 
Circulation can be restored by removal of the obstruction or more long term by angiogenesis, 
the formation of blood vessels from an existing vascular network. After blood flow is 
restored, lost cells can be replaced via diverse mechanisms and are able to regenerate large 
parts of various organs. While in the heart, endothelial cells and fibroblasts can undergo 
mitosis to replace lost cells, cardiomyocytes cannot be replaced in sufficient numbers in 
mammals. Thus the injured myocardium is exposed to a number of molecular and 
biophysical changes which over time in most cases results in heart failure and death. 
 
1.2 Cardiovascular disease 
Cardiovascular diseases (CVD) encompass a diverse spectrum of acquired and congenital 
conditions in human, ranging from valvular disease to hypertrophy, myocardial infarction (MI) 
and heart failure. CVD is the leading cause of death worldwide (World Health Organisation 
2003). 16.7 million (29.2%) of deaths recorded by the World Health Organisation (WHO) in 
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the World Health Report 2003 were caused by CVD. Opposing the old dogma, that CVD is a 
disease of industrialised nations, approximately 80% of deaths occur in middle-income 
countries. This thesis focuses on coronary heart disease and the development of novel 
treatment strategies to more effectively reduce its individual and societal burden. 
 
1.2.1  Coronary heart disease 
Almost half of the deaths due to CVD (7.2 million) are caused by coronary or ischemic heart 
disease (World Health Organisation 2003). Coronary artery disease predominantly refers to 
the occlusion of a coronary artery supplying the myocardium. MI is most frequently caused 
by primary coronary events, such as plaque erosion, rupture or dissection affecting the 
coronary artery but can be secondary to previous ischaemic, hypertensive or anaemic 
cardiac events or following cardiac intervention such as percutaneous coronary intervention 
(PCI) or coronary artery bypass graft (CABG, Davies et al. 1976; Thygesen et al. 2007). 
Patients experiencing classical angina pectoris as a consequence of MI can be swiftly 
diagnosed by a combination of medical history, ECG, as well as imaging by 
echocardiography (ECHO), coronary angiography, magnetic resonance imaging (MRI) and 
by biomarker analysis. Circulating levels of troponin T and troponin I are markers of 
cardiomyocyte necrosis, have high clinical sensitivity and are measured at the onset of 
symptoms but can remain elevated until 7-14 days after infarct (Panteghini et al. 2001; 
Anderson et al. 2007; Thygesen et al. 2007). A wider panel of novel biomarkers are currently 
under investigation to improve differential diagnoses in patients visiting chest pain clinics (Lin 
et al. 2012). Following the diagnosis of MI, a number of pharmacological treatments and 
interventions are available, which will be discussed in the following sections. 
In addition to the high death toll, the disability and individual suffering associated with MI and 
heart failure, long term treatment of patients suffering coronary heart disease is costly and 
poses an increasing burden on societies. In the UK alone 2.6 million people are living with 
coronary heart disease (British Heart Foundation 2005). Finding modern, cost-effective 
treatments is imperative to relieve the socio-economic burden and improve patient quality of 
life. Although, substantial advancements have been made in cardiac research to improve 
cardiac function, after acute injury or chronic disease, a long term cure and regeneration of 
the heart remains a yet unachieved ultimate goal. 
 
1.2.1 Hypertrophy, cardiac remodelling and heart failure 
Given recent advances in management of acute MI increasing numbers of patients are 
surviving the initial cardiac insult and are thus suffering from the long term consequences of 
the loss of functional myocardial tissue and subsequent scarring (British Heart Foundation 
2005). While cardiac hypertrophy also describes the physiological growth of cardiac cells 
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and muscle for example during pregnancy or regular exercise, it is mainly associated with 
the pathological gain of mass due to overcompensation of the organ after chronic or acute 
insult (reviewed in McMullen and Jennings 2007). This is attributed to increased 
cardiomyocyte size rather than increase in cell abundance. In the setting of MI, scar tissue 
formation stabilises the heart from immediate dilatation but it cannot make up for the local 
loss of contractile tissue (reviewed in Cleutjens and Creemers 2002). This loss of cardiac 
contractility results in overload of the remaining cardiomyocytes which thus become 
hypertrophic and thereby increase wall thickness and overall size of the organ. This process 
is further modulated by the release of a number of cytokines and growth factors (Sugden 
1999; Asakura et al. 2002; Liao 2002). Over time, the initially improved contraction of the 
heart due to the compensated cardiac hypertrophy frequently deteriorates into a 
decompensated hypertrophy associated with higher risk of life-threatening arrhythmias and 
reduced coronary flow reserve (reviewed in Sugden 1999). The structural and 
haemodynamic changes of the heart following scarring and maladaptive hypertrophy are 
also associated with electrophysiological changes, such as prolongation of action potential 
duration and Ca2+ transients (Richard et al. 1998; Wickenden et al. 1998), reviewed in Shih 
Shih et al. 2010). This is the result of chronic overload insult and in most cases ultimately 
leads to end-stage heart failure. This is generally accompanied by a range of neurohumoral 
changes, such as alterations in aldosterone and angiotensin type II (Ang II) levels which 
modify collagen type 2 (Col2) synthesis and thereby increase fibrosis (Delcayre and 
Swynghedauw 2002). The remodelling process ultimately cumulates in end stage heart 
failure (Pfeffer and Braunwald 1990). This describes a state at which cardiac function has 
degraded below the minimal functionality required to maintain basal body functions. Blood 
supply and drainage from the lungs and system is insufficient resulting in cyanosis and 
oedema. End stage heart failure is associated with increased apoptosis in cardiomyocytes, 
decreased sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2a) and increased SERCA 
inhibitor phospholamban (Bartling et al. 1999; Minamisawa et al. 1999). It is furthermore 
accompanied with an increase in inflammatory markers. As such, pro-inflammatory cytokines 
tumour necrosis factor α (TNFα), interleukin (IL) 1β, IL-6, IL-8, monocyte chemoattractant 
peptide 1 (MCP1) and macrophage inflammatory protein 1α (MIP1α) were shown to be 
upregulated in heart failure patients (Levine et al. 1990; Testa et al. 1996; Aukrust et al. 
1998; Aukrust et al. 1999; Damas et al. 2000; Adamopoulos et al. 2001). 
 
 
1.3 Current treatments of coronary heart disease and heart failure 
In the acute setting of an MI, intervention is desired at three disease stages. First, oxygen 
and nutrient supply needs to be re-established, as well as removal of toxic waste products 
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from the affected region of the myocardium. Second, acute inflammation needs to be 
reduced to avoid ongoing damage to healthy tissue surrounding the site of injury and to 
allow salvaging of damaged structures. Third, the lost or damaged myocardium needs to be 
regenerated to restore cardiac function. This would entail replacement of dead myocardium 
with new cardiomyocytes, their correct insertion and functional connection to the surrounding 
tissue and prevention of fibrosis, hypertrophy and adverse remodelling of the heart. 
Endogenously, this could hypothetically be achieved by infiltration and differentiation of a 
variety of putative progenitors, by mitosis of existing cardiomyocytes or by the differentiation 
of cardiac stem cells that already reside in the heart (Beltrami et al. 2001; Beltrami et al. 
2003; Pitchford et al. 2009). However, endogenous repair and substitution of cardiomyocytes 
has been shown to be insufficient in adult mammals, and the damaged myocardium is 
quickly replaced by proliferating fibroblasts secreting extracellular matrix (ECM) to provide 
mechanical support thus producing the infamous scar. 
 
1.3.1  Invasive interventional cardiology 
PCI or percutaneous transluminal angioplasty (PCTA) involves catheterisation of the 
coronary artery and mechanical widening of the blood vessel by means of an intracoronary 
balloon (Gruntzig and Schneider 1977). This technique has been a phenomenal success 
and has been further improved significantly by the development of the intracoronary stent 
which is implanted at the time of angioplasty to prevent re-occlusion of the coronary artery 
(Sigwart et al. 1987). More recently stents coated with sirolimus or paclitaxel to prevent stent 
thrombosis by ingrowth of vascular cells have been successfully introduced into clinical 
practice (Morice et al. 2002; Grube et al. 2003). There is compelling clinical evidence from 
registry studies that drug eluting stents are superior to bare metal stents and substantially 
reduce the need for target-vessel revascularisation (Tu et al. 2007). In a Swedish study 
registry, however, an increased mortality in the patient group receiving drug-eluting stents 
compared to bare metal stent recipient was found, highlighting the need for a large, 
prospective, randomised clinical trial for clarification (Lagerqvist et al. 2007). While PCI is the 
first choice of invasive treatment for acute MI, it is associated with a number of risks 
predominantly the aforementioned stent-stenosis, but also myocardial or vessel damage 
from the stent, arrhythmia and bleeds. A more classical but significantly more invasive 
means of restoring myocardial perfusion is CABG which was first performed in 1961 (Goetz 
et al. 1961). This involves autologous transplantation of one or multiple blood vessels 
sourced from patient‟s thigh (saphenous vein) or thorax (left internal mammary artery) to 
circumvent or „bypass‟ the stenotic coronary vessel (Favaloro et al. 1971; Ohki et al. 2002). 
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1.3.2 Pharmacological intervention 
There are a number of pharmacological treatment options which are aimed at resolving the 
thrombus or preventing re-stenosis. The NICE thrombolytic therapy guidelines are based on 
14 clinical trials and give recommendation to the use of plasminogen-activating drugs for this 
purpose (NICE guidelines October 2002). Thrombolytic medication needs to be administered 
early, usually no later than 6-12h following onset of symptoms. In the UK, 4 thrombolytic 
agents are available: alteplase, reteplase, streptokinase and tenecteplase. All of the above 
are given in combination with the anti-platelet drug Aspirin and, except streptokinase, with 
the anticoagulant heparin. Thrombolytic therapy has a risk of haemorrhagic stroke which is 
associated with a high mortality and affects 0.5% - 1% of patients (NICE 2002, Thrombolytic 
therapies). Thrombolytic therapy is often combined with anti-thrombotic therapy. Historically, 
heparin and aspirin have been used as anti-thrombotic agents while platelet glycoprotein 
IIb/IIIa inhibitors came into use in the 1990s (reviewed in Brodie 2008). Developed in the late 
1990s, clopidogrel is now the main anti-thrombotic pharmacological intervention. Similar to 
thrombolytic therapy, there is a risk of severe complications associated with anti-thrombotic 
treatment with the main risk being bleedings which range from insignificant gastrointestinal 
bleeds to major haemorrhages, blood loss and stroke. More recently, a new drug called 
bivalirudin was developed which acts directly on thrombin and shows a reduced incidence of 
bleedings (Stone et al. 2006). 
 
1.3.3 Device therapy for cardiovascular disease 
Mechanical assist devices or left ventricular assist devices (LVADs) are mechanical pumps 
that are used to assist cardiac function, traditionally as a bridge-to-transplant (Goldstein and 
Oz 2000; Zeltsman and Acker 2002). Mechanical unloading of the heart was shown to 
reduce the expression of apoptotic markers in cardiomyocytes during end stage heart failure. 
Furthermore, it was found that preceding LVAD therapy improved patient outcomes after 
transplantation compared to patients immediately receiving a donor heart (Frazier et al. 
1995; Bartling et al. 1999). Cardiogenic shock is the most common acute cause of death 
following MI (5% - 10%) and patients not responding to pharmacological intervention or PCI 
were shown to benefit from LVAD implantation as well (Thiele et al. 2007). Early reports 
about patients that could be weaned from their mechanical assist device, after their hearts 
had recovered to a surprising degree, prompted an ongoing research into a so called bridge-
to-recovery approach (Muller et al. 1997). Combining LVAD therapy with a pharmacological 
regime consisting of lisinopril, carvedilol, spironolactone and the angiotensin type II receptor 
blocker (ARB) losartan and subsequent concomitant treatment with the β2-adrenergic 
receptor agonist clenbuterol supports the recovery of a dilated, failing heart, allowing for 
explantation of the LVAD (Birks et al. 2006; Birks et al. 2012). In this recovering patient 
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population, the functional improvement is accompanied by overall normalisation of cell size, 
reduced phospholamban expression and increased levels of SERCA2a (Yacoub 2001).  
A caveat of the existing clinical data on bridge-to-recovery is the small sample size and a 
large prospective, randomised, double-blind multicentre clinical trial would be required to 
ascertain the observed effect. While device therapy is a step in the right direction, the 
COMET trial has revealed that despite optimal pharmacological (ACE inhibitors and β-
blockers) and device therapy, 50% of congestive heart failure patients die within 4 years 
after onset of the first symptoms (Bristow et al. 2005; Yndestad et al. 2006). Consequently, 
in the absence of alternative treatments, heart transplantation remains in most cases the last 
resort. However, even after transplant, the survival rate in the first 5 years post-operation is 
only 80% (Lloyd 2010). Furthermore, in the USA only 2500 heart transplants can be 
performed annually due to severely limited availability of donor hearts and this highlights the 
need for novel approaches to treat acute and chronic heart disease. 
 
1.3.4 Novel approaches to prevent or cure heart failure 
Cardiac myocytes are naturally turned over in the adult human heart, although to a very 
limited degree with about 50% of cells being replaced by de novo generated cardiomyocytes 
over a lifetime (Bergmann et al. 2009). Depending on age, the annual turnover rate is 
between 0.45% and 1%. Thymidine radiolabelling experiments in mice showed that 0.0006% 
of adult cardiomyocytes proliferate under physiological conditions while 0.0038% of 
cardiomyocyte proliferate in the borderzone following MI (Soonpaa and Field 1998). This 
endogenous regeneration is insufficient considering the disproportionately large loss of heart 
muscle tissue that generally occurs during MI. Nevertheless, these studies demonstrated for 
the first time the intrinsic capability of the heart to regenerate. This encourages research into 
mechanisms and techniques that could enhance the natural regenerative response of the 
heart. Novel cell based and molecular approaches try to coax cardiac cells into a more 
proliferative state to be able to respond to loss of myocardium due to injury in a more timely 
and comprehensive manner. To achieve this, a number of cell or factor based approaches 
are currently being evaluated. 
Cell injection: In the BOOST trial catheter mediated infusion of coronaries with autologous 
bone marrow cells following PCI was assessed (Wollert et al. 2004). This resulted in a slight 
increase (6.7%) of left-ventricular ejection fraction compared to controls 6 months post 
intervention (Meyer et al. 2006). However, no difference was found after 18 months follow-up 
casting doubt over the long term benefit of this treatment. Another cell population that was 
investigated in pre-clinical studies, are lin-/c-kit+ progenitor cells (Beltrami et al. 2003). These 
stem cells reside in the heart and were found to be able to differentiate into myocytes, 
smooth muscle and endothelial cells in infarcted rat heart. Injecting lin-/c-kit+ cells into the 
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borderzone of an experimental MI in rats was shown to salvage parts of the myocardium. 
These findings prompted early phase clinical trials in which c-kit+ cardiac stem cell treatment 
after MI and CABG improved cardiac function (Bolli et al. 2011). However, their limited 
availability and accessibility renders them currently unsuitable for application in the clinics 
(Schuldt et al. 2008). Cardiosphere-derived cell infusion into the coronaries was also shown 
to decrease scar mass and increase viable myocardium, but as for c-kit+ cells, or indeed all 
autologous cell transplantation approaches in general, cardiosphere treatment suffers from 
high cost associated with this highly specialised and individualised technique (Makkar et al. 
2012). Many of the observed beneficial effects of cell injections are attributed to factors 
secreted by stem cells rather than their actual engraftment (Gnecchi et al. 2008). Identifying 
these factors and the mechanisms by which they improve cardiac function or prevent cardiac 
deterioration could provide novel therapies that could have significant advantages over cell 
therapy due to the reduced risk of tumorigenicity, stenosis and immune reactions. 
Factors inducing progenitor cells or mitosis: In order to replace coronary vasculature, to 
improve perfusion of poorly supplied areas of myocardium, the generation of new vessels by 
angiogenesis is pivotal. VEGF treatment induces angiogenesis and increases recruitment of 
circulating endothelial progenitor cells (EPCs, Kalka et al. 2000). While in theory, 
revascularisation could assist to rescue parts of the myocardium, this cannot be achieved in 
a timely manner and is no alternative to PCI as an immediate intervention. Considerable 
damage to the myocardium would have already occurred, highlighting that research has to 
focus on ways to improve the healing process of injured myocardium. A range of interesting 
candidates for factor based therapies are currently under investigation and these could be 
involved in improving the regenerative capacity of the heart or to reduce further damage to 
the heart after initial ischaemic insult. As such, G-CSF treatment of patients in a recent 
clinical trial reduced cardiac remodelling and improved cardiac function, potentially by 
mobilising stem cells from the bone marrow (Orlic et al. 2001; Ince et al. 2005). TWEAK, a 
member of the TNF factor family, is another factor potentially enhancing the endogenous 
regenerative capacities and was shown to induce cardiomyocyte proliferation in vitro 
(Novoyatleva et al. 2009). 
Next to improving regeneration, inhibition of factors contributing to cardiac pathology could 
be a complementary approach to improve outcomes. For example, the inhibition of p38 MAP 
kinase was shown to reduce scarring and wall thinning and to significantly improve cardiac 
function in a rat model of MI (Engel et al. 2006). Replenishing lost myocardium, however, 
remains the holy grail of cardiac research and one approach addressing this involves the 
stimulation of cardiomyocyte cell cycle re-entry. This is a particularly interesting approach, 
since research has shown that after birth, mouse cardiomyocytes briefly retain the ability to 
proliferate but this is lost within the first postnatal days coinciding with cessation of cyclin A2 
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expression (Yoshizumi et al. 1995; Porrello et al. 2011). Cyclin A2 is a potent regulator of the 
cell cycle and drives cell cycle progression through G1/S and G2/M phases (Sherr and 
Roberts 1995). Inducing cardiomyocyte cycle re-entry by adenoviral vector mediated 
overexpression of cyclin A2 in rat myocardium at the time of experimental MI was shown to 
improve wall thickness in the infarct border zone and improve cardiac function (Woo et al. 
2006). While it is not clear whether these improvements are attributable to true cell cycle re-
entry of adult cardiomyocytes or due to induction of a hyperproliferative potential of side 
population cells, these promising results call for further testing of cyclin A2 in clinical trials. 
Further candidates potentially promoting cardiac regeneration include periostin and 
neuregulin 1, which were separately shown to stimulate cell cycle re-entry of cardiomyocytes 
after MI, thereby reducing fibrosis and improving cardiac function (Kuhn et al. 2007; Bersell 
et al. 2009). 
As opposed to cell-based treatments, factor-based approaches have the significant 
advantage that they can be generated industrially, can be easily stored and distributed, are 
generally not immunogenic and  potentially have a lower risk of causing cancers. There is an 
on-going effort to identify and characterise further molecules that could activate endogenous 
mechanisms to act at the three stages of re-vascularisation, reduction of inflammation and 
regeneration of myocardium. Two factors that appear to be promising candidates to achieve 
this are thymosin β4 (Tβ4) and the locally acting insulin-like growth factor 1Ea (IGF-1Ea) 
isoform. 
 
 
1.4 Thymosin β4 
Thymosins derive their name from their first isolation from calf thymus in the 1960s (Klein et 
al. 1965). The extract of a whole thymus was isolated in fractions, with fraction 5 containing 
the α, β and γ thymosins (Goldstein et al. 1977). 
 
1.4.1  The thymosin protein family 
The thymosins are divided into α, β and γ subgroups according to their isoelectric points: α 
for highly acidic pH <5, β for pH 5-7 and γ for basic pH >7. Before this classification it was 
believed that thymosin was a single 14 kDa hormone (Goldstein et al. 1972; Huff et al. 
2001). Today, three α thymosins were isolated: thymosin α1, thymosin des(25-28) α1 and 
the 7 amino acid longer thymosin α11 (Goldstein et al. 1977; Caldarella et al. 1983). All α 
thymosins are derived from prothymosin α by enzymatic cleavage (Haritos et al. 1984). 
The name thymosin β4 (Tβ4) was given in reference to it being the fourth β-thymosin to be 
sequenced in 1981 after isolation from fraction 5 using a combination of ion exchange 
chromatography and gel filtration (Low et al. 1981). Together with Tβ4, mammals express a 
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second β-thymosin, which is thymosin β10 (Tβ10) in some species (human, rat, mouse, 
rabbit, cat) or thymosin β15 (Tβ15) in others (calf, pig, sheep). Mouse Tβ4 and Tβ10 are 43 
and 44 amino acids long, have a MW of ~5 kDa and share 100% identity with their human 
orthologs (Safer et al. 1990; Gerhard et al. 2004). Tβ15 was also discovered in humans, 
however only in tumours, prostate cancer cells and embryonic brain tissue and is devoid 
from other tissues under physiological conditions (reviewed in Bao et al. 1996; Smart et al. 
2007; Dhaese et al. 2009). Tβ15 represents its own subclass distinct from the other β-
thymosins (Tβ4, Tβ10) with regard to its N-terminal amino acid sequence (Dhaese et al. 
2009). However, it shares a functional similarity with Tβ4 in terms of its actin binding 
properties. Thymosin NB is the human homologue of rat Tβ15 but its two isoforms are also 
referred to as Tβ15a and Tβ15b (Banyard et al. 2007). Given its role in the development and 
progression of prostate cancer, Tβ15 is a putative biomarker for this disease. Tβ15 was 
furthermore shown to have pro-angiogenic and anti-migratory properties in rats (Koutrafouri, 
Leondiadis et al. 2003; Dhaese et al. 2007). With regards to its amino acid sequence, Tβ4 is 
very similar to the β-thymosins 10 and 15 and to the thymosins 8, 9, discovered in other 
organisms (Low and Goldstein 1984; Bao et al. 1996; Li et al. 1996; Dhaese et al. 2009). All 
β-thymosins are acetylated at their N-terminal alanine (Tβ4, 10) or serine (Tβ15) respectively 
(Hannappel 2010). 
 
1.4.2 Thymosin β4 structure and actin binding function 
The Tβ4 gene consists of 2.13 kB genomic DNA and contains three exons, of which exon 2 
and exon 3 code for the Tβ4 peptide (Figure 1.1 A, Li et al. 1996; Waterston et al. 2002). 
 
 
Figure 1.1: Tβ4 gene and peptide structure. (A) Simplified depiction of the Tβ4 gene (not to scale). 
(B) Amino-acid sequence and domains of Tβ4. 1 - N-terminal Ac-SDKP peptide, 2 - Actin binding 
domain (Li et al. 1996; Huff et al. 2001). 
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Tβ4 was already synthesised in 1981 by automated solid phase synthesis due to an early 
interest in the immunomodulary role of thymosins suggested by their apparent involvement 
in T lymphocyte maturation (reviewed in Hannappel 2010). It is now established that Tβ4 is a 
highly conserved peptide in the animal kingdom, being almost identical in human, rat, 
mouse, cat, calf, horse, pig, sheep, chicken and gecko. Between different species its length 
varies from 40 to 44 amino acids and it is the most abundant β-thymosin in mammals (Huff 
et al. 2001). Historically, it was characterised to have a molecular weight of 4982 Da and an 
isoelectric point of 5.1 However, more recent data support a PI around 4.58 which is similar 
to the value calculated in silico (4.82, Low and Goldstein 1982, EMBL WWW Gateway to 
Isoelectric Point Service, http://www3.embl.de/cgi/pi-wrapper.pl 22-06-2010, Hannappel 
2010). Unlike the α-thymosin subclass, β-thymosins are not derived from a larger precursor 
peptide. As mentioned previously, cDNA analysis of human, mouse and rat Tβ4 indicate a 
length of 44 amino acids, however the mature peptide is only 43 amino acids long since the 
initiator methionine is removed after translation and the freed N-terminal alanine is 
acetylated (Hannappel 2010). A further post-translational modification of Tβ4 involves 
phosphorylation at two sites (threonine-21 and threonine-23), which was demonstrated in 
HeLa cells but not in human platelets (Zahedi et al. 2008). The function of these post-
translational modifications is not yet fully understood although a role in actin interaction has 
been proposed. Furthermore, the transglutamination of Tβ4 residues Gln-23 and Gln-36 and 
to some degree Gln-39 has been successfully demonstrated, but has not yet been described 
in vivo (Huff et al. 1999). In physiological solutions, Tβ4 appears to be unstructured but 
contains two alpha helices, one consisting of residues 5-15 and the second of residues 30-
40, interconnected by a flexible linker (Zarbock et al. 1990; Stoll et al. 1997). Apart from N-
terminal acetylation and transglutamination, another post-translational modification involves 
enzymatic removal of the N-terminal Ac-SDKP tetrapeptide, which will be discussed in more 
detail in the next section. 
All β-thymosins sequester globular actin (G-actin) and this interaction has probably been the 
most studied aspect of this peptide (Huff et al. 2001). Tβ4 prefers binding of ATP-G-actin 
over ADP-G-actin and it was shown that the nine amino acid long motif (17LKKTETQEK25) 
involved contains the three hydrophobic residues 6Met, 9Ile and 12Phe which are essential 
for this interaction (Safer et al. 1991; Van Troys et al. 1996; Hertzog et al. 2002). The wider 
actin binding domain of Tβ4 and its orthologues comprises the so called β-thymosin domain, 
which like the Wiskott-Aldrich Syndrome protein homology domain 2 (WH2) is characterised 
by a LKKT/V sequence with variable terminal extension (Xue et al. 2007). While the 
interaction of this domain with actin was not directly shown, there is strong indirect evidence 
that β-thymosin and WH2 domain-containing proteins use their N-terminal extension to make 
contact to the hydrophobic cleft at the barbed end of G-actin and this interaction regulates 
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the strength of the interaction (Didry et al. 2012). Actin-binding requires the α-helical 
conformation of the N-terminal part of Tβ4 to allow physical contact of Lys3, Met6, Lys18 
and Lys38 of Tβ4 with the actin residues Asp1-Glu4, Gln41 and Glu167 (Huff et al. 2001). 
While C-terminal interactions with G-actin are minimal, point mutations in the C-terminal 
domain can reverse the function of Tβ4 and WH2 domain-containing proteins from 
stabilisation of a pool of monomeric actin to a role in promoting of filamentous (F-)actin 
assembly (Hertzog et al. 2004). WH2 domain were found in over 500 eukaryotic proteins, all 
of which bind actin and are involved in regulating motility but may have positive or negative 
roles in this process (reviewed in Husson et al. 2010). Intriguingly, it was shown that the 
actin binding domain of Tβ4 is essential for its angiogenic properties and the domain was 
shown to have comparable pro-angiogenic effects on human vein endothelial cells (HUVEC) 
to the full peptide (Philp et al. 2003). 
Tβ4 is present in high cytosolic concentrations throughout the body and in body fluids 
(Gomez-Marquez et al. 1989; Huff et al. 2004). It is expressed in most tissues such as brain, 
spleen, thymus, lung, ovary, kidney, intestine, liver, testis and the heart (Hannappel et al. 
1982; Gomez-Marquez et al. 1989). Its expression was also confirmed in circulatory cells 
such as lymphocytes, macrophages, granulocytes and is found in very high concentrations 
in platelets (Hu et al. 1981; Xu et al. 1982; Gondo et al. 1987). Tβ4 concentrations are 
particularly high in wound fluid highlighting its implication in dermal healing (Frohm et al. 
1996). Intracellular, it is found diffusely distributed in the cytoplasm, but concentrations can 
increase focally near stress fibres and it is relatively abundant in the nucleus (Cha et al. 
2003; Mannherz and Hannappel 2009). This may surprise, given the absence of nuclear 
localisation signal in the peptide. Nevertheless, exogenous Tβ4 localises to the nucleus and 
this occurs likely by active transport, potentially involving α/β importins, rather than by 
passive perfusion due to its small size (Grant et al. 1999; Koerner et al. 2003; Huff et al. 
2004; Mannherz and Hannappel 2009). As for the pro-angiogenic properties, facilitation of 
nuclear localisation of Tβ4 appears to be dependent of the actin binding domain, since after 
enzymatic cleavage only the N-terminal half of the peptide localises to the nucleus (Huff et 
al. 2004). It was more recently shown in vitro that nuclear localisation of Tβ4 can be 
mediated by hMLH, a protein involved in DNA mismatch repair which contains a nuclear 
localisation signal (Brieger et al. 2007). hMLH appears furthermore to be involved in 
regulating the expression of Tβ4. In the nucleus, another binding partner called Ku80 has 
been identified in endothelial cells in vitro (Bednarek et al. 2008). Ku80 is a subunit of ATP-
dependent DNA helicase II and is an essential mediator of the Tβ4-induced expression of 
PAI-1, providing first clues about a role of Tβ4 in the nucleus which has not yet been well 
documented. A potential role of nuclear Tβ4 is binding of nuclear actin which is involved in 
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transcriptional regulation of certain genes but this hypothesis remains to be tested in the 
future (Vartiainen et al. 2007). 
Endogenous and exogenous Tβ4 improves various physiological processes, such as wound 
healing in general and during ageing and diabetes, corneal repair after abrasion, hair 
growth, neurological recovery in experimental autoimmune encephalitis and cardiomyocyte 
survival and improved cardiac function in models of MI (Malinda et al. 1999; Sosne et al. 
2001; Philp et al. 2003; Bock-Marquette et al. 2004; Philp et al. 2004; Zhang et al. 2009). 
Some of these functions have been attributed to its N-terminal Ac-SDKP tetrapetide. 
 
1.4.3 N-acetyl-seryl-aspartyl-lysyl-proline 
The amino-terminal acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) tetrapeptide (Figure 1.1) is 
cleaved off Tβ4 by prolyl oligopeptidase (POP), a serine peptidase (clan SC, family S9) 
abundantly present in many tissues and body fluids in mammals (Polgar 2002; Cavasin et al. 
2004). Tβ4 knockdown in the heart results in up to 62% decreased cardiac AcSDKP 
underlining the peptide-precursor relationship of Tβ4 and AcSDKP (Smart et al. 2007). 
AcSDKP is a pleiotropic peptide, which shares many angiogenic functions with its precursor 
Tβ4, such as stimulation of endothelial cell migration and differentiation in vivo (Cha et al. 
2003; Liu et al. 2003). At the same time, AcSDKP inhibits proliferation of haematopoietic 
pluripotent stem cells by inhibiting an S-phase stimulator in these progenitor cells (Lenfant et 
al. 1989; Stephan et al. 2000). In rats, this response to AcSDKP elevation was shown to be 
accompanied by increased secretion of active MMP-1 and a substantial angiogenic 
response. Increased circulating levels of AcSDKP prevents monocyte/macrophage 
infiltration, collagen deposition and fibrosis in hearts and kidneys of hypertensive rats 
(Rhaleb et al. 2001; Cavasin et al. 2007). In line with these findings it was shown that 
blocking cleavage of AcSDKP using POP inhibitors leads to perivascular fibrosis in the 
kidneys and the heart (Cavasin et al. 2007). In the setting of cardiac hypertrophy after MI in 
rats, infusion with AcSDKP resulted in reduced fibrosis by reduction of collagen deposition 
(Peng et al. 2003; Yang et al. 2004). POP substrates are limited to a size of 30 amino acids 
indicating that Tβ4 needs to be enzymatically cleaved before POP can generate the active 
AcSDKP peptide fragment, but this step has not yet been documented (Myohanen et al. 
2010). 
AcSDKP is upregulated in response to injury and plasma levels of AcSDKP were elevated in 
patients with renal failure (Suzuki et al. 2012). Cardiac levels of AcSDKP were increased 1 
week after experimental myocardial infarct in mice (Smart et al. 2007). The tetrapeptide can 
be degraded by angiotensin converting enzyme (ACE), being a class III substrate for the C-
active site of ACE (Rousseau et al. 1995). Treatment of patients with renal failure with ACE 
inhibitors was shown to augment AcSDKP plasma concentrations and it was hypothesised 
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that the cardioprotective effect of ACE inhibitors may indeed be partially mediated by 
elevating the concentration of this peptide (Rhaleb et al. 2001; Inoue et al. 2011). In the 
setting of hypertension, the abundance of macrophage-released galectin-3 (Gal-3) is an 
indicator of progression into heart failure, since it promotes cardiac inflammation and 
remodelling (Liu et al. 2009). Gal-3–mediated progression was attenuated by AcSDKP 
administration in rats with overall improved outcomes compared to controls. Furthermore, 
TGFβ1-mediated differentiation of cardiac fibroblasts into pathological myofibroblasts was 
attenuated by AcSDKP in human foetal cardiac fibroblast cultures, further highlighting the 
importance of AcSDKP as an antifibrotic agent (Peng et al. 2010). Although these findings 
highlight the potential of AcSDKP for treatment of cardiovascular disease and while there is 
some overlap between the observed functions of Tβ4 and the tetrapeptide, AcSDKP 
supplementation was unable to rescue the cardiac phenotype of a conditional Tβ4 
knockdown mouse indicating a more complex function of whole Tβ4 than the one mediated 
by its AcSDKP domain (Smart et al. 2007). 
 
1.4.4 Thymosin β4 function  
Tβ4 has a beneficial role in wound healing as well as neuroprotection in the brain (Malinda 
et al. 1997; Popoli et al. 2007). It was shown to improve neurological outcomes in a rat 
model of stroke (Morris et al. 2010). After IP injection of Tβ4, increased vessel density and 
numbers of oligodendrocyte progenitors and myelinating oligodendrocytes were observed at 
the boundary of the ischaemic lesion. It was furthermore shown to stimulate progenitor cells 
in the hair follicle (Philp et al. 2004). Bulge residing hair follicle stem cell-like cells displayed 
increased migratory potential and differentiation in response to Tβ4 treatment in culture, as 
well as elevated MMP-2 expression which promotes hair outgrowth from the follicle. 
Another role attributed to Tβ4 is the amelioration of type II diabetes. Initial experiments were 
based on the observation that Tβ4 was upregulated in regenerating skeletal muscle and acts 
as a chemoattractant for myoblasts and satellite cell-derived myocytes (Tokura et al. 2011). 
Since myoblast injection into the hindlimbs of diabetic mice was shown to reduce 
hyperglycemia and hyperinsulinemia, Tβ4 was injected intraperitoneally (IP) into the same 
type II diabetes mouse model to attract endogenous myoblasts (Ye et al. 2009; Zhu et al. 
2012). This resulted in increased insulin sensitivity accompanied by elevated Akt expression. 
It is not surprising that given its involvement in cell motility, growth and survival, that Tβ4 is 
also considered an indicator of malignant progression and metastasis in tumours (Kim et al. 
2009). For example in malignant lung tumour cells Tβ4 is found to be highly expressed 
(Clark et al. 2000). 
Tβ4 is abundant in platelets and is released in pre-thrombotic states upon thrombin 
stimulation (Huff et al. 2002). It is co-released with the transglutaminase factor XIIIa which 
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crosslinks Tβ4 to various molecules such as fibrin and collagen. Crosslinking to fibrin occurs 
in a Ca2+ and time-dependent manner and in competition with the related Tβ10. Without 
physical retention, the highly hydrophilic Tβ4 peptide would easily diffuse away from its site 
of release from platelets. Therefore, Tβ4 tethering is believed to either have a role in the 
fibrin clot or is retained to create a milieu that supports healing and regeneration. In support 
of the first hypothesis, Tβ4 was shown to increase the interaction of platelet receptors with 
their ligands thus promoting local platelet accumulation (Kaur et al. 2010). Binding of Tβ4 to 
fibrinogen in the presence of high concentrations of Tβ4, however, seems to block 
attachment of activated platelets to fibrinogen. Extracellular Tβ4 induced expression and 
release of plasminogen activator inhibitor type 1 (PAI-1) in endothelial cells (Al-Nedawi et al. 
2004; Boncela et al. 2006). This is attributed to an intracellular signalling involving the MAPK 
cascade, which enhances binding of c-Fos/c-Jun to the AP-1 element of the PAI-1 promoter 
and provides a further role of Tβ4 in clot stability. The second hypothesis is supported by the 
fact that factor XIIIa-mediated crosslinking to fibrin occurs at the fibrin αC-domain which is 
associated with tethering of biologically active peptides to increase their local concentration 
(Huff et al. 2002; Makogonenko et al. 2004). Furthermore, Tβ4 exerts antimicrobial effects 
on common pathogens such as E. coli and S. aureus implying an additional protective 
function at lesions of the body surface (Tang et al. 2002). It is noteworthy that the highest 
levels of Tβ4 in the body are observed in platelets, since these are the cells that arrive first 
at the site of injury and by secreting Tβ4 could pre-condition the affected area (Goldstein et 
al. 2012). 
In addition to the described roles in actin binding, cell recruitment and acute response to 
injury, an additional function of Tβ4 is the regulation of inflammation. The immunomodulary 
role of Tβ4 was elucidated in a mouse model of septic shock. Tβ4 treatment not only 
decreased levels of inflammatory cytokines IL-1 and TNFα and reduced the infiltration of 
polomorphonuclear leukocytes (PMN) but also reduced overall the mortality in this model 
(Badamchian et al. 2003). A reduction in PMN-infiltration in response to topical Tβ4 
treatment was also observed in a mouse model of corneal alkaline injury (Sosne et al. 2002). 
This was accompanied by reduction of IL-1β and monocyte chemoattractant protein 1 (MCP-
1) and MIP-1α, MIP-1β and MIP-2. In corneal cells, as well as other cells types, TNFα is a 
main driver of inflammation by activating NFκB. This TNFα-mediated activation of NFκB is 
suppressed by Tβ4 which leads to the observed downregulation of pro-inflammatory 
cytokines and chemokines in Tβ4-treated corneal cells compared to controls in vitro (Sosne 
et al. 2002; Sosne et al. 2007). While Tβ4 directly targeted the RelA/p65 subunit of NFκB, it 
was independently demonstrated to also inhibit TNFα, which leads to a reduction of 
downstream IL-8 expression (Qiu et al. 2011). Furthermore it was shown that Tβ4 interacting 
protein ILK and PINCH have sensitising effects on TNFα-mediated NFκB activity but these 
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effects are diminished in the presence of Tβ4. In vitro data indicates that in natural killer cells 
IL-18 regulates Tβ4 expression by a signalling cascade involving p38MAPK and Jun kinase 
(Lee et al. 2011). In addition, Tβ4 increases IL-18-mediated IFNγ expression in a positive 
feedback loop and this increase can be abolished by knocking down Tβ4 by RNA 
interference (RNAi). Tβ4 has further less well described roles in the immune system. As 
such, it was shown to promote antigen presentation on macrophages and to control thymus-
dependent lymphocyte maturation but no recent studies have further investigated these 
mechanisms (Low et al. 1981; Tzehoval et al. 1989). 
The overall anti-inflammatory role of Tβ4 results in less tissue damage from inflammation 
and consequently decreases fibrosis and improves healing. There are further mechanisms 
by which Tβ4 is thought to directly reduce scar tissue formation, some of which may be 
attributable to the AcSDKP fragment, as discussed previously. One of the best researched 
aspects of Tβ4 is its pro-migratory role. That being said, our current knowledge of the 
intracellular function and signalling of Tβ4 does not yet explain its extracellular role in 
stimulating migration and only a few direct interactors have been identified to date (Freeman 
et al. 2011). As previously described, Tβ4 interacts with G-actin in a 1:1 ratio to maintain a 
dynamic pool of monomeric actin indicating its importance in actin cycling (Safer et al. 1991). 
Actin binding occurs in competition with profilin (PFN), which facilitates the release of Tβ4 
from G-actin and thus facilitates F-actin assembly (Figure 1.2, Pantaloni and Carlier 1993). 
 
 
Figure 1.2: Role of Tβ4 in cell migration and intracellular signalling. In migrating cells, Tβ4 is released 
from monomeric G-actin by profilin (PFN). This allows F-actin formation in the leading edge and 
utilisation of free Tβ4 in a complex consisting of Akt1/2 and integrin-linked kinase (ILK). This complex 
Chapter 1 - Introduction 
35 
facilitates Akt1 phosphorylation and Akt2-mediated phosphorylation of mTOR. While phosphorylated 
Akt2 stimulates the transcription of matrix degrading proteins, phospho-mTOR facilitates the release 
of molecules, such as MMP-2. Tβ4 furthermore induces transcription of MMP-1 and MMP-9 (Philp et 
al. 2006; Qiu et al. 2007; Fan et al. 2009). 
 
These studies highlight the importance of Tβ4 for reorganisation of the cytoskeleton and cell 
locomotion. Cytoskeletal modifications are necessary for lammellipodia formation and 
extension as well as repeated protrusion, adhesion and contraction (Lauffenburger and 
Horwitz 1996; Pollard and Borisy 2003). This process is further facilitated by Tβ4-induced 
expression of matrix metalloproteinases (MMP-1, MMP-2 and MMP-9), which are implicated 
in ECM degradation (Philp et al. 2006; Qiu et al. 2007). The induction of MMPs was shown 
to be dependent on the actin binding domain of Tβ4. Fan and co-workers have proposed a 
Tβ4 signalling pathway in migrating endothelial cells (Fan et al. 2009). They indicated that 
G-actin sequestration by Tβ4 is antagonising cell migration but that this effect, however, is 
overruled by induction of MMPs resulting in the observed increased migratory potential 
(Bock-Marquette et al. 2004; Fan et al. 2009). MMP expression is supposedly induced by the 
interaction of Tβ4 with integrin-linked kinase (ILK), which leads to the activation of Akt1 and 
Akt2. Akt2 activation not only induces survival signalling via mTOR, but also regulates 
production and activity of MMP-2 (Fan et al. 2009). Tβ4-ILK-mediated phosphorylation of 
Akt1 is believed to result in its localisation to the leading edge of the cell and enhance local 
actin polymerisation. 
Consistent with this proposed pathway, Tβ4 was found to be abundant in the leading edge of 
migrating endothelial cells. F-actin assembly and Tβ4 signalling require the release of Tβ4 
from G-actin which is facilitated by PFN (Pantaloni and Carlier 1993). PFN was further 
shown to interact with pro-migratory factors Rac/Rho, ROCK and proline-rich vasodilator-
stimulated phosphoprotein (VASP) and is preferentially localised in the protrusive edge of 
fibroblasts (Buss et al. 1992; Witke 2004). Tβ4-mediated endothelial cell migration and 
induction of MMPs to degrade ECM have obvious implications in angiogenesis. In line with 
the observation made by Fan and co-workers, stable overexpression of Tβ4 is pro-migratory 
most likely due to compensatory mechanisms stabilising F-actin, but cDNA microinjection or 
transient transfections that instantaneously increase Tβ4 inhibit migration by 
depolymerisation of actin (reviewed in Mannherz and Hannappel 2009). This is supported by 
the inverse approach of depleting intracellular Tβ4 by RNA interference (RNAi) which was 
shown to increase cell motility (Fan et al. 2009). Nevertheless, Tβ4 was demonstrated to 
induce migration of HUVEC in vitro and this was shown to be dependent of P2X4 receptor 
(Freeman et al. 2011). Extracellular Tβ4 also increases surface ATP availability by binding 
F1-F0 ATP synthase which is an extracellular receptor for Tβ4. Tβ4 binds the β-subunit of 
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F1-F0 ATP synthase providing evidence for a role of Tβ4 in purinergic signalling (Goldstein 
et al. 2012). Tβ4-mediated elevated surface ATP could provide a further explanation for the 
pro-migratory role of Tβ4 in HUVEC. 
The pro-regenerative effects of Tβ4 can be partially attributable to its role in promoting 
endothelial cell differentiation and angiogenesis (Grant et al. 1999). Angiogenesis is the 
formation of new blood vessel from a pre-existing vascular network and is essential during 
development, repair and tumour growth (Risau and Flamme 1995). In line with this, high 
concentrations of Tβ4 were observed in blood vessels and endocardial cushions during 
development of mouse embryos (Gomez-Marquez et al. 1989; Carpintero, Anadon et al. 
1995; Carpintero et al. 1996). In human patients with coronary artery disease, less well 
developed collateral vessels were shown to be associated with lower circulating levels of 
Tβ4 (Bicer et al. 2011). 
A number of experiments in vitro further underline the role of Tβ4 in blood vessel formation. 
In an aortic ring angiogenesis assay, increased vascular sprouting and a doubling of vessel 
area by increased branching was observed after adding as little as 100 ng of synthetic Tβ4 
(Grant et al. 1999). In HUVEC, Tβ4 was shown to increase tube formation and HUVEC 
differentiating into capillary-like tubes displayed a 5-fold increase of intracellular Tβ4 (Grant 
et al. 1995). Further evidence for the relationship between VEGF and Tβ4 was derived from 
immunofluorescence data indicating that VEGF expression is decreased in the hearts of 
mouse embryos following cardiac specific knock down of Tβ4 (Smart et al. 2007). Earlier 
reports have suggested that hypoxia inducible factor-1α (HIF-1α) co-localises with Tβ4 in 
colorectal cancer cells and that Tβ4 induces VEGF by stabilising HIF-1α (Jo et al. 2010). 
However, despite the fact that HIF-1α is found to be upregulated at the same time with Tβ4 
and VEGF, there is more recent evidence indicating that Tβ4 induces VEGF expression 
independently of HIF-1α (Kang et al. 2011; Kim et al. 2011). Increasing intracellular levels of 
Tβ4 by adenoviral vector increases VEGF and MMP-7 expression in vitro (Cha et al. 2003; 
Wang et al. 2004). In a porcine model of MI not only Tβ4 and VEGF but also MMP-9 was 
found to be upregulated in response to the insult (Shah et al. 2011). 
In the synovial fluid sampled from the joints of rheumatoid arthritis patients, levels of Tβ4 
were strongly associated with levels of the collagenases MMP-9, MMP-13 as well as VEGF 
measured by ELISA (Choi et al. 2011). While an increase of matrix degrading proteins is 
advantageous in the regenerative setting to resolve scar tissue or allow cell migration, it is 
associated with increased disease severity in rheumatoid arthritis since it results in further 
damage to the cartilage. To an extent this holds true for the cardiac setting since increased 
MMP-9 expression has been linked to more severe left-ventricular dilatation after 
experimental MI (Ducharme et al. 2000). In line with this, diminished numbers of 
macrophage and reduced collagen deposition were observed in the left ventricle of MMP-9 
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KO mice. This was accompanied by upregulation of MMP-2, MMP-13 and TIMP-1 indicating 
the diverse roles of the various ECM degrading enzymes. Enzymatic digestion of ECM is not 
only important to clear the path for newly forming blood vessels but could be useful in scar 
resolution during cardiac regeneration to create space for progenitor cells or even new 
myocytes. 
Another mechanism shown to contribute to the diverse effects of Tβ4 is epithelial to 
mesenchymal transition (EMT). EMT is a process naturally occurring for example during 
embryogenesis and describes the loss of tissue adhesion by downregulation of adhesive 
molecules and overall adoption of a promigratory phenotype and ultimately the conversion 
from an epithelial to mesenchymal phenotype (reviewed in Savagner 2001). This involves 
downregulation of adhesion molecules, such as E-cadherin, a process which is reiterated 
during tumour metastasis (reviewed in Vernon and LaBonne 2004). Tβ4 promotes EMT via 
upregulation of ILK (Huang et al. 2007). It was further demonstrated that Tβ4 overexpression 
results in downregulation of E-cadherin at cellular junctions in vitro in colorectal cancer cells 
(Wang et al. 2003). This is further supported by the reverse approach of depleting Tβ4 by 
RNAi which resulted in increased E-cadherin expression in urinary bladder cancer cells 
leading to reduced mobility and invasiveness (Wang et al. 2012). 
 
1.4.5 Thymosin β4 and the heart 
Tβ4 is expressed in the developing and adult animal heart (Hannappel et al. 1982; Gomez-
Marquez et al. 1989). Levels of Tβ4 can increase in the adult animal heart under certain 
conditions, for example following cardiac injury as demonstrated in pig, zebrafish and 
mouse. Tβ4 secretion accelerates from 0.06 pg/mL per minute to 0.16 pg/mL per minute 
(measured in plasma from the right atrium) after left-anterior descending coronary artery 
occlusion, cardiac arrest and resuscitation in porcine MI/reperfusion model (Shah et al. 
2011). Tβ4 is highly expressed in embryonic endothelial progenitor cells (eEPC) and in 
recent studies eEPC-mediated cardiomyocyte survival was shown to be dependent of Tβ4 in 
a pig ischemia-reperfusion model (Kupatt et al. 2005; Hinkel et al. 2008). This underlines the 
beneficial paracrine effects of this molecule which have been well documented previously 
(Bollini et al. 2011; Kraehenbuehl et al. 2011). Tβ4 treatment of pigs with experimental MI 
reduced infiltration of inflammatory cells, pro-inflammatory cytokines and chemokines 
resulting in overall reduction of inflammation and swelling (Hinkel et al. 2008). This study 
also showed that the functional improvement following endothelial progenitor cell injections 
is at least partially attributable to Tβ4, since pre-treatment of eEPC with Tβ4shRNA prior to 
injection abolished some of the beneficial effects. Zebrafish have the surprising capability to 
regenerate functional myocardium after extensive damage. After complete resection of the 
apex, zebrafish heart can completely regenerate, a process in which upregulation of a Tβ4 
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orthologue was observed after 3 days and to lesser extent after 7 days (Lien et al. 2006). 
This could indicate that Tβ4 is part of a program that assists in cardiac regeneration. Also in 
mice, Tβ4 levels measured at one day and one week after ligation were found to be 
significantly increased (Smart et al. 2007). That the mammalian heart is in principle capable 
of regeneration was demonstrated in a recent study. During early postnatal life the mouse 
heart remains a highly plastic organ. Neonatal mice can also regenerate myocardium after 
surgical apex resection with only insignificant hypertrophy or fibrosis during later life but this 
regenerative potential is limited to the first postnatal days (Porrello et al. 2011). Although this 
intrinsic regenerative capability is lost after 7 days of postnatal life it indicates that cardiac 
regeneration in mammals is possible, but only in perinatal life. The Srivastava laboratory 
showed that Tβ4 can rescue the ischemic heart by Akt activation (Bock-Marquette et al. 
2004). Tβ4-mediated reduction infarct size and improved cardiac function was, however, not 
able to rescue Akt deficiency since concomitant treatment with the Akt inhibitor Wortmannin 
abolished this effect (Sopko et al. 2011). Overall, either IP or intracardiac injections of Tβ4 
after coronary artery ligation resulted in increased early cardiomyocyte survival, markedly 
reduced scar formation and overall improved function compared to untreated mice (Figure 
1.3, Bock-Marquette et al. 2004). 
 
 
Figure 1.3: Scar formation is reduced in mice treated with Tβ4. Trichrome stain of mouse hearts 14 
days after coronary artery ligation. (a, b) Control animals injected with PBS, (c, d) intraperitoneal (i.p.) 
or (e, f) intracardiac (i.c.) injections of Tβ4. (g) Quantification of scar volume of infarcted hearts 
following Tβ4 or control treatment (image obtained from Bock-Marquette et al. 2004). 
 
In human patients, serum Tβ4 is significantly downregulated in ST-elevated MI (STEMI) 
patients at time of PCI, but levels return to those of controls 48h following successful 
intervention (Yesilay et al. 2011). PINCH, ILK and α-parvin are components of focal 
adhesions and are upregulated during dilated cardiomyopathy in humans (Sopko et al. 
2011). This was also observed in overloaded and infarcted hearts in mice. PINCH, ILK and 
α-parvin expression was further increased by Tβ4-treatment indicating that Tβ4 potentially 
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augments a natural endogenous response to cardiac injury. In vitro, pre-conditioning of 
cardiac fibroblasts with Tβ4 resulted in decreased intracellular ROS, increased superoxide 
dismutase expression and catalase expression and reduced the Bax/Bcl2 expression ratio 
(Kumar and Gupta 2011). Furthermore, collagen type-1 (Col1), collagen type-3 (Col3) and 
connective tissue growth factor (CTGF) expression were reduced. This was confirmed in 
mice, where Tβ4 treatment was also shown to significantly reduce Col1 and Col3 expression 
in the heart following MI (Sopko et al. 2011). 
The aforementioned role of Tβ4 in recruiting stem/progenitor cells further contributes to the 
improved outcomes after experimental MI in mice, with the epicardium being one of the most 
recently suggested sources for cardiomyocyte, endothelial and smooth muscle precursors 
(Smart et al. 2007; Smart et al. 2011). Exogenous Tβ4 was indeed shown to induce the 
recruitment of epicardium-derived progenitor cells following infarct. In the cardiovascular 
system of early mouse embryos Tβ4 is present mainly in blood vessels and endocardial 
cushions (Gomez-Marquez et al. 1996). Additionally, Tβ4 expression was observed in the 
ventricular myocardium, in the outflow tract, the pericardium and endocardium of mice at 
embryonic day 10 (E10, Smart et al. 2002). Smart and co-workers further established that 
Tβ4 promotes endothelial cell differentiation and epicardial cell migration and 
vasculogenesis during embryonic development (Smart et al. 2007). According to this study, 
epicardium-derived cells (EPDCs) undergo EMT and are subsequently recruited to the 
myocardium by Tβ4, to form either endothelial cells or a smooth muscle collateral support. 
The endothelial fate is determined by the vasculogenic growth determinants VEGF and basic 
fibroblast growth factor (bFGF), while the arteriogenic factors platelet-derived growth factor 
(PDGF) and transforming growth factor β (TGFβ) direct the cells towards smooth muscle 
fate. Tβ4 expression is vital for this process and accordingly for overall development of the 
heart. This was proven by RNAi-mediated Tβ4 knockdown during development, which 
resulted in impaired vasculogenesis and defects of the myocardium and embryonic lethality 
in mice. Pre-treatment of mice with Tβ4 was shown to prime epicardial cells to migrate into 
the myocardium during MI and this leads to improved cardiac outcomes (Smart et al. 2011). 
EPDC migration was traced by GFP and YFP expression under the control of Wilm’s tumour 
gene 1 (Wt1) promoter. While Wt1 is not expressed in the adult epicardium, this embryonic 
expression pattern can be re-iterated by Tβ4 treatment. Cells were transiently labelled by 
EGFP expression under the control of the Wt1 promoter which was activated by Tβ4 
treatment as well as cardiac injury. Permanent labelling was achieved in the adult by use of 
a tamoxifen-inducible Cre recombinase under the control of the Wt1 promoter which 
permanently activated EYFP transgene expression. In the myocardium these cells 
expressed cardiomyocyte-specific markers such as cardiac troponin-T, sarcomeric α-actinin 
and connexin-43. 
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In summary, these studies demonstrate that molecules which are involved in embryonic 
development could provide a means to stimulate a similar program in the adult heart. Tβ4-
mediated induction of cell migration, angiogenesis and survival signalling in the setting of 
myocardial injury, make it a strong candidate to treat human heart disease. The fact that 
some, if not most, of these effects are exerted in a paracrine fashion, indicates an additional 
strength of this peptide. This potential has received recognition by the industry and Tβ4 is 
tested in several early-phase clinical trials (RegeneRx Biopharmaceuticals Inc., Bethesda, 
MD, USA). Unlike growth factors, Tβ4 has the additional advantage that it does not bind to 
heparin, thus allowing it to penetrate deep into tissues to exert its actions locally (Goldstein 
et al. 2012). A recent dose escalating phase I clinical trial in healthy subjects investigated 
systemic Tβ4 injections at pharmacologically relevant concentrations and concluded that it 
can be considered relatively safe since no severe adverse events were reported (Ruff et al. 
2010). 
 
 
1.5 Insulin-like growth factor 1 
The name insulin-like growth factor-1 (IGF-1) derives from early observations in the 1960s 
when the then called somatomedin C was shown to have overlapping functions with insulin, 
while not being detectable by anti-insulin antibodies (Froesch et al. 1963). In 1976 the name 
was changed into IGF-1 to better describe its similarity to insulin and its growth promoting 
function (Rinderknecht and Humbel 1976). IGF-1 has been characterised as an anabolic 
protein mediating muscle growth and repair and fulfilling a host of critical functions during 
development and throughout life (Stewart and Rotwein 1996). Its importance during 
embryonic development was highlighted by the phenotype of IGF-1-deficient mice which 
display substantially reduced body weight at birth, growth retardation and during adult life 
weigh a third less than age-matched wt mice (Baker et al. 1993; Liu et al. 1998). IGF-1 
stimulates glucose transport and utilisation in animals including humans and reduces 
circulating amino acids by decreasing protein degradation (Jacob et al. 1989). High levels of 
IGF-1 can result in hypoglycaemia due to increased glucose uptake. 
 
1.5.1 Insulin-like growth factor 1 structure and post-translational modifications 
The amino acid sequence of the precursor of IGF-1 was first determined in 1983 from 
human liver cDNA (Jansen et al. 1983). Less than ten years later, the complete structure of 
the IGF-1 gene had been identified in the rat (Shimatsu and Rotwein 1987; Hoyt et al. 1992; 
Simmons et al. 1993). It consists of more than 90 kb genomic DNA distributed over six 
exons and five intronic regions (Figure 1.4, Winn et al. 2002). 
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Figure 1.4: Schematic representation of the IGF-1 gene and its four isoforms in the rat. 
Expression of class 1 and 2 signal peptides and Ea and Eb carboxy-terminal peptides are 
regulated by alternative splicing (not to scale). S - signal peptide, E – extension peptide 
(Winn et al. 2002; Dobrowolny et al. 2005; Barton 2006). 
 
Alternative splicing of Exon 1 and 2 produces two different amino-terminal signal peptides 
according to which the isoforms are classified into class 1 or class 2 molecules. Exon 3 and 
4 are present in all transcripts of IGF-1 and are followed by differentially spliced exons 5 and 
6, which give rise to two different carboxy-terminal extension peptides Ea and Eb. Various 
translation initiation site (AUG) are found along IGF-1 transcripts, indicating differential 
regulation on a translational level after splicing (Simmons et al. 1993). Both the signal 
peptide as well as the extension peptide undergo proteolytic cleavage to yield the 70 amino 
acid (7649 Da) long mature form of IGF-1 (Yang et al. 1995). The carboxy-terminal Ea 
peptide is highly conserved across mammalian species, while there is some divergence in 
the Eb peptide sequence (Hepler et al. 1990). The Ea peptide contains an N-glycosylation 
motif which is absent from the highly basic Eb peptide (Shimatsu and Rotwein 1987). To 
date, there is no consensus on the functions of both the Ea and Eb peptide (Santini et al. 
2007). The sequence of the signalling peptide affects the efficiency of translation initiation 
and is a target for glycosylation on the IGF-1 precursor peptide (Simmons et al. 1993; Yang 
et al. 1995). As such, it defines the different localisation and function of the two IGF-1 
classes (Musaro and Rosenthal 2002). The class 1 IGF-1 is described as the local isoform, 
opposed to the circulating class 2 molecule. Class 1 molecules are expressed by most, if not 
all tissues and act in an auto- or paracrine fashion while IGF-1 class 2 are mainly expressed 
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in the liver as endocrine signalling molecules in response to growth hormone (GH) 
stimulation. 
Recent studies using decellularised tissue preparations have indicated that the function of 
the extension peptides (Ea and Eb) is their retention in situ and provides a rationale why 
unlike the processed mature IGF-1 they are not found in circulation (Hede et al. in press). 
 
1.5.2 Insulin-like growth factor 1 signalling 
Extracellular IGF-1 binds IGF-1 receptor (IGF-1R), which in turn autophosphorylates eight 
intracellular tyrosine residues (Figure 1.5, Kato et al. 1994). Phosphorylated IGF-1R 
activates insulin receptor substrates (IRS), preferentially IRS-1 (Rother et al. 1998). 
Activated IRS are highly potent regulators upstream of Ras-MAPK and phosphoinositide 3-
kinase (PI3K) signalling cascades (Myers et al. 1994; Tanaka et al. 1996). PI3K 
phosphorylates Akt, also known as protein kinase B (PKB), and its signalling was shown to 
regulate heart growth during development (Alessi et al. 1996; Shioi et al. 2000). Akt, a 
serine/threonine kinase, in turn phosphorylates target of rapamycin (TOR), which is not 
essential but sufficient to mediate phosphorylation of the S6 ribosomal subunit (Sekulic et al. 
2000). Mammalian TOR (mTOR), is achieving this as part of the mTORC1 protein complex, 
which phosphorylates various serine and threonine residues on the p70S6 kinase (p70S6K, 
Isotani et al. 1999). Phosphorylated p70S6K is recognised and further phosphorylated by 
phosphoinositide-dependent kinase 1 (PDK1) in a final activating step (Pullen et al. 1998). 
Hyperphosphorylated p70S6K activates 40S ribosomal subunit 6, which is stimulating 
protein synthesis and cell cycle progression (Chung et al. 1992; Chung et al. 1994; Ferrari 
and Thomas 1994). 
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Figure 1.5: Simplified IGF-1 signalling pathway. Upon binding of extracellular IGF-1, IGF-1R 
autophosphorylates itself. Hyperphosphorylated IGF-1R activates PI3 kinase which subsequently 
phosphorylates Akt and PDK1. Akt then phosphorylates mTOR. Phosphorylated PDK1 and mTOR 
hyperphosphorylate p70S6K, which in turn activates the ribosomal subunit S6, which induces protein 
synthesis. PDK1 may alternatively activate SGK1, independently of mTOR, which mediates cell cycle 
progression and survival signalling. 
 
Alternatively, IGF-1 signalling through PI3K can activate the growth factor serum- and 
glucocorticoid-regulated kinase 1 (SGK1) via PDK1, independently of mTOR (Kobayashi and 
Cohen 1999; Park et al. 1999). Activated SGK1 translocates to the nucleus and is 
considered the nexus between several intracellular signalling and phosphorylation cascades 
(Buse et al. 1999; Park et al. 1999). SGK1 mediates cell cycle progression and cell survival 
signalling by phosphorylating forkhead transcription factor FKHRL1 (FOXO3a), p300 and 
NFκB (Brunet et al. 2001; Tai et al. 2009). Additionally, SGK1 upregulates K+ channels, 
which contributes to its proliferative function (Gamper et al. 2002). Like Tβ4, IGF-1 is present 
in platelets where it is involved in autocrine signalling (Karey and Sirbasku 1989; Hers 2007). 
It was shown to bind platelet IGF-1R to induce insulin receptor substrate (IRS)/PI3K/Akt 
signalling and induce platelet aggregation. 
 
1.5.3 IGF-1 and its propeptides in cardiac regeneration 
IGF-1: IGF-1 treatment of embryonic cardiomyocytes in culture was shown to have anti-
apoptotic effects by suppressing DNA fragmentation, bax and caspase-3 cleavage (Wang et 
al. 1998). It was also shown to increase proliferation of G0/G1 arrested HUVECs (Ma et al. 
2009). In human heart transplant patients low serum levels of IGF-1 were found to be 
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associated with the development cardiac allograft vasculopathy and IGF-1 supplementation 
has been proposed as a treatment for recipients with low serum IGF-1 (Aharinejad et al. 
2012). Conversely, ACE inhibitor treatment is associated with elevated circulating levels of 
IGF-1 in patients with ischaemic heart disease however there is some indication that high 
IGF-1 levels increase mortality in the elderly (Chisalita et al. 2011). However in a prospective 
cohort study (PRIME), high IGF-1 serum levels were shown to be protective against 
coronary artery disease (Ruidavets et al. 2011). 
Both IGF-1 and IGF-1R are expressed in the heart during embryonic development in rats 
(Haskell and Tucker 1994). In order to study the importance of IGF-1R in cardiac progenitor 
cells, myocardial human cardiac stem cell (hCSC) were isolated from patients undergoing 
elective cardiac surgery for ischaemic heart disease (D'Amario et al. 2011). A patient 
subgroup characterised by higher expression of IGF-1R on hCSC compared to the other 
patients was identified. In this group, hCSC retained a “young” phenotype with long 
telomeres, enhanced cell proliferation and attenuated apoptosis and marked expression of 
IGF-1 and IGF-2. The cardioprotective role of IGF-1R was demonstrated in IGF-1R 
overexpressing mice, which were shown to be resistant to experimental type I diabetes-
induced cardiomyopathy (Huynh et al. 2010). Intriguingly in zebrafish, that can regenerate 
lost myocardium, a gene duplication event resulted in two similar copies of the IGF-1R gene 
termed igf-1ra and igf-1rb (Maures et al. 2002). 
There are a number of cardioprotective effects associated with IGF-1 overexpression or 
supplementation. For example myocardial hypoxia/reperfusion normally results in inhibited 
respiratory chain citrate synthase and mitochondrial complex IV and V activity but this was 
shown to be ameliorated by IGF-1 pre-treatment (Pi et al. 2007). It also increased 
mitochondrial membrane potential and decreased ROS, indicating that IGF-1-mediated 
cardioprotection is partially achieved by stabilising mitochondria. It was furthermore 
demonstrated that IGF-1 treatment increases the current through the L-type Ca2+-channel in 
cardiomyocytes via PI3Kα-mediated Akt activation and this was hypothesised to assist in 
contractility and cardiac growth (Sun et al. 2006). Furthermore, IGF-1 enhanced grafting of 
fluorescently labelled mesenchymal cells in the heart in a rat model of MI (Enoki et al. 2010). 
However, this effect was lost after 1 month, indicating that either the selected cell type is 
inappropriate or that the effect of IGF-1 is only transiently improving cell engraftment. 
Nevertheless, increased neovascularisation and reduced cardiomyocyte apoptosis were 
observed at 3 days as well as 1 month following injury. Virally transducing mesenchymal 
stem cells (MSC) to induce overexpression of IGF-1 activated survival molecules Akt and 
PI3K as well as antiapoptotic Bcl-xL and increased the secretion of stromal derived factor-1α 
(SDF-1α, Haider et al. 2008). Transplanting transduced MSCs into rat myocardium after 
experimental MI resulted in an increased recruitment of ckit+, MDR1+, CD31+ and CD34+ cell 
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populations which likely contribute to the observed functional improvement compared to 
hearts treated with non-transduced MSCs.  
More recent designs involved novel biomaterials as carriers for IGF-1. As such, alginate-
based injectable beads were shown to be an excellent mode of delivering IGF-1 to the heart 
(Ruvinov et al. 2011). The biomaterial confers protection from proteolysis, which normally 
poses a significant deterrent to injected factors due to the adverse conditions in situ. In a rat 
model of MI, sequential release of IGF-1 and hepatocyte growth factor (HGF) using this 
technique demonstrated attenuated apoptosis, infarct expansion and scar fibrosis alongside 
increased angiogenesis and density of mature blood vessels and induced cell cycle re-entry 
of cardiomyocytes. Combinatorial therapy of IGF-1 and HGF was further investigated in a 
porcine model of MI (Ellison et al. 2011). IGF-1 and HGF were perfused into the culprit artery 
following reperfusion. This increased the abundance of c-kit+/CD45- endogenous porcine 
CSC, improved cardiac myocyte survival and reduction of fibrosis and hypertrophy. For this 
study and a clinically relevant experimental design of 60 min ischaemia and injection of 
factors after 30 min reperfusion had been used, highlighting the potential of this approach in 
clinical use. Another recent study tethered IGF-1 to self-assembling peptide nanofibres and 
co-injected these together with CSC into the MI borderzone in rat (Padin-Iruegas et al. 
2009). This was designed to allow for gradual release of IGF-1 to promote activation and 
differentiation of injected and resident CSC. The approach was successful, showing 
increased formation of de novo myocytes compared to injecting either cells or IGF-1 alone. 
While overall cardiac function was improved by this combination therapy, long term 
functionality of these new myocytes was not assessed. 
Despite these promising results, circulating IGF-1 was also shown to contribute to cardiac 
hypertrophy by downregulating anti-hypertrophic micro RNAs (mIRs, Hua et al. 2012). Mice 
were subjected to aortic banding to induce cardiac hypertrophy. mIR1 and mIR133a were 
significantly reduced in wt mice resulting in heart enlargement (Hua et al. 2012). This effect 
was abolished in mice with IGF-1 deficiency in the liver. mIR-1 negatively regulates cardiac 
hypertrophy by downregulating GATA4, Mef2a and calmodulin and mIR-133a regulates 
proteins RhoA, GDP-GTP exchange protein and Cdc42 which are all implicated in this 
process (Care et al. 2007; Ikeda et al. 2009). In neonatal rat cardiomyocyte cultures, IGF-1-
mediated hypertrophy is abolished by overexpression of mIR-1 and mIR133a (Hua et al. 
2012). 
 
IGF-1Eb: While a substantial amount of research has been directed towards fully processed 
IGF-1 a significant effort has been made to understand the diverse roles of the IGF-1Ea and 
IGF-1Eb propeptides which somewhat differ from circulatory IGF-1. Recent research has 
shown that expression of IGF-1Eb in the brain is increased following traumatic cerebral 
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injury in rats indicating that this isoform potentially plays a role in a natural defence 
mechanism (Schober et al. 2012). In the heart, early experiments have already shown the 
beneficial effect of cardiac-specific IGF-1Eb isoform overexpression (Li et al. 1997). Mice 
overexpressing IGF-1Eb in the heart showed decreased expansion of the lesion by 
apoptosis and necrosis as well as reduced remodelling following experimental MI. Another 
beneficial effect of IGF-1Eb was observed in the setting of diet-induced cardiomyopathy. A 
number of pathological changes in mice are associated with high fat diet reflecting the 
situation in human (Zhang et al. 2012). These include reduced fractional shortening, glucose 
intolerance, increased circulatory IL-6 and insulin, cardiac hypertrophy (indicated by 
increased wall thickness and increased end systolic/end-diastolic dimensions) and reduced 
circulatory IGF-1. This was accompanied by increased ROS, apoptosis, mitochondrial 
dysfunction and reduced ATP on the molecular level. While also presenting an obese 
phenotype in response to high fat diet, mice overexpressing the IGF-1Eb isoform in the heart 
did not show increased ROS production, apoptosis or mitochondrial dysfunction. In addition, 
insulin signalling and cardiac contractility where preserved while glucose intolerance and 
cardiac hypertrophy were not reduced. 
 
IGF-1Ea: ROS reducing properties have also been attributed to the locally acting IGF-1Ea 
isoform in vitro. Overexpression of IGF-1Ea, but not IGF-1, conferred protection from Ang II-
mediated oxidative stress and hypertrophy in HL-1 and neonatal cardiomyocytes 
(Vinciguerra et al. 2010). In recent years IGF-1Ea has received considerable attention as a 
putative candidate for therapy of cardiac conditions. Although IGF-1Ea is widely expressed 
in neonatal tissues, high expression in the adult seems to be restricted to the liver, but 
increases in extrahepatic tissues after injury (D'Ercole et al. 1984; Hill and Goldspink 2003). 
In skeletal muscle, this increase triggers the activation of satellite cells and increases protein 
synthesis (Hill and Goldspink 2003). In mice, muscle specific overexpression of IGF-1Ea 
increases numbers of myogenic progenitors, promotes healing after muscle injury and 
reduces muscle loss in cachexia and ageing (Musaro et al. 2001; Musaro et al. 2004). 
Cardiomyocyte-specific overexpression of IGF-1Ea in mice was shown to support recovery 
and reduce scar formation after MI, also reducing pro-inflammatory cytokines IL-1β and IL-6, 
while anti-inflammatory IL-4 and IL-10 expression were increased compared to wt mice 
(Figure 1.6, Santini et al. 2007). 
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Figure 1.6: Fibrosis in αMHC/IGF-1Ea transgenic and wt mouse hearts following MI. (A) Whole 
mount and Masson‟s trichrome analysis of sham-operated control wt heart (left). wt (top panels) and 
αMHC/IGF-1Ea hearts (bottom panels) 2 months following coronary artery ligation. Arrows indicate 
fibrotic tissue. LA - left atrium, LV - left ventricle, RA - right atrium, RV - right ventricle (image obtained 
from Santini et al. 2007). 
 
Furthermore, decreased apoptosis was observed at the site of the lesion, which is at least in 
part attributable to the IGF-1Ea-mediated increase in the expression of UCP-1, 
metallothionein 2 and the cardioprotective molecule adiponectin. While contributing to 
preserved organ function in the setting of MI, IGF-1Ea overexpression in cardiomyocytes 
does not produce sustained hypertrophy under physiological conditions. 
Despite being downstream of IGF-1/PI3K signalling and its role as a cardioprotective 
mediator and key regulator of physiological heart growth, Akt does not seem to mediate IGF-
1Ea cardioprotection since this seems to involve an alternative signalling pathway (Figure 
1.7, Matsui et al. 1999; Fujio et al. 2000; DeBosch et al. 2006; Santini et al. 2007). 
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Figure 1.7: Simplified alternative IGF-1Ea signalling pathway in injured hearts. In animals that 
overexpress IGF-1Ea in the heart, an alternative signalling cascade was identified. IGF-1R binds IGF-
1Ea and transduces the signal through PI3K, PDK1 and SGK1. While PDK1 phosphorylation leads to 
S6 ribosomal subunit activation and protein synthesis, SGK1 induces cell survival signalling. The 
observed effects in vivo include increased expression of anti-inflammatory cytokines pro-inflammatory 
molecules are suppressed (Santini et al. 2007). 
 
PDK1 can directly phosphorylate p70S6K and activate the PI3K dependent kinase SGK1, 
which was shown to regulate cardiomyocyte survival (Pullen et al. 1998; Aoyama et al. 
2005). It has been proposed that many functions attributed to Akt are potentially mediated by 
SGK, which has an inactivating function on Akt, but is a strong contributor to cell survival 
signalling in its own right (Kobayashi and Cohen 1999; Lang and Cohen 2001). In line with 
this, no Akt-PDK1 complex formation in the heart and a downregulation of mTOR was 
observed in uninjured and challenged hearts of IGF-1Ea transgenic mice (Santini et al. 
2007). In contrast, an increase in the levels of phosphorylated PDK1, PDK1-SGK1 complex 
formation and S6 phosphorylation were observed. Taken together, these results indicate that 
in the hearts of mice overexpressing IGF-1Ea, survival signalling is directed by an alternative 
pathway via PDK1 and SGK1 and not via mTOR of the classical pathway. Increased cell 
proliferation was detected in the vessels close to the lesion in IGF-1Ea overexpressing mice 
after MI suggesting that IGF-1Ea may additionally be responsible for the recruitment of 
endogenous EPCs (Santini et al. 2007). In summary, the presented evidence indicates that 
IGF-1, IGF-1Ea and IGF-1Eb are interesting candidates for future approaches to enhance 
cardiac repair after chronic or acute injury. 
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1.5.4 Autophagy 
In addition to the described cardioprotective mechanisms, IGF-1 also modulates autophagy. 
Autophagy is an essential mechanism of normal cell homeostasis, as it regulates the lifetime 
of organelles (predominantly mitochondria) and long-lived proteins and is mediated by 
autophagy-related proteins (Atg). Macromolecules and organelles destined for autophagic 
recycling are enucleated by a double membrane vesicle called phagophore (Figure 1.8, 
reviewed in Mizushima et al. 2003 and Levine and Kroemer 2008). 
 
 
Figure 1.8: Simplified graphic representation of autophagy process. (A) Nucleation of cytosolic 
macromolecules and organelles into the pre-phagophore complex is mediated by Beclin1 and the 
Atg5-Atg12 complex. (B) LC3 conversion and insertion into autophagosomal membrane completes 
autophagosome formation. (C) Fusion of lysosome with the mature autophagosome. (D) Degradation 
of autophagolysosomal contents by lysosomal enzymes. (E) Release of nutrients and breakdown 
products release into the cytoplasm. 
 
Once phagophore assembly is completed, the now mature autophagosome fuses with 
lysosome to give rise to the late autophagolysosome. After degradation of the internalised 
content, the autophagolysosome dissociates and amino acids and other products are 
released into the cytoplasm. Hence it is upregulated during starvation to provide nutrients for 
essential basal protein synthesis (Maiuri et al. 2007). Impaired autophagy results in various 
diseases such as Lafora disease, Fabry disease and heart failure (Tannous et al. 2008; 
Chevrier et al. 2010; Knecht et al. 2010). This highlights the importance of autophagy not 
only as provider of nutrients but also as a cell maintenance mechanism to remove defective 
protein and organelles. Autophagosome assembly starts with the binding of beclin-1 (Atg6) 
to PI3K and p150 to initiate nucleation of the pre-phagophore (reviewed in Petiot et al. 2000; 
Yang et al. 2005). LC3I (Atg8) and Atg 12 are activated in a first step by Atg7 (Noda et al. 
2011). LC3I activation further involves lipidation by covalent cross-linking to 
phosphatidylethanolamine yielding the active LC3II form, which is inserted into the 
autophagosomal membrane (Kabeya et al. 2000). Atg12 is covalently linked to Atg5 by 
Atg10 and this Atg5-Atg12 complex, like LC3II, is essential for autophagosomal membrane 
formation (Shintani et al. 1999). Most Atgs are only required for formation of the 
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autophagosome and LC3II appears to be the only more permanent marker of 
autophagosomal membranes (Kabeya et al. 2000). After fusion with the lysosome, the 
autophagolysosomal contents are degraded by lysosomal hydrolases (reviewed in 
Mitsushima et al. 2007). The resulting breakdown products, such as amino acids, are 
released back into the cytoplasm by molecules called vacuolar effluxers and can be recycled 
(Yang et al. 2006). 
While autophagy is critical for physiological function of post-mitotic tissues, it was shown that 
it needs to be carefully regulated in the heart to support normal cardiac function (Kostin et al. 
2003; Tsujimoto and Shimizu 2005; Tannous et al. 2008). 
 
 
1.6 Researching factors for cardiac protection: Transgenics, global and 
inducible knockout and knockdown mice 
Some of the most ground breaking discoveries of basic molecular mechanisms have been 
made in yeast, bacteria, plants or cell culture. However, for the study of human physiology 
and disease on the organ level, the use of in vivo animal models is indispensable and is a 
main driver of translational research. 
Both IGF-1Ea and Tβ4 have been shown to reduce inflammation, increase myocyte survival, 
reduce scar volume and overall to preserve cardiac function in animal models of ischaemic 
injury. The substantially improved outcome after experimental MI following IGF-1Ea and Tβ4 
supplementation in animals indicates the importance of further examining their mode of 
action to fully understand their function and evaluate potential risks. The animal models used 
in the present study to better our understanding of the function of Tβ4 and IGF-1Ea will be 
described in the next sections. 
 
1.6.1 Global versus tissue specific gene overexpression 
Global gene overexpression in all tissues is achieved in transgenic animals by introducing 
transgenes under promiscuous, often viral promoters such as simian virus 40 (SV40) and 
cytomegalovirus (CMV, Qin et al. 2010). The disadvantage of this approach is that the 
overexpression of genes has different effects in different tissues. The effect of gene 
overexpression in one tissue can affect the tissue of interest for example by paracrine 
signalling, hormone secretion, cell interaction or metabolic changes. To circumvent this 
limitation, the use of tissue-specific promoters to overexpress genes of interest was 
developed. Every tissue has its own specific gene expression profile and the knowledge of 
when promoters are active (for example during which developmental stage) allows for 
precise timing of transgene expression within the tissue of interest. The choice of promoter 
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will also affect how strongly the transgene will be expressed. The myosin heavy chain family 
of proteins, which form the subunit of cardiac myosin, are by weight the most dominant 
contractile protein in vertebrate skeletal and cardiac muscle (Ng et al. 1991). βMHC is 
predominantly expressed in the heart during embryonic development but cardiac aMHC is 
strongly expressed during late gestational stages and throughout postnatal life (Gulick et al. 
1991). The timing of its expression and its cardiomyocyte specificity have made αMHC a 
popular promoter to express transgenes exclusively in ventricular myocardium. For this 
study, two mouse strains expressing transgenes under the control of the αMHC promoter 
were used: αMHC/IGF-1Ea and αMHC/MerCreMer mice. 
 
1.6.2 Global gene knockout 
A global or conventional knockout describes the loss of a gene in every tissue and can be 
achieved by introducing into embryonic stem cells DNA that has a certain degree of 
sequence homology with the region of the target gene, but is lacking vital parts or the full 
gene to be studied (Capecchi 1989). The standard technique involves gene targeting by 
homologous recombination in mouse embryonic stem cells in vitro and subsequent 
introduction of positively selected knockout clones into a mouse embryo at the blastocyst 
stage (Grant and Silva 1994). The introduced cells become part of the host blastocyst and 
this gives rise to chimeric mice which are backcrossed into the strain of interest to purify the 
genetic background. As is true for global overexpression of transgenes, conventional or 
global knockouts suffer the caveat of off-target effects, which can affect observations in the 
tissue of interest. In order to achieve temporally and spatially controllable downregulation of 
genes without these confounding factors, the Cre/loxP system is now frequently used to 
study gene function in physiological and pathological conditions. 
 
1.6.3 The Cre/loxP system 
Complementing global knockouts, cutting edge inducible gene manipulation has found its 
way into the mainstream of basic research. Among the most popular techniques to induce 
genetic modifications in vivo is the Cre/loxP system. Bacterial DNA loxP sequences are 
recognised by Cre recombinase (Enterobacteria phage P1 cyclization recombinase), an 
enzyme derived from P1 bacteriophage (Sternberg and Hamilton 1981; Sauer and 
Henderson 1988). Cre facilitates homologous recombination of DNA at these loxP sites, 
which results in the excision of the flanked sequence and the leading loxP site. The choice of 
promoter driving Cre confines this recombination to a specific tissue or developmental stage. 
Furthermore, expression of Cre can be regulated by external means for example by the use 
of heat inducible promoters. The use of tissue specific Cre driver strains has been a success 
story in mouse research and the European Conditional Mouse Mutagenesis Program Tools 
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for Functional Annotation of the Mouse Genome (EUCOMMTOOLS) is currently developing 
further 500 Cre ES cell lines to stream-line translational research based on the Cre/loxP 
technology. This is part of an international effort to generate thousands of crosses to floxed 
alleles as part of the International Knockout Mouse Consortium (IKMC) program 
(www.knockoutmouse.org, Skarnes et al. 2011). 
 
1.6.4 Cre driver strains: αMHC/MerCreMer mice 
A host of Cre driver strains have been generated in the recent years, allowing for tissue 
specific Cre transgene expression in virtually every organ. As discussed previously the 
αMHC promoter remains one of the most frequently used promoters to achieve transgene 
expression restricted to the cardiac ventricles,. The αMHC/MerCreMer strain (also referred 
to as αMHC/CreERT2) was generated by cloning MerCreMer cDNA into a vector 
downstream of the αMHC promoter (Figure 1.9, Gulick et al. 1991; Zhang et al. 1996). 
 
 
Figure 1.9: Schematic representation of the αMHC/MerCreMer transgene. Not to scale (Sohal et al. 
2001). 
 
MerCreMer refers to a fusion protein consisting of the Cre enzyme core and two flanking Mer 
domains. The mutated oestrogen receptor (Mer) domains were generated by mutating the 
glycine at position 525 of the oestrogen receptor to arginine (G525R), hence abolishing the 
binding of oestrogen/17β-oestradiol (Danielian et al. 1993). Mer binds the synthetic 
oestrogen analogue tamoxifen or its metabolite 4-hydroxytamoxifen with high affinity. 
Fusion-proteins containing Mer domains are restricted to the cytoplasm but upon binding of 
tamoxifen are shuttled to the nucleus in a steroid receptor-like mechanism, comparable to 
ligand-bound oestrogen receptor (Feil et al. 1996; Kocanova et al. 2010). Nuclear exclusion 
of MerCreMer is safeguarded heat shock protein 90 (Hsp90) which binds MerCreMer in the 
cytoplasm (Koitabashi et al. 2009). Upon tamoxifen binding to Mer domains Hsp90 
dissociates from the fusion-protein which can subsequently enter the nucleus. The fusion of 
two Mer domains to the Cre enzyme core instead of one leads to more tightly regulated Cre 
activity (Zhang et al. 1996). To generate the αMHC/MerCreMer strain, transgene DNA was 
injected into pronuclei of fertilised oocytes of FVB mice (Sohal et al. 2001). The FVB 
founders were backcrossed into a C57Bl/6SV129 background and maintained as a C57Bl/6 
strain. 
Chapter 1 - Introduction 
53 
The success of the conditional genomic deletion or knockout can be determined by PCR or 
by investigating the corresponding reduction of mRNA or protein. The time required for 
sufficient reduction of the target gene can vary from 6 days to 4 weeks depending on the 
route of administration and dose of tamoxifen (Kiermayer et al. 2007; Andersson et al. 2010; 
Stokke et al. 2010). Serum tamoxifen peaks 3-6 h following oral administration and 
tamoxifen is rapidly metabolised into its active form 4-hydroxytamoxifen, while the 
predominant metabolite N-desmethyltamoxifen reaches peak levels only after 24-48 h 
following administration (Robinson et al. 1991). Oral administration of 200 mg/kg tamoxifen 
every 24h resulted in tamoxifen accumulation over for 4 days before a plateau was reached. 
For this work, tamoxifen pellets and tamoxifen injections were used at concentrations 
established in previous studies (Welle et al. 2009). 
 
1.6.5 RNA interference-mediated knockdown 
RNA interference (RNAi) is a post-transcriptional regulatory mechanism that was discovered 
in the late 1990s by Andrew Fire and Craig Mello, who were jointly awarded the Nobel prize 
for this work in 2006 (retrieved 22/07/2012, source: 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/2006/press.html/, Fire et al. 
1998). RNAi is a technique that exploits the endogenous double stranded RNA (dsRNA) 
degradation machinery involving an RNase III (Tuschl et al. 1999). Small interfering RNA 
(siRNA) can be directly introduced into the cell or the respective code be inserted into the 
genome depending of the model system. Endogenous small RNA transcripts form larger 
hairpin or stem-loop structure. This is truncated at both the 5‟ and 3‟ ends by the 
endonuclease drosha in the nucleus yielding a so called pre-miRNA (Han et al. 2006). This 
stem-loop pre-miRNA of around 50-60 nucleotides length is cleaved to produce double-
stranded siRNA of ~22 nucleotides length by removal of the loop and is transported to the 
cytoplasm (Elbashir et al. 2001, reviewed in Kim 2005). This process is catalysed by dicer, a 
member RNase III family (Bernstein et al. 2001). This short double- stranded siRNA 
associates with members of the diverse argonaute protein family to form the RNA-induced 
silencing complex (RISC) and simultaneously processed into a single-stranded guide strand 
(reviewed in Parker and Barford 2006). The complementary „passenger strand‟ is degraded 
in the process (Matranga et al. 2005). The role of the guide strand is targeting the correct 
mRNA by Watson-Crick base-pairing of its 5‟ end to the 3‟ UTR of the target (reviewed in 
Martin and Caplen 2007). Once bound to the target mRNA, there are a variety of pathways 
inhibiting the formation of a protein product. For example, a RISC complex containing 
argonaute 2, also referred to as „slicer‟, which has an RNase H-like catalytic domain, is able 
to degrade the target mRNA (Song et al. 2004). This form of post-transcriptional regulation is 
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referred to as knockdown and is clearly distinct from a knockout as it does not affect the 
genome sequence. 
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1.7 Hypothesis 
1. Tβ4 is a molecule of diverse physiological functions that has been shown to improve 
various disease conditions. Given the importance of Tβ4 during embryonic development, the 
increase of endogenous Tβ4 during cardiac injury and the absolute requirement for Tβ4 
during cardiac development, a loss of function in the adult mouse heart was expected to 
potentially have small effects under physiological conditions. I hypothesised that following MI 
Tβ4 depletion would show more significant effects, the nature of which could provide further 
clues about the role of Tβ4 in the heart. 
 
2. Complementary to the analysis of an adult Tβ4 knockdown phenotype in vivo, the 
production of a recombinant Tβ4 molecule in vitro for the use in proteomics was aimed at 
advancing the mechanistic understanding Tβ4 and to identify novel interactors of the peptide 
in the heart. 
 
3. The beneficial effect of IGF-1Ea overexpression or supplementation to the heart following 
experimental MI has been well documented. The subcellular morphology of αMHC/IGF-1Ea 
cardiomyocytes however had not been previously assessed. To gain novel insights into the 
working mechanisms of IGF-1Ea in the heart a transmission electron microscope analysis 
cardiac tissue from αMHC/IGF-1Ea mice was to be performed. 
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Chapter 2 -  Methodology 
 
2.1 Mouse models 
Animal models provide unparalleled insights into disease mechanisms and novel therapeutic 
approaches. In cardiovascular research, animals such as zebrafish, mouse, rat, guinea pig, 
cat, dog and pig are used to study myocardial infarction, heart failure and regeneration (Corr 
et al. 1978; Gao et al. 2010; Guo et al. 2012; Johnson et al. 2012; Jopling et al. 2012; 
Rosenblatt-Velin et al. 2012; So et al. 2012). The plethora of transgenic mice available, their 
ease of breeding, handling and relatively cheap maintenance makes them the favourite in 
vivo tool for developmental and pre-clinical studies. 
 
2.1.1 αMHC/MerCreMer mice 
αMHC/MerCreMer (B6.FVB(129)-Tg(Myh6-cre/Esr1*)1Jmk/J) mice were purchased from 
JAX lab. 
 
2.1.2 Tβ4shRNAflox mice 
Tβ4shRNAflox mice were generated in Paul Riley‟s laboratory at University College London. 
This mouse was created with the aim to downregulate Tβ4 mRNA by RNAi. Tβ4shRNAflox 
mice contain a Tβ4 short hairpin RNA (Tβ4shRNA) transgene with a leading 5T stop 
sequence inhibiting its expression (Smart et al. 2007). The stop sequence is flanked by loxP 
sites and can therefore be removed by Cre recombinase resulting in the expression of 
Tβ4shRNA (Figure 2.1). 
 
 
Figure 2.1: Schematic representation of the Tβ4shRNAflox transgene. Not to scale (Smart et al. 
2007). 
 
By crossbreeding Tβ4shRNAflox mice with a Cre driver strain, expression of the shRNA can 
be induced. In this project, αMHC/MerCreMer mice were crossbred with Tβ4shRNAflox 
animals to allow for controlled knockdown of Tβ4 by inducible expression of the Tβ4shRNA 
(Figure 2.2). 
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Figure 2.2: Cre-mediated excision of genomic inhibitory target sequences in 
Tβ4shRNAflox/MerCreMer mice. MerCreMer fusion protein translocates to the nucleus upon 
tamoxifen administration (top panel). Nuclear MerCreMer recombines DNA at loxP sites, excising the 
inhibitory 5T sequence. This results in the expression of Tβ4shRNA (lower panel). Not to scale (Smart 
et al. 2007). 
 
The pol III promoter driving the expression of the Tβ4shRNA is not tissue specific but the 
αMHC promoter driving MerCreMer fusion protein expression limits recombination to 
cardiomyocytes. Consequently, MerCreMer activation will results in expression of Tβ4shRNA 
and subsequent knockdown of Tβ4 in the cardiac ventricles. 
 
2.1.3 αMHC/IGF-1Ea mice 
Transgenic αMHC/IGF-1Ea mice were generated on the FVB background in Nadia 
Rosenthal‟s laboratory at the EMBL Monterotondo using standard techniques (Figure 2.3, 
(Santini et al. 2007). 
 
 
Figure 2.3: Schematic representation of the αMHC/IGF-1Ea transgene. Not to scale (Santini et al. 
2007). 
 
Briefly, rat IGF-1Ea cDNA was cloned into an expression vector under the control of the 
αMHC promoter. This was achieved by random insertion of the rat IGF-1Ea transgene DNA 
into the genome, as opposed to targeted insertion. 
 
  Chapter 2 - Methodology 
 
58 
2.1.4 Genotyping 
Mice were anaesthetised briefly using 3% (v/v) isofluorane (Merial Animal Health Ltd., 
Harlow, UK). A 5 mm piece of tail was removed and animals marked with numbered metal 
ear tags. Tails were digested at 56 °C overnight in 0.05 mg/mL proteinase K (Roche Applied 
Science, Burgess Hill, UK, # 03115801001). Digested samples were vortexed and 
centrifuged at 16,000 g for 10 min at 4 °C. The supernatant containing the DNA was directly 
used to amplify the relevant transgene DNA by PCR (GeneAmp PCR System 9700, Applied 
Biosystems, Carlsbad, CA, USA).  
The following primers were used: 
 
αMHC/IGF-1Ea 
Sense: 5‟-TTCCTGTCTACAGTGTCTGTG-3‟ 
Antisense: 5‟-GAGCTGACTTTGTAGGCTTCA-3‟ 
 
αMHC/MerCreMer 
Sense: 5‟-AACATTCTCCCACCGTCAGT-3‟ 
Antisense: 5‟-CATTTGGGCCAGCTAAACAT-3‟ 
 
Tβ4shRNAflox 
Sense: 5‟-TGCATGTCGCTATGTGTTCTG-3‟ 
Antisense: 5‟-AAGTCGTGCTGCTTCATGTG-3‟ 
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Table 2.1: Recipes and thermocycler conditions for genotyping PCR. 
Transgene Recipe Thermocycler 
conditions 
Size of 
amplicon 
αMHC/IGF-1Ea 30 μL reactions: 
6 μL Buffer (5x) 
1.2 μL MgCl2 (25 mM) 
0.6 μL dNTP (10mM) 
3 μL IGF-1Ea rev/fw primer 
mix (10μM) 
0.3 μL Taq Polymerase 
17.9 μL ddH2O 
+ 1 μL sample DNA 
 
5 min at 94 °C 
35x   1 min at 94 °C 
 
1 min at 52 °C 
 
20 s at 72 °C 
 
7 min at 72 °C 
 
∞ 4 C 
440 bp 
Tβ4shRNAflox 30 μL reactions: 
6 μL Buffer (5x) 
1.2 μL MgCl2 (25 mM) 
0.6 μL dNTP (10mM) 
3 μL Tβ4shRNAflox rev/fw 
primer mix (10μM) 
0.3 μL Taq Polymerase 
17.9 μL ddH2O 
+ 1 μL sample DNA 
 
5 min at 94 °C. 
35x   1 min at 94 °C 
 
1 min at 60 °C 
 
20 s at 72 °C 
 
7 min at 72 °C 
 
∞ 4 C 
703 bp 
αMHC/MerCreMer 25 μL reactions: 
5 μL Buffer (5x) 
2 μL MgCl2 (25 mM) 
0.5 μL dNTP (10mM) 
1 μL Cre rev/fw primer mix 
(10μM) 
0.2 μL Taq Polymerase 
14.3 μL ddH2O 
+ 1 μL sample DNA 
 
5 min at 95 °C 
30x   30 s at 95 °C 
 
45 s at 56 °C 
 
45 s at 72 °C 
 
7 min at 72 °C 
 
∞ 4 C 
350 bp 
Buffer, MgCl2, taq polymerase and dNTP were purchased from Promega, Southampton, UK 
(# M8306 and U1240). 
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PCR products were electrophoresed at 100 V (PowerPac300, Bio-Rad Laboratories, Hemel-
Hempstead, UK) on 2% (w/v) agarose gels prepared using 1X TAE buffer (0.4 M, 10 mM 
EDTA) containing 10 µL/mL ethidium bromide. Gels were analysed using GeneSnap v7.07 
software and a SynGene ChemiGenius2 gel documentation system (SynGene, Cambridge, 
UK). 
 
Figure 2.4: Agarose gel (2%) gels of genotyping PCR products. (A) Lane 1 shows results for a wt 
mouse with a faint aspecific band at ~350 bp. Lane 2 shows the characteristic band at 440 bp for a 
IGF-1Ea transgenic animal. (B) PCR results for MerCreMer (top panel) and Tβ4shRNAflox (lower 
panel) transgenes of various genotypes. Lanes 1 and 2: MerCreMer, Lane 3: wt, Lane 4: 
Tβ4shRNAflox/MerCreMer-double transgenic (faint), Lane 5: Tβ4shRNAflox (faint), Lane 6: double 
transgenic positive control and Lane 7: wt negative control. A 1 kb molecular weight marker 
(Invitrogen, Carlsbad, CA, USA, # 10787-018) was used as reference. 
 
2.1.5 Experimental MI: Left anterior descending coronary artery ligation 
Ligation of the left anterior descending coronary artery (LCA) is the most accurate model of 
MI in animals and is used from large mammals, such as pig and dog to small animals, such 
as rat and mouse (Podzuweit et al. 1981; Richeson et al. 1982; Salto-Tellez et al. 2004). LCA 
ligation in mice was first developed in 1995 and has since been constantly developed further 
to increase reproducibility and experimental outcome as well as to improve animal welfare by 
decreasing the duration of surgery and unnecessary trauma (Michael et al. 1995). More 
recently, models of ischaemia-reperfusion have increased in popularity since they reflect 
today‟s clinical practice of re-establishing blood supply through the affected coronary vessel 
by PCI and stent (Ellison et al. 2011). For the present work, the simpler and more time 
effective standard experimental MI was chosen over ischaemia-reperfusion. 
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2.1.6 Mouse model of myocardial infarction: Left anterior descending coronary 
artery ligation 
The left anterior descending coronary artery (LCA) ligation protocol described by Salto-Tellez 
and colleagues was used with some significant improvements especially regarding the 
intubation technique (Salto-Tellez et al. 2004). Mice between 3 and 4 month of age were 
weighed and then anaesthetised in a small animal induction chamber using 4% (v/v) 
isofluorane (Merial Animal Health Ltd., Harlow, UK). After approximately 4 min, depth of 
anaesthesia was sufficient to proceed with intubation. The non-invasive intubation technique 
developed by Hamacher and co-workers was the preferred option over the commonly used 
tracheotomy (Hamacher et al. 2008). Mice were removed from the induction chamber and 
hung on a self-built stand by passing a suture under their incisor teeth. A fibre optic light was 
placed in front of the throat to illuminate the larynx. The tongue was retracted using 
atraumatic forceps to reveal clear view on the trachea with the characteristic epiglottal 
opening and closing motion visible during each breath. A 25 G wire guide was inserted into 
the trachea and the intubation cannula carefully slid over the wire into the trachea. After 
removing the guidewire, the animal was placed in a supine position and connected to a small 
animal respirator (MiniVent Type 845 microrespirator, Harvard Apparatus, Hollston, MA, 
USA). The respirator was set to 200 μL stroke volume at 110 strokes per minute. Both front 
paws were taped to the working surface and the chest was shaved. Prior to the first incision, 
the animals were injected subcutaneously with 0.002 mg of analgesic buprenorphine 
(Vetergesic®, Reckit Benckiser Healthcare UK Ltd., Hull, UK). A single 15 mm incision in 
parallel to the sternum was made into the skin covering the left lower quadrant in the area 
covering the 3rd intercostal space. The left pectoralis major muscle and lower muscle layers 
were retracted to allow access to the 3rd intercostal space. Blunt forceps were used to tear 
the tissue between the 3rd and the 4th ribs. Particular attention was paid to avoiding damage 
to the lower side of the ribs, which are lined with blood vessels and nerves. Four retractors 
were used to retract the 3rd and 4th rib and permit access the thoracic cavity. The pericardium 
was carefully opened to provide adequate exposure of the heart. The LCA was identified with 
the aid of a Leica S6E microscope at 8x magnification (Leica Microsystems, Milton Keynes, 
UK). A 8/0 polyamide suture (Ethicon, Johnson & Johnson, Brussels, Belgium) was passed 
underneath the LCA, through the myocardium and carefully tightened in a double-double 
square knot to restrict blood supply to the lower left ventricle. The success of the ischemia 
was controlled by observing blanching of the lower left ventricle. The pericardium was 
allowed to slide back into its original position and the retractors were removed. The 
intercostal space was closed by two non-continuous sutures using non-absorbable 6/0 
polypropylene suture material (Ethicon, Johnson & Johnson, Brussels, Belgium). Previously 
retracted muscles were pushed back in their native position and the skin was sutured using 
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the 6/0 polypropylene material. Isofluorane delivery was terminated and animals kept on pure 
oxygen until independent breathing was setting in. Following LCA ligation animals had 
access to wet diet and were allowed to recover in a 30 °C incubator overnight. Additional 
injections of pain relief were administered as described above, 6 hours following the 
procedure and optionally the next morning if signs of pain and distress were observed. 
Extent of infarct was assessed by Echocardiography (ECHO) (Figure 2.5). 
 
 
Figure 2.5: ECHO traces of mouse heart after coronary artery ligation. M-mode ECHO recordings of 
mouse heart 1 month following LCA ligation (left panel) and under physiological conditions (right 
panel). 
 
Histology was used to investigate tissue remodelling and fibrosis after 1 month (Figure 2.6). 
 
 
Figure 2.6: Left-descending coronary artery ligation in mice. Masson‟s Trichrome staining of mouse 
heart 1 month following coronary artery ligation (left panel) and normal heart (right panel). 
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2.2 Conditional knockdown of Thymosin β4 
Double transgenic Tβ4shRNAflox/MerCreMer mice were treated with tamoxifen to induce 
nuclear localisation of MerCreMer and subsequent excision of an inhibitory sequence flanked 
by loxP sites. This was aimed to induce Tβ4shRNA expression and subsequent 
downregulation of Tβ4 mRNA (see Chapter 3). 
 
2.2.1 Tamoxifen delivery 
Choosing the appropriate method of tamoxifen delivery to mice carrying the MerCreMer 
transgene is essential to ensure sufficient abundance of MerCreMer in the nucleus for long 
enough to allow successful recombination of targeted loxp sites with minimal impact on 
general health and homeostasis. Tamoxifen can be delivered via diet, drinking water or by IP 
injections (Gail et al. 1999; Andersson et al. 2010). With the aim to avoid unnecessary 
distress for the animals, I initially opted for tamoxifen delivery via diet. This avoided handling 
and restraining the animals as for gavage (delivery in drinking water) or IP injections. IP 
injections were later used after unexpected problems arose from feeding tamoxifen chow as 
described in Chapter 3. 
Tamoxifen delivery via diet: Normal chow was replaced by tamoxifen containing (0.025% 
w/w) chow (Harlan Laboratories, Horst, The Netherlands, # TD.110069) for two weeks. 
Nuclear translocation was assessed immediately after two weeks by immunofluorescence 
analysis for Cre on cardiac sections. To avoid any potential transient side effects of 
tamoxifen, experimental outcome of knockdown was assessed after additional two weeks 
recovery. 
Tamoxifen delivery via IP injections: Tamoxifen (Sigma-Aldrich, Gillingham, UK, # T5648) 
was dissolved in 100% Ethanol to a concentration of 100 mg/mL. It was then further diluted 
1/10 in soybean oil (Sigma-Aldrich, Gillingham, UK, # S7381) to a final concentration of 10 
mg/mL. Animals were manually restrained and injected IP in the lower left quadrant of the 
abdomen to reduce the risk of unintentional damage to the liver. Tamoxifen was delivered at 
20 mg/kg daily over five consecutive days or as a single injection of 40 mg/kg. Control 
injections consisted of pure EtOH diluted in soybean oil at identical concentration. Animals 
were rested for 4-11 weeks before assessment of experimental outcomes. 
 
 
2.3 Echocardiography 
Cardiac function of mice was determined by echocardiography (ECHO). Several different 
ultrasound-based techniques such as transthoracic, transoesophageal and epicardial surface 
ECHO and intravascular, transjugular or transperitoneal ultrasound are available for small 
animal research. The latter 4 techniques have the disadvantage of being invasive. 
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Transthoracic ECHO was shown to be the best approach in terms of procedure and 
temporal/spatial resolution to permit the most accurate estimation of cardiac function in the 
mouse (Gardin et al. 1996). 
 
2.3.1 Transthoracic echocardiography 
Cardiac function was assed using a Siemens Acuson Sequoia 256 workstation and a 14.0 
MHz 15L8-S transducer (Siemens Healthcare, Camberley, UK). Aqueous ultrasound gel 
(Ana Wiz, Hersham, UK, # UGEL250) was pre-warmed to 37 °C to increase signal 
transduction and prevent hypothermia of the mice. Low level of anaesthesia was induced in 
the mice using 3% (v/v) isofluorane in oxygen and further maintained at 1.5% (v/v) 
isofluorane via facemask. The animals were placed in a supine position on a heated pad to 
maintain a stable body temperature and the thorax was shaved from the sternum to the left 
side, from the lowest rib to the left axilla and commercially available hair removal cream was 
used to remove residual hair. A thin layer of ultrasound gel was applied on the shaved area 
and a generous amount was placed on the probe before commencing the measurement. 
Short axis view measurements were obtained with treatment and genotype blind to the 
investigator. Traces were recorded at least in duplicate over consecutive days and results 
averaged. This was aimed at eliminating user bias and reducing variation. The term “short 
axis” refers to measuring the lumen of the left ventricle at an angle parallel to the base of the 
heart. Long axis refers to measurements taken along the axis from the tip of the apex to the 
base of the heart (Figure 2.7). 
 
 
Figure 2.7: Schematic representation of echocardiography axes. Short axis and long axis ECHO 
planes are indicated by the dashed lines. 
 
Left-ventricular ejection fraction (EF) and fractional shortening (FS) were determined. EF 
refers to the fraction of blood volume that is ejected during systole (stroke volume) in relation 
to the maximum cardiac volume during diastole. M-mode and two-dimensional (2D) mode 
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measurements were performed at a sweep speed of 150 mm/s. Before continuing with data 
analysis, residual ultrasound gel was removed, animals were allowed to recover from 
anaesthesia and placed back in their cages. The analysis of M-mode traces was performed 
by manually measuring the anterior wall thickness, lumen of the LV and the thickness of the 
posterior wall using the ECHO workstation. LV EF and FS were calculated using the 
formulas shown in below. 
 
Short axis M-mode: 
 
EF = [(end-diastolic3 – end-systolic3)/end-diastolic3] x 100 (%) 
 
FS = [(end-diastolic – end-systolic)/end-diastolic] x 100 (%) 
 
Left-ventricular inner diameters during systole and diastole (LVIDs/d) were also determined 
from M-mode ECHO traces. EF measured in 2D-mode provides more accurate results and is 
the method of choice to measure cardiac function in human patients. This is attributable to 
the fact that in a two-dimensional measurement only one dimension has to be interpolated, 
whereas in M-mode, a linear measurement is used for volume calculations (two dimensions 
interpolated). This mathematical caveat and the increased susceptibility to measuring 
inaccuracies (e.g. accidental offset from the correct measuring line or angle) indicate that 
where possible 2D EF measurements should be preferred over M-mode analysis. 
Measurements obtained in 2D-mode were analysed by manually delineating the inner and 
outer boundaries of the left-ventricular myocardium. Ejection fraction and fractional 
shortening were calculated using the formula indicated below. 
 
Short axis 2D-mode: 
 
EF = [(end-diastolic area – end-systolic area)/end-diastolic area] x 100 (%) 
 
Calculation of 2D EF using the area method, as described above, is reasonably accurate but 
less accurate than using end-diastolic/systolic volumes (Wisneski et al. 1981). Determination 
of 2D EF using the volume method was not available during this study due to technical 
limitations of the ultrasound equipment. 
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2.4 Tissue harvesting from mice 
Mice were weighed, anaesthetised using 4% (v/v) isofluorane and placed in a supine position 
on the procedure surface. Ventilation with isofluorane was maintained via facemask. 
Sufficient depth of anaesthesia was controlled by monitoring responsiveness to pain. A semi-
lunar shaped incision was made into the peritoneal cavity of the mouse using a scissor. 
Intestines and fat tissue were carefully pushed out of the peritoneal cavity to the left using a 
cotton bud. Great care was taken not to damage the digestive organs to prevent bacterial 
contamination of the area. Following this step, the inferior vena cava (IVC) was identified 
proximal to the right kidney. A 25 G needle was used to slowly draw up to 1 mL of blood from 
the IVC just above the point where it gives rise to the right renal vein. The blood was 
transferred to a Vacutainer tube (Fisher Scientific, Loughborough, UK, # VCT-090-050W). 
The syringe was briefly rinsed and then filled with PBS. Two incisions were made through the 
rib cage left and right of the sternum. The sternum was folded back over the head of the 
mouse. The IVC and abdominal aorta were severed to allow drainage of blood and buffer 
following the injection of 0.5 to 1 mL of PBS into the left ventricle. Transcardiac flushing was 
performed slowly and carefully to avoid overstretching of the left ventricle to avoid tissue 
damage. This had to be prevented to maintain structural integrity and to avoid molecular 
changes in response to overstretching potentially causing interference during subsequent 
RNA expression analysis. The heart was carefully removed from the thorax without 
damaging it with the scissors and without applying excessive pressure on the myocardium 
with the forceps. It was then placed in a dish with PBS and allowed to further purify itself from 
any residual blood by on-going contractions. The heart was then carefully blotted dry on a 
tissue, atria removed and cardiac mass recorded. It was then placed back into the dish 
containing PBS (4 °C) and dissected with a scalpel. The dissection pattern used to ensure 
tissue availability for all required analyses is shown in Figure 2.8. 
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Figure 2.8: Schematic depiction of the mouse heart dissection pattern used. To obtain samples for 
most standard applications from a single specimen, hearts were dissected into 5 pieces as indicated in 
the cartoon above. Formal saline-fixed tissue was used for immunohistochemistry and histological 
staining, the OCT embedded ring for cryosections, the PFA fixed specimen of the left ventricle for 
electron microscopy analysis and each half of the lower ventricles for protein and RNA isolation 
respectively. 
 
Tissue samples for the study of RNA and protein composition were minced carefully to 
remove any residual blood, placed in 2 mL microcentrifuge tubes and frozen immediately in 
liquid nitrogen. Samples destined for paraffin embedding and transmission electron 
microscopy (TEM) analysis were placed in a 2 mL tube containing formal saline and 4% (w/v) 
paraformaldehyde (PFA) in 0.2 M phosphate buffer respectively and stored at 4 °C overnight 
to allow for sufficient crosslinking. 0.2 M phosphate buffer consisted of aqueous mono 
(NaH2PO4 * H2O) and di-basic (Na2HPO4 * 2 H2O) phosphate buffers adjusted to pH 7.2. 
Formal saline and PFA was replaced by 0.2 M phosphate buffer after overnight incubation at 
4 °C. To preserve tissue for immunofluorescence staining of cryosections, a small ring of 
cardiac tissue from the middle of the heart was placed in a square mold containing sufficient 
OCT compound to cover the sample. This was followed by immediate freezing in liquid 
nitrogen. Quick freezing of OCT embedded samples prevents formation of tissue-damaging 
ice crystals which appear during slow freezing on dry ice. In addition to cardiac samples, four 
1 cm pieces of tail were removed in addition. Three pieces were stored in -80 °C freezers for 
future DNA isolation and the remaining piece was used for re-genotyping the animals after 
sacrifice, as described in Section 2.1.4. Lungs and livers were dissected, blotted dry and 
weights recorded. 
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2.5 Protein biochemistry 
Investigation of cardiac protein composition is important to understand how altered mRNA 
expression profiles translate into changes on the protein level. 
 
2.5.1 Protein extraction 
Tissue samples destined for protein isolation stored at -80 °C were kept on dry ice prior to 
isolation. 1x RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA,  1 mM 
EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin) containing 1x DTT (1.25 M, Cell 
Signaling, Danvers, MA, USA, # 9806) and a cocktail of protease and phosphatase inhibitors 
(Roche Applied Science, Burgess Hill, UK, # 11206893001, 04906845001) was prepared 
following manufacturer‟s instructions. The whole isolation procedure was carried out on ice to 
prevent degradation or dephosphorylation of proteins. The tissue sample was transferred into 
a glass homogeniser, 300 μL RIPA buffer were added and the sample homogenised by 
rotating the pestle while carefully sliding it in and out of the glass shaft. Homogenised tissue 
suspension was transferred to a fresh 1.5 mL tube on ice and further disrupted by three brief 
continuous pulses (~1 s each) at 90 W using a Vibra Cell sonicator (Sonics & Materials, 
Newtown, CT, USA). The samples were centrifuged at 16,000 g for 20 min in a pre-cooled (4 
°C) microcentrifuge (Heraeus, Osterode, Germany) to pellet insoluble tissue fragments and 
cellular debris. The supernatant was transferred into a fresh 1.5 mL tube. After protein 
quantification, aliquots of known concentrations were prepared and the stock samples stored 
long term at -80 °C. 
 
2.5.2 Protein quantification 
Proteins were quantified using the DC protein assay following manufacturer‟s instructions 
(Bio-Rad Laboratories, Hemel-Hempstead, UK, # 500-0116). The colorimetric quantification 
kit is an improvement of the classical Lowry assay, which is based on Folin reduction (Lowry 
et al. 1951). This is achieved in a two-step reaction: protein samples are exposed to copper 
in an alkaline solution before Folin is added and subsequently reduced (loss of 1-3 oxygen 
atoms) by the protein-copper complexes. This results in a colour shift to blue with a peak 
absorbance at 750 nm (Peterson 1979). The amount of Folin reduced in the reaction is 
proportional to the quantity of protein available and hence allows absorbance values to be 
related to protein concentration. A standard curve was prepared from a bovine serum 
albumin (BSA) sample of known concentration. Concentrations used are displayed in Table 
2.2. 
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Table 2.2: Generation of a standard curve for quantification of unknown protein samples by DC 
protein assay. BSA protein concentrations for each of the 9 data points are indicated. 
mg/mL 
BSA final 
0 0.2 0.4 0.6 0.8 1.0 1.2 1.6 2.0 
BSA 
(2mg/mL) 
0 5 10 15 20 25 30 40 50 
ddH2O 50 45 40 35 30 25 20 10 0 
 
Protein samples from larger pieces of cardiac tissue were highly concentrated and could 
therefore not be measured directly, since absorbance values would exceed the linear range 
of the standard curve. Consequently samples were diluted 1/10 in ddH2O before 
measurement. To allow for automated evaluation of the absorbance using a µQuant 
microplate reader (Bio-Tek Instruments, Potton, UK), 5 μL of the BSA dilutions for the 
standard curve as well as the 5 μL of each sample were pipetted in separate wells of a 96-
well cell culture plate. Following the manufacturer‟s instructions, 25 μL solution A/S (alkaline 
copper tartrate solution; consisting of 1mL reagent A and 20 µL reagent S) and 200 μL 
solution B (Folin reagent) were added to each well. After 15 min incubation in the dark the 
absorbance at 750 nm was stable for at least 1h. Samples were measured in duplicate to 
correct for pipetting errors. Absorbance measurements for the each standard were plotted 
against their know concentration and the slope m and the intersection with the y-axis b of the 
linear regression line calculated by MS Excel (Microsoft, Reading, UK). 
 
Formula of a linear function: 
 
f(x) = m * x + b 
 
By inserting the measured absorbance f(x) for each sample into the formula, it was possible 
to deduct the concentration x for each sample. The coefficients of determination R2 were 
calculated in MS Excel and were consistently >0.99 indicating a good fit of the data points 
with the linear regression meaning that it is highly likely to get correct predictions from the 
regression line (Figure 2.9). 
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Figure 2.9: Example of a standard curve used for protein quantification. DC protein assay was used to 
determine absorbance at 750 nm of BSA samples of known concentrations. The absorbance of each 
protein concentration was assayed in duplicate and averaged. The coefficient of determination R
2
 is 
indicated. 
 
 
2.6 Protein immunoblotting 
The protein immunoblot was developed in 1981 in the Laboratory of W. Neal Burnette and is 
also known as Western blot in reference to Edwin Southern and his Southern blot (Burnette 
1981). Protein samples to be analysed were quantified (see Section 2.5.2), diluted to a 
standard concentration and combined with reducing SDS sample buffer (1X SDS sample 
buffer final, 1X DTT final, Cell Signaling, Danvers, MA, USA, # 7722). The protein solution 
was boiled at 95 °C for 5 minute to denature the proteins and briefly centrifuged to collect 
vapour droplets. After boiling, the samples were stored at -20 °C or immediately loaded onto 
a 1D polyacrylamide gel. 
 
2.6.1 Western blotting procedure for normal sized proteins 
Electrophoresis acrylamide gels were self-made for proteins >10 kDa. A commercially 
available 30% solution of acrylamide mix (29:1) with the cross-linker bis-acrylamide (Bio-Rad 
Laboratories, Hemel-Hempstead, UK, # 161-0157) was used. The volume percentage of 
acrylamide and cross-linker in the total volume determines the pore size of the gel with 
higher total percentages resulting in smaller pore sizes in the gel. Consequently, lower 
percentage gels (≤ 10%) were used to analyse proteins of higher molecular weight, while 
higher percentage gels (≥ 12%) were used to achieve better separation of smaller proteins. 
Table 2.3 shows the recipes used for the preparation of the resolving/separation gels. 
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Electrophoresis and transfer were carried out using a BioRad Mini-PROTEAN® system (Bio-
Rad Laboratories, Hemel-Hempstead, UK, # 165-8000, 165-8004). 
 
Table 2.3: Recipe list for most common concentrations of bis-acrylamide resolving gels used for 1D 
protein electrophoresis. The volumes indicated (5 mL total) are sufficient for 1 gel in a 0.75 mm cast. 
 Percentage of bis-acrylamide gels 
Components 10% 12% 15% 
ddH2O 1.9 mL 1.6 mL 1.1 mL 
Acrylamide mix 
(30%) 
1.7 mL 2.0 mL 2.5 mL 
1.5 M Tris (pH 8.8) 1.3 mL 1.3 mL 1.3 mL 
SDS (10%) 50 mL 50 µL 50 µL 
TEMED 2 µL 2 µL 2 µL 
Ammonium 
persulfate 
50µL 5 µL 5 µL 
 
The components were added to a 15 mL tube in the order displayed. Ammonium persulfate 
(APS) and tetramethylethylenediamine (TEMED, Bio-Rad Laboratories, Hemel-Hempstead, 
UK, # 161-0700, 161-0801) catalyse the polymerisation of acrylamide and were added 
immediately before the gel was poured into the cast. The solution was transferred into the 
cast using a 5 mL serological pipette. The cast was filled to approximately 2 cm below the 
top to keep sufficient space for the stacking gel. The surface of the gel was covered with 
100% EtOH to level the surface as well as to prevent it drying from drying. The gel was 
allowed to polymerise for 15 min before the EtOH cover layer was removed. In the meantime 
the stacking gel was prepared in a 15 mL plastic tube according to the recipe shown in Table 
2.4. 
 
Table 2.4: Recipe list for bis-acrylamide stacking gel used for 1D protein electrophoresis. Volumes 
indicated (1 mL total) are for sufficient for 1 gel in a 0.75 mm cast. 
Components 5% bis-acrylamide gel 
ddH2O 0.68 mL 
Acrylamide mix (30%) 0.17 mL 
1.5 M Tris (pH 8.8) 0.13 mL 
SDS (10%) 10 µL 
TEMED 1 µL 
Ammonium persulfate 10 µl 
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Using a 5 mL serological pipette the stacking gel was transferred into the remaining space of 
the cast and the comb was carefully inserted in the top. The gel was allowed to polymerise, 
stored for several days at 4 °C or used immediately for 1D separation of proteins. 
1D gel electrophoresis: The gel was assembled into the Bio-Rad system and placed inside 
the buffer reservoir which was then filled with 1x electrophoresis tank buffer (25 mM tris 
base, 0.192 M glycine, 0.1% (v/v) SDS). Boiled protein solution was pipetted into the wells 
leaving one well for running a pre-stained molecular weight marker (Invitrogen, Carlsbad, 
CA, USA, # LC5800). Samples were electrophoresed at 150 V (PowerPac300, Bio-Rad 
Laboratories, Hemel-Hempstead, UK) at RT until the running dye reached to lower bottom of 
the gel. 
Protein transfer: The gel was removed from the system and placed onto 0.45 µm pore size 
nitrocellulose membrane (Bio-Rad Laboratories, Hemel-Hempstead, UK, # 162-0150). Gel 
and membrane were placed into a transfer cassette between 2 layers of Whatman 3 MM Chr 
chromatography paper (Thermo Fisher Scientific, Loughborough, UK, # CJF-500-050X) and 
a fibre pad on each side (Figure 2.10). The transfer cassette was then inserted between 
anode and cathode of the Mini Trans-blot Cell Electrophoretic Transfer Cell (Bio-Rad 
Laboratories, Hemel-Hempstead, UK, # 170-3930) with the nitrocellulose membrane located 
between the gel and the anode. 
  
 
Figure 2.10: Assembly of the transfer cassette. The gel and nitrocellulose membrane were placed 
between 2 layers of chromatography paper. The resulting stack was placed between filter pads and 
secured in the transfer cassette (Bio-Rad Laboratories [Internet], Hercules, CA, Mini Trans-Blot® 
Electrophoretic Transfer Cell Instruction Manual, ©2011, Cited 27/02/2012, Available from: 
http://www.bio-rad.com/webroot/web/pdf/lsr/literature/M1703930.pdf). 
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The buffer tank was filled with transfer buffer (Tris base 25 mM, 0.192 M glycine, 15% (v/v) 
MEOH) and the protein transferred to the nitrocellulose membrane at 100 V for 2 h at 4 °C. 
Blocking: To prevent aspecific binding of the primary antibody, membranes were blocked in 
5% (w/v) BSA blocking solution (TBS-T, 50 mM tris, 150 mM NaCl, 0.1% (v/v) Tween, pH 8) 
for 1 h at RT. 
1° antibody: The membrane was incubated overnight at 4 °C in 5 mL of 5% (w/v) BSA 
blocking solution containing the primary antibody (concentrations dependent on antibody 
specificity). 
1st washing: After overnight incubation the membrane was washed twice in 1X TBS-T (0.1%) 
for 5 min at RT. 2° antibody: Secondary antibodies targeting the Fc portion of the respective 
primary antibody were used at a dilution of 1:2000 in 5% (w/v) milk blocking solution. The 
membrane was incubated for 1 h at RT. 2nd washing: The membrane was washed twice in 
1X TBS-T (0.1%) for 15 min at RT. 
Following the second wash, the membrane was incubated in ECL for 5 min and exposed to 
Amersham Hyperfilm ECL in a darkroom (GE Healthcare, Little Chalfont, UK, # 28-9068-37). 
Quantification of band intensity was performed using ImageJ 1.45S. 
 
2.6.2 Western blotting procedure for small proteins and peptides 
Proteins smaller <10 kDa were resolved using commercially available Tris-Tricine gradient 
gels ranging from 10-20% (Bio-Rad Laboratories, Hemel-Hempstead, UK, # 456-3114). The 
electrophoresis procedure was performed as described in the previous section with some 
deviations. During electrophoresis, two different buffers were used: anode buffer (0.2 M tris, 
pH 8.9) and cathode buffer (0.1 M tris base, 0.1 M tricine, 1% (v/v) SDS). The cathode buffer 
was placed inside the inner reservoir between two gels (or a gel and a buffer dam) and the 
anode buffer filled in the outer reservoir. The samples were electrophoresed for ~1 h 45 min. 
The transfer setup was used as described above using a modified transfer buffer (25 mM tris 
base, 0.192 M glycine, 40% v/v MeOH). Increased MeOH concentrations promote small 
peptide transfer to the membrane. Blotting and development were carried out as described in 
Section 2.6.1. 
 
 
2.7 RNA extraction 
Extraction of RNA from cells or tissues requires two steps: disruption and homogenisation 
(QIAGEN Ltd [Internet], Hilden, RNeasy® Mini Handbook 09/2010, ©2003-2012, Cited 
27/02/2012, Available from: www.qiagen.com/literature/render.aspx?id=352). Disruption is 
necessary to release the RNA by breaking down tissue and cell/organelle membranes and 
has to occur immediately after the sample is removed from ice to expose the RNA to 
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protective buffers. Homogenisation is required to reduce viscosity of the sample by shearing 
DNA and other high-molecular-weight cell components to allow optimal binding of the RNA to 
the column during purification. 
 
2.7.1 RNA isolation from cells 
In a fume cabinet TRIzol reagent (Invitrogen, Carlsbad, CA, USA, # 15596-026) was added 
to the wells of cultured cells: 500 µL/well for 12 well plates and 1 mL/well for 6 well plates. 
Cells were mechanically disrupted and detached by scraping the wells with a bent pipette tip 
and the suspension transferred to a 2 mL centrifuge tube. For isolation from pelleted cells, 
TRIzol reagent was directly added to the cell pellet and the suspension transferred to a 2mL 
tube. To assist homogenisation and to shear released genomic DNA, the suspension was 
passed ten times through a 23 G syringe needle before storage at -80 °C or immediate 
processing. 200 µL chloroform for each mL TRIzol used were added and the samples 
incubated for 3 min at RT before 15 min centrifugation at 16,000 g at 4 °C. This separates 
the protein debris, the organic phase, the DNA containing interphase and the RNA containing 
aqueous phase. The latter was transferred to a new 2 mL centrifuge tube. 0.56 volumes of 
EtOH (100%) were added and the solution and any precipitate were transferred to an 
RNeasy Mini spin column. RNA isolation was performed according to the manufacturer‟s 
protocol using the RNeasy Mini Kit (QIAGEN, Crawley, UK, # 74104) including optional 
DNase I (QIAGEN, Crawley, UK, # 79254) treatment to remove contaminating DNA. This 
isolation procedure is based on ion exchange chromatography. By varying the pH and/or salt 
concentration in the buffers, RNA is either bound or released from the silica membrane. 
Small RNAs (< 200 bp) such as miRs are lost during this procedure. 
 
2.7.2 RNA isolation from tissue 
Frozen tissue was placed in RLT lysis buffer (1% (v/v) β-ME) and disrupted by use of a rotor-
stator homogeniser (Polytron PT 2500 E), which achieves tissue/cell disruption and 
homogenisation simultaneously by fluid turbulence and mechanical shearing. Samples were 
loaded on QIAshredder columns (QIAGEN, Crawley, UK, # 79654), centrifuged for 2 min at 
16,000 g to further disrupt any remaining cellular components. The tissue lysates was 
enzymatically digested by adding 1 mL proteinase K (0.35 mg/mL, Roche Applied Science, 
Burgess Hill, UK, # 03115879001) and incubation at 55 °C for 10 min. Digested proteins and 
cellular debris were pelleted by centrifugation at 16,000 g for 3 min and 1.5 µL of supernatant 
transferred to a 2 mL centrifuge tube. 1 mL EtOH was added and the sample (including 
precipitates) transferred to an RNeasy Mini spin column. Downstream purification was 
performed using an RNeasy mini kit (QIAGEN, Crawley, UK, # 74104) including optional 
DNase I digestion, as described in section 2.7.1. 
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2.7.3 RNA quantification and quality control 
After RNA elution in nuclease-free H2O, RNA aliquots were diluted in Tris-EDTA buffer (TE, 
100 mM tris-HCl, 10 mM EDTA, pH 8.0). Shifting to this slightly alkaline pH increases the 
ability to detect protein contamination by photospectrometry (Wilfinger et al. 1997). When a 
low yield was expected e.g. after isolation from cells in culture with eluent volumes of 35 μL, 
5 μL RNA solution were diluted in 55 μL TE buffer. If larger yields were anticipated e.g. in 
tissue-derived preparations, RNA was eluted in 50 μL H2O and 1 μL RNA was added to 59 
μL TE for measurement. After blanking against 60 μL TE, the light absorbances of the diluted 
samples were measured in a UVette plastic cuvettes (Eppendorf, Cambridge, UK, # 0030 
106.318) over a spectrum of wavelengths using a photospectrometer (BioPhotometer plus, 
Eppendorf, Cambridge, UK). At 260 nm wavelength, the linear range for accurate 
quantification is A260 = 0.10-1.0. In TE, the ratio between the absorbance measured at 260 
nm and 280 nm (A260/A280) should ideally range between 1.9 and 2 to indicate good sample 
purity. Depending on the sample type (specific cell lines/tissues etc.) and on the buffer pH 
the actual A260/A280 value can be slightly higher or lower. Contaminating proteins and some 
chemicals such as phenol absorb light at a wavelength of 230 nm. A260/A230 ratios >1.7 
indicate sufficient purity of RNA from these contaminants. The concentration of RNA in the 
sample was determined by applying the Beer-Lambert law. 
 
Beer-Lambert law: 
 
A  = ε * c * l 
 
A = Absorbance 
ε = Extinction coefficient 
c = Concentration 
l = Path length (of the cuvette) 
 
The extinction coefficient of RNA (εRNA) is 0.025 mg/mL
-1cm-1. Consequently the 
concentration of RNA (cRNA) can be calculated by the following formula considering that l = 1 
cm. 
 
cRNA = 40 µg/mL * A260 * dilution factor 
 
Following quantification, RNA samples were either stored at -80 °C or immediately used for 
complementary DNA (cDNA) synthesis (Section 2.8.1). 
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2.8 mRNA copy number analysis 
The most robust and widely used technique to study mRNA transcript abundance in whole 
organs, tissues or specific cells is real-time polymerase chain reaction (rtPCR). As the name 
indicates, this technique is based on specific sequence amplification by PCR. To achieve 
this, two separate reactions are required. First, the mRNA sequence needs to be reversely 
transcribed into complementary DNA (cDNA). This process is non-specific, meaning that a 
cDNA copy is generated for every polyadenylated strand of RNA present. cDNA is 
synthesised by the commercial enzyme Multiscribe® Reverse Transcriptase which is a 
recombinant protein derived from Moloney murine leukaemia virus reverse transcriptase 
(Stoye and Coffin 1987), Applied Biosystems [Internet], Carlsbad, CA, TaqMan® Reverse 
Transcription Reagents, © 2012, Cited 16/04/2012, Available from: 
http://products.invitrogen.com/ivgn/product/4304134?ICID==Search-Product). The relative 
quantity of a particular cDNA can be determined by rtPCR using a highly expressed internal 
standard, such as 18S ribosomal subunit or GAPDH as a reference. The amount of the 
corresponding cDNA is directly proportional to the amount of the mRNA of interest in the 
original RNA sample. 
 
2.8.1 cDNA synthesis 
RNA samples stored at -80 °C were thawed on ice. The reverse transcription reaction was 
setup on ice using the chemicals shown in Table 2.5. Briefly, a master mix was prepared 
containing all components except the RNA and was aliquoted into nuclease-free PCR tubes. 
RNase inhibitors (Applied Biosystems, Carlsbad, CA, USA, # N8080234) were included to 
prevent RNA degradation before or during reverse transcriptase PCR.  
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Table 2.5: Recipe for cDNA synthesis. All reagents were supplied with the MultiScribe® 
reverse transcription kit (Applied Biosystems, Carlsbad, CA, USA, # N8080234). 
Components Volume 
RT Buffer (10X) 1.0 μL 
Random Hexamers (50 µM) 0.5 μL 
dNTP Mixture (10 mM) 2.0 μL 
MgCl2 Solution (25 mM) 2.2 µL 
RNase inhibitor 0.2 µL 
MultiScribe® MuLV Reverse Transcriptase 0.625 µL 
Nuclease-free H2O (Sigma-Aldrich Company 
Ltd., Gillingham, UK, # W4502) 
0.475 µL 
RNA (100 ng/μL) 1 μL 
Total Volume 10 μL 
 
RNA was added in the last step and the tubes loaded on a PHC-3 Thermal Cycler (Techne 
Bibbi Scientific, Stone, UK). Thermocycler conditions for cDNA synthesis are displayed in 
Table 2.6. 
 
Table 2.6: Thermo cycler program for cDNA synthesis. 
Stage Duration Temperature [°C] 
1 cycle 
10 min 25 
30 min 48 
5 min 95 
 
cDNA was either stored at -20 °C or immediately used for rtPCR. Stock cDNA (~10 ng/µL) 
was diluted 1/5 to achieve a final concentration of ~2 ng/µL which was used for subsequent 
rtPCR. The concentration of 10 ng/µL of the cDNA stock solution was not precisely 
determined but estimated based on the amount of RNA used for cDNA synthesis. 
 
2.8.2 Real-time polymerase chain reaction 
Real-time polymerase chain reaction (rtPCR) was performed on a ABI 7500 FAST (Applied 
Biosystems, Carlsbad, CA, USA) platform using Fast optical tubes and 96-well plates (0.1 
mL, Applied Biosystems, Carlsbad, CA, USA, # 4358297, 403012) and Taqman® Fast 
Advanced Master Mix (Applied Biosystems, Carlsbad, CA, USA, # 4444557). A master mix 
for all samples was prepared according to Table 2.7 (omitting the cDNA) and aliquoted into 
the reaction wells.  
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Table 2.7: Recipe list for fast real-time PCR reactions. The concentration of cDNA is estimated from 
the amount of RNA used during the reverse transcription reaction. For genes of interest (GOI) with low 
transcript abundance, higher volumes of cDNA (e.g. 4 μL for measuring cytokines) were used. 
Components Volume 
Taqman® Fast Advanced Master Mix 10 μL 
18S Reference (20X) 1 μL 
GOI Probe (20X) 1 μL 
Nuclease-free H2O (Sigma-Aldrich Company 
Ltd., Gillingham, UK, # W4502) 
5 µL 
cDNA (~2 ng/μL) 3 μL 
Total Volume 20 μL 
 
Finally cDNA samples were added, the plates sealed using optical adhesive film (Applied 
Biosystems, Carlsbad, CA, USA, # 4311971) and centrifuged for 3 minutes at 1500 g to 
remove any air bubbles from the bottom of each well potentially introduced during pipetting. 
Table 2.8 shows the cycler conditions for the rtPCR reaction. 
 
Table 2.8: Thermo cycler program for Fast rtPCR reactions. 
Stage Temperature [°C] Time 
Hold 95 10 min 
40 Cycles 
95 15 s 
60 60 s 
 
The probe for the gene of interest (GOI) is frequently labelled with the reporter dye FAM™ at 
the 5‟ end and a non-fluorescent quencher (NFQ) as well as minor grove binder (MGB) 
situated at the 3‟ end. FAM™ is fluorescent dye emitting light at 520 nm upon excitation. In 
the native state of the probe, NFQ suppresses FAM™ fluorescence by Förster-type energy 
transfer (Förster 1948). MGBs increase melting temperature (Tm) and hence allow for design 
of shorter probes (Afonina et al. 1997; Kutyavin et al. 1997). A reference probe, labelled with 
a 5‟ VIC® reporter dye and a TAMRA™ quencher at the 3‟ end, is used for simultaneous 
analysis with the target gene a process referred to as duplex rtPCR. Upon excitation VIC 
emits light at 580 nm. Following hybridisation of each probe to their respective target cDNA, 
DNA polymerase cleaves off the FAM™ or VIC™ labels during the PCR reaction. Without 
quenching, free FAM™/VIC® emit a detectable fluorescent signal. The intensity of light 
emitted can be directly correlated to the number of target strands in the reaction. The cycle at 
which the emitted light reaches a certain threshold (set at the beginning of the linear range) 
defines the cycle threshold (Cт). The Cт of the GOI is normalised against the Cт of a 
  Chapter 2 - Methodology 
 
79 
housekeeping gene, the expression of which must not be affected by the experiment (i.e. the 
drug used to treat the cells or animals). The housekeeping gene used throughout this study 
was the 18s ribosomal subunit. 
 
Figure 2.11: Exemplary result of a rtPCR reaction. (1.) Amplification curves of 18s reference. (2) 
Amplification curves of the GOI. The experiment was performed in duplicate and good matching of 
curves for individual targets was observed. (#) Cycle threshold (ΔCт) and (##) baseline are indicated. 
 
The ΔCт value is achieved by subtracting Cт18s from CтGOI, as indicated in the formula below. 
 
Example calculation for determination of the relative expression: 
 
ΔCт = CтGOI - Cт18s  
 
Relative expression = 2-ΔCт- ΔCт ref 
 
ΔCтref refers to the ΔCт value of the sample which is arbitrarily set as the expression 
reference (most commonly a sample of the control group). The relative expression of this 
sample is consequently 1. 
The real-time PCR was performed in duplicate for each cDNA to decrease the impact of 
small pipetting inaccuracies. The resulting relative expression values were averaged. 
Validation of probes that are order made, such as the Tβ4 probe used in this study, is good 
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practice to ensure comparable PCR efficiencies between the mRNA of interest and the 
reference gene. This was performed by comparing expression of the GOI and the reference 
gene over a range of cDNA concentrations (0.03 to 25 ng) to generate a standard curve for 
each PCR from which the respective efficiencies were deducted. 
 
2.8.3 Autophagy PCR Array 
The RT2 Profiler PCR Array (SABiosciences QIAGEN, Crawley, UK, # PAMM-084C-2) was 
used which contains a 96-well plate pre-primed with probes to 83 genes involved in the 
autophagy pathway. RNA was isolated from tissue following the protocol but commercial 
sterile nuclease-free water (Sigma-Aldrich Company Ltd., Gillingham, UK, # W4502) was 
used instead of DEPC treated ddH2O. RNA purity and integrity were assessed using an 
Agilent BioAnalyzer 2100 (Figure 2.12, Agilent, Wokingham, UK). RNA integrity numbers 
(RIN) were routinely >8.0 indicating adequate RNA quality of the samples for PCR array 
analysis (minimum RIN >7, (Schroeder et al. 2006). 
 
 
 
Figure 2.12: Exemplary result of RNA quality control using a BioAnalyzer 2100. Bands on the left 
panel represent 18s (lower band) and 28 ribosomal (upper band) subunits. RIN values are indicated 
above the electropherograms on the four panels on the right and are >8. Smearing or shouldering of 
the peaks of 18s/28s ribosomal subunits is not observed in any of the electropherograms. 
 
As opposed to conventional rtPCR reactions, several GOIs are analysed on a PCR array 
simultaneously. Hence, the cDNA was added to the master mix during this experiment while 
the probes have been pre-plated into the wells by manufacturer. Genomic DNA elimination: 
As a precautionary measure, RNA is pre-treated before cDNA synthesis to remove any 
potentially remaining gDNA contamination. 1 µg of clean RNA and 2 µL of the proprietary 
gDNA Elimination Buffer (5X) were combined in a PCR tube and the total volume brought up 
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to 10 µL using nuclease-free H2O. Components were mixed and incubated for 5 min at 42 °C 
and cooled on ice for at least 1 min. cDNA synthesis: cDNA was synthesised using the RT2 
First Strand Kit (SABiosciences QIAGEN, Crawley, UK, # C-03-330401) using the recipe 
displayed in Table 2.9. 
 
Table 2.9: cDNA synthesis for PCR arrays. Quantities shown are for a single sample to be used on a 
single PCR array 96-well plate. 
Components Volume 
RT Buffer 3 (5X) 4 μL 
Primer & External Control Mix 1 μL 
RT Enzyme Mix 3 2 μL 
Nuclease-free H2O (Sigma-Aldrich Company 
Ltd., Gillingham, UK, # W4502) 
3 µL 
cDNA (after gDNA elimination) 10 μL 
Total Volume 20 μL 
 
After adding all components to a PCR tube, the cDNA synthesis reaction is initiated by 
incubating the mixture for exactly 15 min at 42 °C. The reaction was stopped immediately by 
transferring the tube to a second heat block at 95 °C for 5 min. 91 µL of nuclease-free H2O 
were added and the sample kept on ice followed by long term storage at -20 °C or used 
immediately. To investigate differential regulation of genes associated with autophagy, a 
Mouse Autophagy RT2 Profiler PCR Array (SABiosciences QIAGEN, Crawley, UK, # PAMM-
084C-2) containing 84 relevant probes was used. The plate included 5 different reference 
housekeeping genes to determine the relative expression of each of the 84 targets genes, as 
well as 1 mouse genomic DNA contamination control, 3 reverse transcription controls and 3 
positive PCR controls. The rtPCR master mix was prepared in 50 mL falcon tube according 
to Table 2.10. 
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Table 2.10: rtPCR master mix recipe for Mouse Autophagy RT2 Profiler PCR Array (96-well 
plate). 
Components Volume 
RT2 SYBR Green ROX qPCR Mastermix 
(2X, SABiosciences QIAGEN, Crawley, UK, 
# 330520) 
1350 μL 
Diluted First Strand cDNA Synthesis Mix 102 μL 
Nuclease-free H2O (Sigma-Aldrich Company 
Ltd., Gillingham, UK, # W4502) 
1248 µL 
Total Volume 2700 μL 
 
Precisely 25 µL were added to each well of the 96-well plate. The plate was sealed using the 
provided adhesive film and centrifuged for 1 min at 1,000 g to remove air bubbles. The plate 
was inserted into the ABI 7500 FAST rtPCR system which was programmed as indicated in 
Table 2.11. 
 
Table 2.11: ABI 7500 FAST rtPCR machine settings for 96-well RT
2
 Profiler PCR arrays (modified 
from SABiosciences QIAGEN [Internet], Crawley, RT2 Profiler PCR Array Handbook 11/2011, ©2011, 
Cited 16/04/2012, Available from: http://www.sabiosciences.com/Manual/1070190.pdf). 
Stage Temperature [°C] Time 
Hold 95 10 min 
40 Cycles 
95 15 s 
60 60 s 
 
The experiment was performed in triplicate, using 3 separate plates for cardiac RNA samples 
of αMHC/IGF-1Ea transgenic mice and 3 separate plates for FVB control mice. This allowed 
statistical evaluation of the results without reproduction of data by single-gene rtPCR. 
Evaluation of raw data was performed using the SABiosciences online tool (SABiosciences 
QIAGEN, Crawley, UK). 
 
 
2.9 gDNA extraction for gene copy number analysis 
Genomic DNA was isolated from mouse tail samples using a QIAGEN DNeasy Blood and 
Tissue kit (QIAGEN, Crawley, UK, # 69504). The columns used in this kit contain a silica 
membrane which binds DNA (QIAGEN Ltd [Internet], Hilden, DNeasy® Blood & Tissue 
Handbook 07/2006, ©2003-2012, Cited 28/02/2012, Available from: 
http://www.qiagen.com/literature/render.aspx?id=523). Consecutive washes with buffers 
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containing high concentrations chaotropic salts (guanidine hydrochloride) remove water from 
hydrated macromolecules, which promotes DNA binding to silica and denatures proteins. 
180 µL ATL lysis buffer and 20 µL proteinase K (QIAGEN, Crawley, UK, # 19131) were 
added to each tail sample in a 1.5 mL microcentrifuge tube. The sample was incubated 
overnight at 56 °C, thoroughly vortexed the following day and incubated for additional 30 min 
at 56 °C. To remove any undigested solids and debris the samples were centrifuged at 
20,000 g for 5 min and the supernatant transferred to a fresh 1.5 ml tube. Although RNA 
does not generally amplify during normal PCR, it is good practice to remove unwanted 
nucleic acids to reduce the risk of interference. Residual RNA was removed by adding 4 µL 
of RNase A (100 mg/mL, QIAGEN, Crawley, UK, # 19101), mixing the sample, incubating at 
RT for 2 min and then vortexing again for 15 s. 200 µL of buffer AL (containing guanidine 
hydrochloride) and 200 µL EtOH (100%) were mixed separately, added to each sample and 
the suspension mixed immediately by vortexing to yield a homogenous solution. The 
suspension was loaded onto DNeasy Mini spin column and centrifuged at 6,000 g for 1 min. 
The flow-through was discarded and the membrane bound DNA washed with 500 µL buffer 
AW1 (containing guanidine hydrochloride), followed by a wash with 500 µL of buffer AW2. 
Buffers AW1 and AW2 contain EtOH to ensure that DNA remains precipitated on the 
membrane while other contaminants are washed out. The column was dried by centrifuging 
for 1 min at 20,000 g. 200 µL buffer AE (10 mM Tris-HCl, 0.5 mM EDTA; pH 9.0) were added 
directly on the membrane to rehydrate the DNA. The sample was incubated at RT for 1 min 
and then centrifuged for 1 min at 6,000 g to elute the purified gDNA. 
 
2.9.1 DNA quantification and quality control 
DNA concentrations were determined by spectrophotometry as previously described for RNA 
with minor deviations. As during RNA quantification, the absorbance is strongly dependent 
on pH. DNA sample were diluted 1/5 (v/v) in 10 mM Tris-HCl (pH 7.5). The linear range for 
this assay is between 0.1 and 1.0 absorbance units at 260 nm. Using the absorbance 
measured at a wavelength of 260 nm (A260) the concentration of DNA (cDNA) in the sample 
was determined using the following formula: 
 
CDNA = 50 µg/mL * A260 * dilution factor 
 
A260/A280 values for purified DNA routinely ranged between ~1.8-2.0 indicating good purity of 
the DNA. A260/A230 ratios were measured to detect any potential protein contamination in the 
sample. 
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2.10 Cre gene copy number analysis 
The relative abundance of Cre gene copies was determined using a TaqMan® Copy Number 
Assay (Applied Biosystems, Carlsbad, CA, USA, # Mr00635245_cn). Procedure and 
principle are identical to mRNA copy number analysis with two exceptions: 1. synthesis of 
cDNA is not required since the starting material is gDNA and 2. a reference gene with a 
known copy number has to be selected as internal reference. During this study mouse 
transferrin receptor gene (Tfrc), chromosome 16, cytoband 16qB3 was selected. It is present 
in two copies in the diploid mouse genome. The Reference Assay (Applied Biosystems, 
Carlsbad, CA, USA, # 4458366) contains two primers and a VIC® dye labelled TAMRA™ 
probe. The assay to target Cre (Applied Biosystems, Carlsbad, CA, USA, # Mr00635245_cn) 
contains Cre specific primers and a FAM™ dye labelled MGB probe. As recommended by 
the manufacturer, TaqMan® Genotyping Master Mix (Applied Biosystems, Carlsbad, CA, 
USA, # 4371355) as opposed to conventional TaqMan® Universal Master Mix was used 
during this study. After isolation and purification gDNA samples were diluted in nuclease-free 
water to a concentration of 5 ng/µL. The PCR reaction mix was prepared as indicated in 
Table 2.12. 
 
Table 2.12: PCR reaction setup for Cre gene copy number analysis using a 96-well reaction plate 
(modified from Applied Biosystems [Internet], Carlsbad, CA, TaqMan
®
 Copy Number Assays Manual 
09/2010, ©2010, Cited 16/04/2012, Available from: 
http://tools.invitrogen.com/content/sfs/manuals/cms_062368.pdf). 
Reaction Mixture Component Volume 
2X TaqMan® Genotyping Master Mix 10 µL 
TaqMan® Copy Number Assay (20X) 1 µL 
TaqMan® Copy Number Reference Assay (20X) 1 µL 
Nuclease-free H2O (Sigma-Aldrich Company 
Ltd., Gillingham, UK, # W4502) 
4 µL 
gDNA (5 ng/µL) 4 µL 
Total Volume 20 µL 
 
A master mix containing all components except gDNA was prepared and loaded on 
MicroAmp® Fast Optical 96-well reaction plates (Applied Biosystems, Carlsbad, CA, USA, # 
4349609) before adding gDNA to each well. The reaction plates were sealed with optical 
adhesive film (Applied Biosystems, Carlsbad, CA, USA, # 4311971) and inserted into the ABI 
7500 Fast System real-time PCR instrument. The run was performed using the conditions 
displayed in Table 2.13. 
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Table 2.13: Instrument settings for gene copy number analysis using TaqMan
®
 reagents (modified 
from Applied Biosystems [Internet], Carlsbad, CA, TaqMan
®
 Copy Number Assays Manual 09/2010, 
©2010, Cited 16/04/2012, Available from: 
http://tools.invitrogen.com/content/sfs/manuals/cms_062368.pdf). 
Stage Temperature [°C] Time 
Hold 95 10 min 
40 Cycles 
95 15 s 
60 60 s 
 
Threshold and baseline values were set manually into the linear portion of the amplification 
curve (log view). Cт values of Tfrc and Cre were exported into Excel and the relative 
expression calculated as reported in Section 2.8.2. gDNA samples from C57Bl/6 wt animals 
were used as negative controls. 
 
 
2.11 Histology 
Investigating abundance and localisation of proteins inside organs, tissues or individual cells 
provides valuable information about their function frequently obtained by 
immunofluorescence staining and immunohistochemistry. Briefly, binding of specific 
antibodies to the protein or peptide of interest in processed tissue sections or cell 
preparations is following by interaction of a species specific secondary antibody conjugated 
to a fluorescent label used for detection. The fluorescent tag is excited by laser and the 
signal captured by fluorescence or confocal microscopy. Depending on the nature of the 
staining either frozen sections (cryosections) or paraffin-embedded sections are used. While 
the structural integrity of the tissue is better preserved in the latter technique, epitopes are 
masked to a higher degree compared to cryosections. The trade-off between structural 
preservation and good epitope presentation has to be considered depending on the aim of 
each experiment. 
 
2.11.1 Staining of OCT embedded sections 
Samples were harvested from mice and blood removed as described in section 2.4. The full 
heart or the relevant part thereof was placed in a rectangular plastic mould containing 
sufficient OCT compound to fully cover the sample. The mould was immediately placed in 
liquid nitrogen to instantly freeze the sample. Samples were stored at -80 °C. 6-10 μm 
sections were cut at -20 °C using a Leica CM 850 cryostat (Leica Microsystems, Milton 
Keynes, UK) and transferred to polysine slides (VWR, Lutterworth, UK, # 631-1349). The 
slides were allowed to dry at RT and fixed by immersion in acetone (100%) at RT for 5 min. 
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Slides were then air-dried at RT, wrapped in foil and stored at -20 °C. In preparation for 
staining, slides were thawed and washed once briefly with PBS. After blocking with 3% (w/v) 
BSA in PBS, slides were incubated with primary antibody in PBS for 1 h at RT. After three 5 
min washes with PBS, slides were incubated with fluorophore-coupled secondary antibody in 
PBS for 1 h at RT. To mask elastin fibre autofluorescence pontamine skye blue (Sigma-
Aldrich, Gillingham, UK, # C8679) was added and the slides incubated for 6 min at RT 
(Cowen et al. 1985). Slides where then washed twice and nuclei stained with DAPI (Sigma-
Aldrich, Gillingham, UK, # 32670) at a concentration of 1/20,000 for 7 min each (Kapuscinski 
1995). Slides were mounted with PermaFluor™ (Thermo Fisher Scientific, Loughborough, 
UK, # LVTA006FM) and analysed using a Nikon DMx1200 camera mounted on a Zeiss 
Axioscope microscope. Images were captured using NIS elements software V (Nikon 
Instruments, Melvile, NY, USA). Method specificity was tested by use of secondary antibody 
alone (negative control) which did not result in a specific staining pattern. 
 
2.11.2 Paraffin-embedding of tissue 
Samples destined for paraffin embedding were harvested as described in Section 2.4 and 
placed in 10% v/v formal saline (1.54 M NaCl, 10% v/v formaldehyde). Formaldehyde is a 
fixative that crosslinks primary amino groups thus preserving tissue and protein integrity. 
Following overnight incubation at 4 °C, formal saline was replaced with 0.2 M phosphate 
buffer. Fixed samples stored at 4 °C are stable for years. After fixing, samples were 
embedded in paraffin using a Leica TP 1020 tissue processor (Leica Microsystems, Milton 
Keynes, UK). During this process water is removed by an increasing gradient of EtOH before 
incubation in xylene and embedding into paraffin blocks. 
 
2.11.3 Masson’s Trichrome Staining 
All dyes used during this procedure were filtered before use. Paraffin-embedded tissue 
sections were deparaffinised and brought to water by immersion into the following reagents 
for 2 min each: xylene, xylene, EtOH (100%), EtOH (100%), EtOH (70%), H2O followed by a 
final wash under running tab water for 5 min. Slides were transferred into Celestine blue 
(Sigma-Aldrich, Gillingham, UK, #206342) for 5 min to stain nuclei, followed by a dH2O wash 
for 3 min. The sections were then immersed in haematoxylin (Sigma-Aldrich, Gillingham, UK, 
# HT15), a second nuclear stain for 5 min, washed under running water for 5 min. To stain 
muscle tissue red, slides were then immersed in acid fucsin (Sigma-Aldrich, Gillingham, UK, 
#HT15) for 5 min before washing twice by immersion in dH2O. The slides were then 
differentiated in phosphomolybdic acid solution (Sigma-Aldrich, Gillingham, UK, # HT15) for 
10 min. The dye was drained carefully from the slide but no wash step performed. Slides 
were then immersed in methyl blue (Sigma-Aldrich, Gillingham, UK, # M6900) to stain 
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collagen and washed briefly under running tab water. Finally, the sections were dehydrated 
by increasing EtOH gradient and xylene (70%, 100%, 100%, xylene, xylene), mounted with 
DPX (VWR, Lutterworth, UK, # LEIC08600E) and dried for 30 min at RT. 
 
 
2.12 Transmission electron microscopy 
Day 1: PFA-fixed samples were removed from the 0.1 M phosphate storage buffer. The ~2 
mm3 tissue blocks were fixed by incubation in 2.5% glutaraldehyde (9 mL 0.1 M phosphate 
buffer, 1 mL 25% glutaraldehyde, Agar Scientific, Stansted, UK # R1020) for 2 h. Samples 
were washed twice for 5 min each before 1% osmium tetroxide (Agar Scientific, Stansted, 
UK, # R1019) in EM buffer was added. Osmium tetroxide fixes lipoproteins of membranes 
and is consequently very important for structural preservation. Samples were incubated on a 
rotor in a fume cabinet for 1 h at RT. Samples were then washed twice as described and 
dehydrated via acetone gradient (50%, 70%, 95%, 100%, 100% acetone - 30 minutes each) 
and placed in propylene oxide (Agar Scientific, Stansted, UK, # R1080) for 30 min on a rotor. 
Propylene oxide further dehydrates the samples and facilitates resin penetration into the 
specimen in subsequent steps. Araldite resin consists of three-components: 100 mL of 
araldite CY212 (Agar Scientific, Stansted, UK, # R1040) and dodecenyl succinic anhydride 
(DDSA, Agar Scientific, Stansted, UK, # R1051) mixed with 2 mL crosslinker/accelerator 
benzyl dimethylamine (1:1 v/v, BDMA, Agar Scientific, Stansted, UK, # R1060). Samples 
were incubated at RT overnight in a 1:1 mixture of propylene oxide and the epoxy resin 
araldite (Agar Scientific, Stansted, UK, # R1040) to allow complete penetration of araldite 
into the sample block. The samples were placed into embedding molds and covered with 
resin and dried at 60 °C overnight. 
Day 2: Samples were placed in pure araldite resin and incubated without a cover, at RT for 
>2 h on a rotor. This allowed propylene oxide to evaporate from the sample. The resin was 
replaced by fresh resin and the samples incubated for another 2 h, as described. 
Day 3: Using a self-made glass blade, tissue blocks were trimmed and coarse 1 µm sections 
cut. Coarse sections were placed on a coverslide and quick-stained with 1% toluidine blue 
(Agar Scientific, Stansted, UK, # R1727) in 1% sodium tetraborate (Borax, Taab, 
Aldermaston, UK, # B021). Following a quick rinse with water the orientation and integrity of 
the section was determined by light microscopy. After identification of a suitable cutting area, 
ultra-thin sections (100 nm) were cut from the block using a diamond blade on a Reichert-
Jung Ultracut E ultramicrotome and placed on 200 µm EM copper grids. Ultra-thin sections 
were stained with 2% aqueous uranyl acetate for 10 min, washed with ddH2O (three times 5 
minutes by immersion in separate baths) and placed on lead nitrate droplets consisting of 
lead nitrate (Agar Scientific, Stansted, UK, # R1217) in tri-sodium citrate (Agar Scientific, 
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Stansted, UK, # R1106) for 30 min at RT according to Reynolds‟ Lead Nitrate stain method. 
After 10 min, the specimens were washed as described and counterstained with lead citrate 
(Agar Scientific, Stansted, UK, # R1210) for 10 minutes and washed with ddH2O. After final 
stream-washing with ddH2O the samples were analysed using a Jeol 1200 XE electron 
microscope (Jeol, Herts, UK) and micrographs captured using a Gatan digital camera 
(Gatan, Abingdon Oxon, UK). 
 
2.12.1 Immunogold labelling 
For immunogold labelling, PFA-fixed cardiac tissue was quenched in 0.5 M ammonium 
chloride for 30 min to bind free aldehyde hindering staining. Specimens were washed with 
0.1 M phosphate buffer and embedded according to the method of Roth et al. (Roth et al. 
1978). Dehydration by graded acetone series was performed at 4 °C (30%, 50%) and -20 °C 
(70%, 90%, 100%). Samples were then embedded in the acrylic resin Lowicryl HM20 (Agar 
Scientific, Stansted, UK, # R1210) which was prepared in 1:1 and 1:2 mixtures with MeOH 
(100%) and incubated for 1 h each at -20 °C. The specimen were then incubated in pure 
Lowicryl resin over 2 days at -20 °C with 3-4 resin changes in the course. This is performed 
to eliminate all alcohol from the sample which would disturb sample integrity during 
sectioning. The specimen were placed in Taab embedding capsules (Taab, Aldermaston, 
UK, # C050) and covered in Lowicryl resin and the resin cured in a UV box at -20 °C. Sample 
integrity and orientation was examined using the quick-staining technique before cutting of 
ultra thin sections as described in Section 2.12. Sections were placed on formvar-coated 
nickel grids and blocked with Aurion 1% (w/v) BSA-c™ (Aurion, Wageningen, The 
Netherlands, # 900.022) solution for 30 min following incubation with the respective antibody 
at concentrations of 1/10 rabbit anti-LC3 (Abgent) or 1/20 rabbit anti-cathepsin D (Merck 
Calbiochem) for 1 h at RT. Sections were washed three times for 5 min with filtered PBS and 
incubated with 15 nm gold conjugated anti-rabbit goat IgG (BBInternational BioCell, Cardiff, 
UK, R14010) at a concentration of 1/100 for 1 h at RT. Post-staining was performed using 
Reynolds‟ Lead Nitrate stain method and electron micrographs recorded as described 
previously. 
 
 
2.13 Production of recombinant V5-His6-tagged thymosin β4-V5/His protein 
Total RNA was isolated from the hearts of 3 month old male FVB mouse by phenol-
chloroform extraction and purified as described in Section 2.7.2. cDNA was produced by one 
cycle of rtPCR from 200 ng RNA starting material as described (Section 2.8.1). Using Tβ4 
specific primers (forward 5‟ – ACC ATG TCT GAC AAA CCC GAT ATG – 3‟ and reverse 5‟ – 
CGA TTC GCC AGC TTG CTT CTC TTG - 3‟), cDNA was amplified by PCR using Pfx 
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proofreading polymerase (Invitrogen, Carlsbad, CA, USA, # 11708-013) which has a higher 
fidelity compared to normal Taq polymerase. 
 
cDNA sequence of Tβ4: 5‟ AT GTCTGACAAA CCCGATATGG CTGAGATCGA 
GAAATTCGAT AAGTCGAAGTTGAAGAAAAC AGAAACGCAA GAGAAAAATC 
CTCTGCCTTC AAAAGAAACA ATTGAACAAGAGAAGCAAGC TGGCGAATCG TAA – 3‟ 
(CDS, GenBank: AL731735.14) 
 
Table 2.14: PCR conditions for Tβ4 amplification from cDNA. 
Gene Recipe Thermocycler 
conditions 
Size of amplified 
fragment 
Thymosin β4 60 μL reaction: 
5 μL Pfx Buffer (10x) 
1 μL MgSO4 
1.5 μL dNTP 
5 μL Tβ4 primer mix (10μM 
each) 
1 μL Pfx Polymerase 
(Invitrogen, Carlsbad, CA, 
USA, # 11708-013) 
36.5 μL ddH2O 
5 µL Enhancer solution 
 
+ 5 μL cDNA ( 
 
5 min at 95 °C 
 
30 x  30 s at 95 °C 
 
1 min at 55 °C 
 
2 min at 72 °C 
 
10 min at 72 °C 
 
∞ 4 °C 
 
135 bp 
 
On ice, 1 µL standard Taq polymerase (Promega, Southampton, UK, # M8306) was added to 
the PCR product and the sample incubated at 72 °C for 10 min. This resulted in the addition 
of 3‟ adenine overhangs on the PCR products which was required for subsequent cloning. 
The presence of a single band indicating a specific reaction was assessed by agarose gel-
electrophoresis. 
 
2.13.1 Cloning of Tβ4 
Tβ4 cDNA was cloned into vector pcDNA3.1/V5-His© TOPO® TA (Invitrogen, Carlsbad, CA, 
USA, # K4800-01, Figure 2.13).  
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Figure 2.13: Vector used for the generation of recombinant Tβ4. Tβ4 cDNA was cloned into the 
pcDNA3.1/V5-His-TOPO vector. (Invitrogen [Internet], Carlsbad, CA, pcDNA™3.1/V5-His TOPO® TA 
Expression Kit Manual 10/04/2009, ©2009, Cited 16/04/2012, Available from: 
http://tools.invitrogen.com/content/sfs/manuals/pcdna3.1topota_man.pdf). 
 
Briefly, 3 µL undiluted PCR product were mixed with 1 µL salt solution (Invitrogen, Carlsbad, 
CA, USA, # 4800-01) and 1 µL vector. The 2 µL of this reaction mix were added to 50 µL 
DH5α™ Library Efficient® Escherichia coli suspension (E. coli, Invitrogen, Carlsbad, CA, 
USA, # 18263-012) and incubated for 30 min on ice, 30 s at 42 °C and 2 min again on ice. 
Control transformations were performed using the empty and a LacZ expressing control 
vectors. Transformed bacteria were incubated in 250 µL SOC medium (Invitrogen, Carlsbad, 
CA, USA, # 15544-034) at 37 °C for 1h. Volumes of 50 µL and 200 µL were streaked out on 
LB ampicillin agar plates (0.1 mg/mL ampicillin) and incubated at 37 °C overnight. The 
following morning 10 individual colonies were picked from the plates and grown in 4 mL Luria 
broth containing 4 µL ampicillin (100 mg/mL) overnight. The following day 150 µL glycerol 
were added to an aliquot of 850 µL LB culture and the sample stored at -80 °C. The 
remaining bacterial culture was used for DNA isolation using a QIAprep Spin Miniprep kit 
(QIAGEN, Crawley, UK, # 27104) according to manufacturer‟s instructions. This technique is 
based on alkaline lysis of bacteria with subsequent adsorption of DNA to a silica membrane, 
washing and elution in 10 mM TrisCl, pH 8.5 (Birnboim and Doly 1979). To control the 
transformation procedure LacZ control-plasmid transformed clones were tested by β-
galactose activity assay. X-gal plates were prepared by covering regular LB ampicillin agar 
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plates with 40 µL X-gal solution (40 mg/mL in dimethylformamide) and drying for 15 min. 
LacZ-V5-His6-transformed bacteria and clones containing the empty vector were streaked 
out on X-gal plates and incubated over night The E. coli strain used is deficient for LacZa, a 
β-galactosidase subunit, but expresses the complimentary LacZ∆M15 subunit. Together 
these peptides form the functional β-galactosidase enzyme. Active β-galactosidase is 
observable by blue coloured colonies on X-gal plates. This colour arises when X-gal is 
hydrolysed into an insoluble blue compound. This can be detected by eye and indicates 
successful transformation and LacZ expression. 
 
2.13.2 Confirmation of positive clones 
To confirm the presence and orientation of Tβ4 cDNA within the vector, purified plasmid DNA 
was digested with MfeI endonuclease (New England BioLabs, Ipswitch, MA, USA, # R0598L) 
at 37 °C for 1 h. Plasmids containing the insert in the correct orientation yielded two 
fragments of 891 bp and 4767 bp after separation on 2% agarose gels. Bands of 826 bp and 
4832 bp were observed for the inverse orientation. MfeI-digested control vectors yield bands 
of 8592 bp (linearised LacZ vector) and 5536 bp (linearised empty vector). DNA from positive 
Tβ4 clones was sent for sequencing to the Imperial College Genomics Laboratory core 
facility using the following primers: T7 (forward) 5´ - TAA TAC GAC TCA CTA TAG GG - 3´ 
and BHG (reverse): 5´ - TAG AAG GCA CAG TCG AGG - 3´. 
 
2.13.3 Tβ4-V5-His protein expression in E. coli 
Bacterial stocks of positive clones were thawed and grown overnight in a 200 mL LB 
containing ampicillin (100 μg/mL). Aliquots were stored at -80 °C as described. 4 mL of the 
bacterial suspensions were used for DNA isolation using the Miniprep kit with subsequent 
MfeI digest to control continued presence of the correctly oriented insert. The remaining 
culture volumes were used for protein isolation using a Bacterial PE LB™ kit (G-Biosciences, 
Maryland Heights, MO, USA, # 786-176). Bacterial cells were pelleted by centrifugation at 
5,000 g for 10 min, the supernatant discarded and the pellet dissolved in 5-10 volumes of 
proprietary Bacterial-PE-LB buffer. After homogenisation by vortexing and brief chilling of the 
sample (4 °C), lysozyme was added (5% v/v final) and the suspension incubated at 37 °C for 
60 min. The sample was vortexed several times for 30 s each to complete lysis. Genomic 
DNA was sheared by passing the lysate 10 times through a 20 G needle. Finally, the sample 
was centrifuged at 20,000 g for 30 min at 4 °C and the clear supernatant collected. 
In the event of protein aggregation as intracellular inclusion bodies, pellets were washed 
twice in 10x diluted Bacterial-PE LB buffer. For every 100 mg of pellet, 1 mL of proprietary 
IBS buffer and 1M DDT (to 20 mM final) were added and the pellets resuspended. Samples 
were agitated on a shaker for 1 h at 4 °C before centrifugation at 30,000 g for 15 min at 4 °C 
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and collection of protein-containing supernatant. Protein extracts were quantified and 
recombinant Tβ4-V5-His6 expression analysed by immunoprecipitation and Western blotting 
using HRP conjugated anti-V5 antibodies (Invitrogen, Carlsbad, CA, USA, # R960-25). 
 
2.13.4 Tβ4-V5-His protein expression in mammalian cells 
HeLa cells were selected as the mammalian expression system due to their fast growth and 
ease of culture. Cells were grown in 10 cm2 tissue culture dishes in standard cell culture 
medium consisting of high glucose DMEM (Sigma-Aldrich, Gillingham, UK, # D5671), 10% 
fetal bovine serum (FBS, Sigma-Aldrich, Gillingham, UK, # F6178), 1% L-glutamine (Sigma-
Aldrich, Gillingham, UK, # G8540) and 1% penicillin/streptomycin (P/S) mix (Sigma-Aldrich, 
Gillingham, UK, # P4333). One day before transfection cells were washed with PBS to 
remove P/S which would exert cytotoxicity in combination with the transfection reagent. Cells 
were cultured in normal medium lacking P/S overnight. On the day of transfection, at 80-90% 
confluency, a transfection mix consisting of 100 µL opti-MEM (Invitrogen, Carlsbad, CA, 
USA, # 11058-021) containing 1-2 µg vector DNA was prepared. In a second reaction, 100 
µL opti-MEM and 1-2 µL Lipofectamine (Invitrogen, Carlsbad, CA, USA, # 18324-012) were 
mixed. The two solutions were combined, gently mixed and incubated at RT for 30 min. 
Additional 600 µL opti-MEM were added. The total volume of 800 µL was combined with 3.2 
mL transfection medium, which is normal growth medium without P/S and serum. The old 
medium was removed from the cells and the culture incubated with the 4 mL transfection 
solution for 6 h in a CO2 incubator. The transfection medium was removed and the cells 
washed with PBS to remove residual Lipofectamine. Cells were allowed 2-3 days to recover 
in normal medium before harvest of proteins as described in Section 2.5.1. To generate a 
stable Tβ4-V5-His6 overexpressing cell line, transfected HeLa cells were selected against G-
418 for 1 week at 400 µg/ml and 2 weeks at 200 µg/mL. One day before harvesting G-418-
containing medium was exchanged for normal growth medium. 
 
2.13.5 Purification of His-tagged recombinant proteins 
Isolation and purification of Tβ4-V5-His6 was performed using the ProBond purification kit 
(Invitrogen, Carlsbad, CA, USA, # 45-0055) with modification to the original protocol 
(Invitrogen [Internet], Carlsbad, CA, ProBondTM Purification System Manual 02/09/2004, 
©1997-2004, Cited 16/04/2012, Available from: 
http://tools.invitrogen.com/content/sfs/manuals/xprpur_man.pdf). Cells (bacteria or 
mammalian) were pelleted and resuspended in 8 mL guanidium lysis buffer (6 M guanidine 
HCl, 2 mM NaH2PO4, 500 mM NaCl) and agitated for 15-20 min. The suspension was pulsed 
3 times for 10 s each using a sonicator, shock frozen in liquid nitrogen and warmed up to 37 
°C. Homogenates were passed through a 16 G syringe to shear DNA and the samples 
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centrifuged at 3,000 g to pellet cell debris and the supernatant transferred. 2 mL nickel resin 
were used per column, which is sufficient to bind 10-20 mg of His6-tagged protein. Binding 
was allowed for 30 min at RT. Since low expression levels were expected from previous 
experimentation the column was re-loaded with additional 8 mL lysates. After additional 30 
min binding, columns were washed once with 4 mL denaturing binding buffer (8 M urea, 20 
mM NaH2PO4 pH 7.8, 500 mM NaCl) and thrice with 4 mL denaturing wash buffer (8 M urea, 
20 mM NaH2PO4, pH 6.0). This was followed by 4 washes using a more acidic denaturing 
wash buffer (pH 5.3). Finally, 4 mL denaturing elution buffer (8 M urea, 20 mM NaH2PO4 pH 
4.0, 500 mM NaCl) were added and the solution eluted in ~1 mL fractions by gravity. To 
remove urea from the sample, fractions were dialysed against tris buffer (10 mM Tris pH 8.0, 
0.1% Triton X-100) overnight at 4 °C using SnakeSkin Pleated Dialysis Tubing™ with a 
MWCO of 3.5 kDa (Thermo Fisher Scientific, Rockford, IL, USA, # 68035). Samples were 
stored at -80 °C until analysis by Tris-Tricine gel electrophoresis. 
 
 
2.14 Immunoprecipitation 
Day 1: Recombinant Tβ4-V5-His6 was incubated with 2 mg cardiac protein extract in a total 
volume of 100 µL RIPA buffer for 2 h at RT. Pre-clearing was performed to remove 
substances that exhibit aspecific reactions with protein A/G from the protein mixture. Briefly, 
20 µL Protein A/G beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA, # sc-2003) were 
mixed with 100 µL protein sample and incubated on a rotor for 45 min at 4 °C. Samples were 
centrifuged at 600 g for 3 min and the supernatant transferred into fresh microcentrifuge 
tubes. 1.5 µL anti-V5 antibodies were added and the suspension incubated on a rotor 
overnight at 4 °C. 
Day 2: 20 µL Protein A/G beads were added to sample. After 1 h incubation on a rotor at RT 
the samples were centrifuged at 600 g for 3 min and the supernatant aliquoted into a 
separate microcentrifuge tube. This supernatant was used as during Western blotting for 
quality control. The samples were washed by adding 500 µL RIPA buffer, mixing and 
centrifugation at 600 g for 3 min at RT. The supernatant was discarded and the procedure 
repeated once. A final wash was performed by adding 500 µL Tris (50 µM, pH 8.0), mixing 
and adding of 500 µL RIPA buffer. The sample was mixed again and a final centrifugation 
performed as for previous washes. The supernatant was discarded and pelleted beads re-
suspended in 40 µL SDS sample buffer including β-mercaptoethanol in preparation for SDS 
PAGE analysis. Samples were boiled at 100 °C for 5 min and stored at -80 °C or used 
immediately. Prior to loading the gel, the samples were centrifuged to pellet the beads and 
only the supernatant was used for Western blotting analysis as described in section 2.6.2. 
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2.15 Thymosin β4 knockdown in neonatal cardiomyocyte preparations from 
mice 
The culture of rodent neonatal cardiomyocytes (NCM) is a valuable technique in cardiac 
research from pharmacological safety testing to basic studies on CM function and molecular 
signalling. This technique exploits the resilience NCM retain during the first 1-2 days 
following birth (Porrello et al. 2011). 
 
2.15.1 Neonatal cardiomyocyte preparation 
This protocol is a modified version of the rat NCM protocol supplied with a kit of the same 
name by Worthington (Worthington Biochemical Corp., Lakewood, NJ, USA). Enzyme 
solutions were prepared in advance and stored at 4 °C (-20 °C for long term storage). 
Trypsin (~213 u/mg) was dissolved in 2 mL HBSS (Sigma-Aldrich, Gillingham, UK, # H6648), 
trypsin inhibitor in 1 mL HBSS and collagenase mix (1,085 u/mg) was reconstituted in 5 mL 
L-15 medium (all enzymes Worthington Biochemical Corp., Lakewood, NJ, USA). In 
preparation for plating the NCM on the following day, 6- or 12-well tissue culture plates were 
coated with fibronectin (Sigma-Aldrich, Gillingham, UK, # F0895). Briefly, fibronectin was 
dissolved in HBSS to a final concentration of 0.01 mg/mL using a total volume per well of 1 
mL for 6-well plates and 400 µL for 12-well plates. After 12 h incubation at 4 °C most of the 
solution was aspirated leaving ~100 µL in the wells. Plates were dried in a cell culture hood 
and stored at 4 °C. Fibronectin was chosen since it resembles a physiological extracellular 
matrix component unlike digested gelatine preparations. 
NCM prep day 1: A litter of 8-10 neonatal (P0 to P1) mouse pups was separated from their 
parents. After cervical dislocation the bodies were sprayed with 70% industrial methylated 
spirits (IMS) for sterilisation and placed in a tissue culture hood. Heads were removed and a 
~ 5 mm anterior-posterior incision made into the thorax. Hearts were exteriorised by gentle 
lateral squeezing, excised and placed in approximately 10 mL HBSS in a 50mL Falcon tube 
on ice. Tools were sterilised between animals by spraying with 70% IMS. The tube 
containing the hearts was transferred on ice into a sterile tissue culture hood. Blood 
contaminated HBBS was aspirated and the hearts were washed twice with fresh, ice-cold 
HBSS. Following the last wash, 1 mL HBSS was added and the hearts transferred into a 10 
cm2 Petri dish. Atria were removed and discarded and the ventricular tissue finely minced 
using two sterile, disposable scalpels. Excess HBSS was aspirated. If significant blood 
contamination was still observed, the tissue was carefully washed by rinsing with HBSS. The 
homogenised tissue was transferred into a cm2 Petri dish and 3 mL HBSS and 333 µL trypsin 
solution were added. Digestion was allowed for 12 h at 4 °C. 
NCM prep day 2: The tissue was transferred into a 75 cm2 cell culture flask using a plastic 
Pasteur pipette and at this point the homogenate should appear viscous indicating 
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successful pre-digestion. 166 µL trypsin inhibitor solution were added to the digest and the 
flask was placed in a 37 °C humidified CO2 incubator for 15 minutes. After trypsin inhibition, 
833 µL collagenase solution were added to the flask which was then placed in a shaking 
water bath. Digestion was checked after the first 30 minutes and every 5 minutes thereafter 
to prevent over-digestion. Once digestion was estimated to be 80-90% the flask was 
removed from the shaking waterbath. This was usually achieved within 45 min. Any residual 
chunks of tissue were further disrupted mechanically by pipetting the solution ten times up 
and down using a serological 10 mL pipette. A 70 μm mesh size cell strainer was pre-wetted 
with warm L-15 medium and placed on top of a new 50 mL falcon tube. Leaving any solid 
pieces of tissue in the flask, the suspension was carefully removed and filtered. The residual 
tissue was further disrupted by adding another 10 mL of L-15 medium and repeating the 
mechanical digestion. The resulting suspension was filtered, the suspensions pooled 
together and centrifuged at 1,000 g for 5 min to pellet the cells. The supernatant was 
aspirated and the cell pellet re-suspended in pre-warmed (37 °C) normal cell culture medium 
(as described in section 2.13.4). 
Pre-plating: In order to separate cardiomyocytes from other cardiac cell populations, two to 
three pre-plating steps were performed. During these relatively short incubations, non-
cardiomyocyte populations (mainly fibroblasts) attached to the tissue culture flask. 
Cardiomyocytes require more time to attach to plastic and were therefore retained in 
suspension and transferred. Repeating this step at least two times yielded a culture 
predominantly consisting of cardiomyocytes. 1st pre-plating: The cell suspension was 
transferred into a 75 cm2 tissue culture flask and placed in a CO2 incubator for 30 min at 37 
°C. The attached cells were rinsed twice with the supernatant to detach any cardiomyocytes 
that had started to attach and the suspension transferred to a 50 mL falcon tube. The plated 
cells were washed with additional 5 mL normal medium, the supernatant removed and both 
supernatants pooled together. Normal growth medium was added to the cells attached to the 
flask which was then placed in a CO2 incubator and treated like a normal primary cell culture. 
These cultures consist mainly of fibroblasts and are used as experimental controls. The cells 
from the supernatants were pelleted by centrifugation as described in the previous steps. 2nd 
pre-plating: The pre-plating procedure was repeated as described but allowing 40 min 
incubation time. 3rd pre-plating (optional): A 3rd pre-plating was only performed if a large 
number of cells were observed to have attached to the tissue culture flask during the 2nd pre-
plating indicative of considerable amounts of non-myocyte cells. In that case another re-
plating for 30 min was performed. 
NCM quantification: After pre-plating, the cardiomyocyte fraction was pelleted and re-
suspended in 5 mL normal growth medium and the number of NCM was determined using a 
haemocytometer (VWR, Lutterworth, UK, # HECH47112). Briefly, 10 μL cell suspension were 
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mixed with 10 μL filtered Trypan Blue (Sigma-Aldrich, Gillingham, UK, # T8154) and 10 μL of 
the suspension transferred into the counting chamber of the haemocytometer.  
 
Calculation to estimate the concentration of cells in suspension: 
 
Ncells counted in four squares /4 * 10,000 * dilution factor =  ncells/mL 
 
Since 10 μL Trypan Blue were added to distinguish dead from living cells, the dilution factor 
is 2. 
 
Example of an estimated cell concentration from a NCM preparation: 
 
80 /4 * 10,000 * 2   = 105 cells/mL 
 
Inherent inaccuracies of this cell quantification technique mean that the cell number is an 
estimate. 
NCM plating: Since NCM are post-mitotic cells, it is important to plate total cell numbers that, 
once attached to the culture plate, will be near 100% confluency. Unoccupied space on the 
plate will be rapidly colonised by dividing fibroblasts that have escaped the purification 
procedure. For 12-well plates 6 * 105 NCM were plated per well in a total volume of 1 mL. 
NCM were used for experiments after 72 h incubation in a CO2 incubator at 37 °C. At this 
point beating colonies were observed indicative of a healthy culture. Fibroblast cultures 
derived from the pre-platings were cultured until passage 2 (P2) and plated in uncoated 6-
well plates for experimental procedures. 
 
2.15.2 Induction of Cre recombinase in vitro 
The use of optimal concentrations of tamoxifen is crucial to induce sufficient nuclear 
translocation of the MerCreMer fusion-protein without cytotoxicity. The concentrations used 
in previous publications varied from 2 μM to 10 μM but different cell types were used (Furr 
and Jordan 1984). Lactate dehydrogenase (LDH) cytotoxicity assays (Promega, 
Southampton, UK, # G1780) were performed to determine a non-lethal dose of tamoxifen. 
This colorimetric assay is based on the indirect measurement of the release of LDH from 
dying cells at a wavelength of 490 nm. NCM and fibroblasts were isolated from litters of 
Tβ4shRNAflox/MerCreMer homozygous breedings, as described above. Control NCM 
preparations were derived from pure αMHC/MerCreMer breedings. The experiments were 
carried out in serum free culture conditions (medium changed on the day) to prevent binding 
and inactivation of tamoxifen by components of the serum. Tamoxifen was dissolved in 100% 
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EtOH and NCM and fibroblast cultures treated with 200 nM tamoxifen (Sigma-Aldrich, 
Gillingham, UK, # T5648) or with the same volume of 100% EtOH. After 24 h incubation at 
standard conditions, the medium was aspirated and the cells washed twice with cold PBS (4 
°C). RNA was isolated as described in Section 2.7.1. 
 
 
2.16 Isolation of adult cardiomyocytes 
Mice were sacrificed by cervical dislocation. The thorax was opened and the sternum folded 
backwards over the head of the animal to expose the heart. Without touching the atria or 
ventricle, a pair of forceps was used to lift up the heart on the larger vessels, which were 
subsequently severed and the heart immediately placed in normal tyrodes including heparin 
(140 mM NaCl, 6mM KCl, 10 mM HEPES, 1 mM MgCl2, pH 7.4, 1 mM CaCl2) at RT. The 
heart had to be still contracting at this point which assisted in clearing blood from the tissue. 
The heparin in the solution prevented the blood from clotting which could otherwise have 
blocked the coronary vessels. After the heart had purified itself from blood for about 20 beats 
it was transferred into the dish containing the needle holder filled with perfusion buffer (120.4 
mM NaCl, 14.7 mM KCl, 0.6 mM KH2PO4, 0.6 mM Na2HPO4, 1.2 mM MgSO4-7H2O, 10 mM 
HEPES, 4.6 mM NaHCO3, 30 mM Taurine, 10 mM BDM, 5.5 mM Glucose, pH 7.0) and 
containing heparin (Figure 2.14). BDM was included in the buffer due to its cytoprotective 
properties during Ca2+ depletion (Thum and Borlak 2001). The aorta was cannulated and tied 
to the cannula with a 6/0 polypropylene suture (Ethicon, Johnson & Johnson, Brussels, 
Belgium). The cardiac chambers and coronary circulation were flushed with heparin-
containing perfusion buffer. 
 
 
Figure 2.14: Langendorff setup required for adult cardiomyocyte isolation. Needle holder (left panel) 
and Langendorff perfusion system (right panel) used during adult cardiomyocyte isolation are shown. 
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The cannula was connected to the Langendorff perfusion system (Figure 2.14). The isolation 
procedure was performed at 37 °C and the temperature constantly monitored. All solutionas 
were continuously bubbled with O2. The heart was washed with perfusion buffer for 4 min. 
Tissue digestion was initiated by perfusing the heart with myocyte perfusion buffer containing 
2.4 mg/mL collagenase type II (Worthington Biochemical, Lakewood, NJ, USA) with an 
average activity of 340 u/mg for 3 min. The final digestion was performed using low Ca2+ 
myocyte digestion buffer (as above but containing 15 µL of 100 mM CaCl2) for 6 min and 30 
s. The heart was removed from the Langendorff apparatus and placed in 5 mL stopping 
solution (perfusion buffer, 10% (w/v) FCS, 12.5 µM CaCl2) at RT. Venae cavae, aorta and 
atria were removed and the ventricles coarsely minced using scissors. The tissue was further 
disrupted using a plastic Pasteur pipette. Great care was taken to avoid creating air bubbles 
which could damage the cells. The cell suspension and any tissue fragments were 
transferred into a 15 mL reaction tube containing additional 5 mL stopping solution (RT) and 
further digested with a plastic Pasteur pipette. The sample was centrifuged for 3 min at 20 g 
and the supernatant discarded. The cells were washed in 10 mL additional stopping solution 
as above. Finally the cells were resuspended in perfusion buffer and a sample investigated 
by light microscopy to determine the percentage of viable cardiomyocyte. The cells were 
pelleted by centrifugation at 20 g for 3 min and frozen at -80 °C until RNA isolation. 
 
 
2.17 Statistics 
Statistical calculations were performed using Microsoft® Office Excel 2010 (Microsoft, 
Reading, UK) and GraphPad Prism® V.5 (GraphPad Software, LaJolla, USA). Comparison of 
3 or more samples was performed by analysis of variance (ANOVA) and Bonferroni post-
testing (compare all pairs of columns). * p < 0.05, ** p < 0.01, *** p < 0.001. 
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2.18 Real-time PCR probes 
 
Table 2.15: Real-time PCR probes used during this study. All probes were purchased from Applied 
Biosystems, Carlsbad, CA, USA. 
Species reactivity/Target Probe Code Catalogue # 
Mouse CCL2  Mm00441242_m1 # 4331182 
Mouse COL3A1 Mm01254476_m1 # 4331182 
Mouse 18s rRNA N/A # 4310863E 
Mouse TMSB4X Mm01129684_g1 # 4331182 
Mouse Nppa Mm01255747_g1 # 4331182 
Mouse Nppb Mm01255770_g1 # 4331182 
Mouse IL1β Mm00434189_m1 # 4331182 
Mouse IL6 Mm00446190_m1 # 4331182 
Mouse IL10 Mm00439614_m1 # 4331182 
Mouse IFNγ Mm01168134_m1 # 4331182 
Mouse TGFβ1 Mm01178820_m1 # 4331182 
Mouse TNFα Mm00443260_g # 4331182 
Rat IGF1 Rn00710306_m1 # 4331182 
Cre Mr00635245_cn # 4400291 
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2.19 Antibodies 
Table 2.16: Antibodies used during this study. 
Target Manufacturer Product Number 
α-synuclein Cell Signaling, Danvers, MA, USA # 4179 
α-tubulin Sigma-Aldrich, Gillingham, UK # T6074 
Bax Cell Signaling, Danvers, MA, USA # 2772 
Bcl2 Cell Signaling, Danvers, MA, USA # 2876 
Beclin-1 Cell Signaling, Danvers, MA, USA # 3495 
Battenin Abcam, Cambridge, UK # ab75959 
Caspase-3 Cell Signaling, Danvers, MA, USA # 9662/9661  
Cathepsin D (EM) Merck Calbiochem, Nottingham, UK # IM16 
Cre Merck Novagen, Darmstadt, Germany # 69050-3 
Cytochrome c Cell Signaling, Danvers, MA, USA # 4272 
GAPDH Cell Signaling, Danvers, MA, USA # 2118 
LAMP1 Novus Biologicals, Littleton, CO, USA # NB110-82353 
LC3  Abgent, San Diego, CA, USA # AM1800A 
LC3B Cell Signaling, Danvers, MA, USA # 2775 
IGF-1 Sigma-Aldrich, Gillingham, UK # I2157 
Mouse IgG GE Healthcare, Bucks, UK # Na931V 
Rabbit IgG Cell Signaling, Danvers, MA, USA # 7074 
Rabbit IgG GE Healthcare, Bucks, UK # Na934V 
Thymosin β4 (EM) Santa Cruz Biotechnology, Santa Cruz, 
CA, USA 
# sc-67114 
Thymosin β4 Abcam, Cambridge, UK # ab14334 
Thymosin β4 Immundiagnostik, Bensheim, Germany # A9522.1/A9522.2 
Ubiquitin Cell Signaling, Danvers, MA, USA # 3933 
V5 Invitrogen, Carlsbad, CA, USA # R960-25 
  Chapter 3 
 
101 
Chapter 3 -  Tamoxifen-dependent Cardiomyocyte-specific 
Knockdown of Thymosin β4 
 
3.1 Introduction 
The importance of Tβ4 during development of the heart was demonstrated among others by 
the work of Paul Riley‟s group, who described a substantial cardiac phenotype and 
embryonic lethality after shRNA-mediated depletion of Tβ4 mRNA during mouse 
development (Smart et al. 2007). This was attributed to a failure to induce inward migration 
of progenitor cells from the epicardium and ectopic EMT of EPDC in epicardial regions. The 
epicardium was also shown to be important in cardiac regeneration in zebrafish, a process 
dependent on EMT of an epicardial cell population and increased expression of a Tβ4 
ortholog (Lepilina et al. 2006; Lien et al. 2006). 
In adult mammals, exogenous Tβ4 peptide, delivered intracardially or systemically after 
myocardial infarction, decreased scar volume and LV function in mouse and pig models 
highlighting its therapeutic potential (Bock-Marquette et al. 2004; Hinkel et al. 2008). 
Furthermore, Tβ4-priming mammalian hearts in the context of experimental MI reportedly 
induced epicardial cells positive for Wilm‟s tumour 1 (Wt1), a marker of adult cardiac 
progenitors underpinning the potential therapeutic potential of this peptide in stem cell-
mediated cardiac regeneration (Smart et al. 2011). 
With the focus of previous research on the role of Tβ4 during development and wound 
healing, the importance of Tβ4 under physiological conditions and the consequences of an 
adult loss of function in the mammalian heart had not been previously addressed. The aim of 
the present study was to investigate the role of Tβ4 in normal adult mouse heart and how this 
affects recovery after experimental MI. In order to understand the effects of downregulating 
Tβ4 in adult mammalian hearts under physiological and pathological conditions, the 
Tβ4shRNAflox/MerCreMer mouse strain was generated and analysed. The following chapter 
describes challenges of cardiomyocyte-specific conditional gene manipulation as well as 
three different approaches of determining the success of the inducible shRNA-mediated 
knockdown of Tβ4 in cardiomyocytes. These approaches can be classified as in vivo, in vitro 
and ex vivo. 
 
 
3.2 Thymosin β4 knockdown by tamoxifen administration in the diet 
In order to downregulate Tβ4 by Tβ4shRNA expression in the adult heart, 3-4 month old 
male Tβ4shRNAflox/MerCreMer mice were fed tamoxifen-containing diet. At baseline, 
cardiac function of these mice was unremarkable as analysed by transthoracic ECHO 
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(Figure 3.1). Left-ventricular (LV) ejection fraction (EF) and LV fractional shortening (FS) 
were normal across all experimental groups which consisted of Tβ4shRNAflox/MerCreMer 
mice (EF% 70.51 ± 5.95, FS% 34.92 ± 4.78) as well as Tβ4shRNAflox (EF% 64.26 ± 7.46, 
FS% 30.44 ± 5.20) and MerCreMer-single genotype (EF% 69.72 ± 6.11, FS% 34.81 ± 4.24) 
littermates.
 
Figure 3.1: Baseline cardiac function of Tβ4shRNAflox/MerCreMer mice measured by 
transthoracic ECHO. Left-ventricular (LV) ejection fraction (EF) and LV fractional shortening 
(FS) were normal compared to controls prior to tamoxifen treatment. Groups labelled 
“Tamox” are animals on normal diet that were later subjected to tamoxifen treatment. Data 
are expressed as ± SD. 
 
Following 14 days of tamoxifen diet, nuclear localisation of the MerCreMer fusion-protein was 
assessed in Tβ4shRNAflox/MerCreMer mice by immunofluorescence analysis of frozen 
cardiac sections. MerCreMer was frequently found localised to the nuclear compartment, but 
not in all cells, indicating a partial success of this mode of tamoxifen delivery (Figure 
3.2).Tβ4shRNAflox/MerCreMer mice on normal diet did not show nuclear localisation of 
MerCreMer. 
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Figure 3.2: Immunofluorescence staining for Cre on cardiac cryosections. MerCreMer localisation is 
shown in left-ventricular cardiac tissue of Tβ4shRNAflox/MerCreMer mice after 14d of tamoxifen diet 
or normal diet (Control). Green – Anti-Cre, blue – DAPI. Scale bar 100 μm. n = 3 per group. 
 
 
3.3 Cardiac function following tamoxifen diet 
From approximately day 7 into tamoxifen treatment onwards, the animals displayed signs of 
poor health, such as weight loss and excessive urination. In addition, animals showed 
behavioural disturbances including aggression and apathy.  
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At day 14 post-treatment, ECHO analyses revealed high variability within experimental 
groups, with a large portion of the animals showing severe arrhythmia and depression of 
cardiac function, while the remaining mice appeared to be completely unaffected (data not 
shown). Considering the weight loss and excess urination, the observed phenotype 
suggested diet refusal in some of the mice or strong side effects of tamoxifen, since 
Tβ4shRNAflox/MerCreMer mice on normal diet were healthy. Animals were rested for 14 
days on normal diet to allow for recovery from the effects of the supposed diet refusal and/or 
potential side effects of tamoxifen. After 14 days rest, cardiac function had normalised (%EF 
~ 60, %FS ~30) and was similar across all experimental groups (Figure 3.3). 
 
 
Figure 3.3: Cardiac function measured by transthoracic ECHO following tamoxifen delivery via diet. 
Normal LV EF and LV FS were observed in all groups following 14 days of tamoxifen diet and 14 days 
recovery on normal diet. Data presented as ± SD. 
 
As expected, untreated Tβ4shRNAflox/MerCreMer mice showed a significantly higher body 
weight compared to tamoxifen-treated Tβ4shRNAflox/MerCreMer, Tβ4shRNAflox and 
MerCreMer littermates at sacrifice after 14 days of rest (Figure 3.4 A). Heart weights were 
similar across all groups, but the higher body weight of control-treated 
Tβ4shRNAflox/MerCreMer resulted in a significantly decreased heart-weight-to-body-weight 
(HW/BW) ratio in that group (Figure 3.4 B, C). HW/BW ratios between tamoxifen-treated 
Tβ4shRNAflox/MerCreMer and tamoxifen-treated control groups were comparable indicating 
no hypertrophy at this point. Lung weights were recorded as an indirect measure of cardiac 
insufficiency and pulmonary oedema, but were unchanged between experimental groups 
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(Figure 3.4 D). The lung-weight-to-body-weight (LuW/BW) ratio was altered as a 
consequence of decreased body weight in the tamoxifen-treated groups, as reported for the 
HW/BW ratio (Figure 3.4 E). Liver weights were recorded to assess the metabolic status of 
the animals and were found to be significantly reduced in tamoxifen-treated Tβ4shRNAflox 
and MerCreMer animals compared to Tβ4shRNAflox/MerCreMer mice on normal diet 
(Figure 3.4 F, G). This supports the hypothesis of food rejection in these animals. While 
overall liver weight loss suggested a similar effect in the tamoxifen-treated 
Tβ4shRNAflox/MerCreMer group, this change did not reach statistical significance.
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Figure 3.4: Recordings of physiological parameters after tamoxifen delivery in the diet. (A) Body 
weights, (B) heart weights, (C) heart-weight-to-body-weight (HW/BW) ratios, (D) lung weights, (E) 
lung-weight-to-body-weight (LuW/BW) ratios, (F) liver weights and (G) liver-weight-to-body-weight 
(LiW/BW) ratios of Tβ4shRNAflox/MerCreMer and control mice after 14 days tamoxifen or normal diet 
and 14 days of rest. Data are expressed as ± SD. 
 
Overall, Tβ4shRNAflox/MerCreMer mice on normal diet showed a natural weight increase 
over the treatment period while tamoxifen-treated groups lost weight 
(Tβ4shRNAflox/MerCreMer, MerCreMer) or maintained their weight (Tβ4shRNAflox) during 
that period (Figure 3.5 A). This effect did not stem from differences in starting weight, which 
was the same for all groups (Figure 3.5 B). 
 
Figure 3.5: Body weight change of mice after one month of tamoxifen diet. (A) Significant loss of body 
weight was observed in Tβ4shRNA/MerCreMer and MerCreMer animals. Tβ4shRNAflox/MerCreMer 
mice on normal chow showed a normal increase of weight of ~2 g. Tamoxifen-treated Tβ4shRNAflox 
mice did not show a gain in weight and were not significantly different from untreated 
Tβ4shRNAflox/MerCreMer animals. (B) Body weights of all groups before start of treatment (n per 
group ≥ 7). 
 
Despite concerns about the overall impact of the observed effects of the diet, the knockdown 
efficiency of Tβ4shRNA was assessed by rtPCR and Western blotting as a proof of principle. 
The PCR efficiency of the Tβ4 real-time probe was determined by preparation of standard 
curves for both PCR reactions and was found to be comparable (89%) to that of the 18s 
probe (85%) indicating its suitability for comparative ΔCτ analysis. Levels of Tβ4 mRNA and 
protein were unaltered in tamoxifen-treated Tβ4shRNAflox/MerCreMer animals compared to 
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tamoxifen-treated MerCreMer littermates (Figure 3.6 A, B). The antibodies used showed 
substantial aspecific binding and the resulting blots were of poor quality indicating the 
superiority of rtPCR to determine the degree of Tβ4 knockdown in this model. 
 
 
Figure 3.6: Tβ4 mRNA and protein levels measured by real-time PCR and Western blotting. (A) 
Levels of Tβ4 mRNA are unaltered in Tβ4shRNAflox/MerCreMer mice following 14 days of tamoxifen 
diet and 14 days of rest. (B) Changes in Tβ4 protein levels cannot be detected by Western blotting. 
Anti-Tβ4 antibodies (Abcam) show very limited specificity in Western blotting. 
 
The overall negative effects of feeding tamoxifen diet on animal physiology and welfare, the 
fact that nuclear localisation of MerCreMer was only moderate and the failure of down-
regulation cardiac Tβ4 called for a change in tamoxifen delivery protocol. Since, oral 
tamoxifen delivery either involved the risk of rejection by the animals or considerable stress 
in the case of gavage, an IP injection protocol was the most feasible option. The original 
report on αMHC/MerCreMer mice described a 5 day injection regime of 20 mg/kg tamoxifen 
daily (Sohal et al. 2001). This protocol was adopted for the subsequent study. 
 
 
3.4 Thymosin β4 knockdown via intraperitoneal tamoxifen injections 
3-4 month old Tβ4shRNAflox/MerCreMer and control mice were injected with tamoxifen or 
EtOH for 5 consecutive days (20 mg/kg daily). After 3-4 weeks of rest body, heart, lung and 
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liver weights and their respective ratios to body weight were unremarkable compared to 
controls (Figure 3.7 A-G). 
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Figure 3.7: Recordings of physiological parameters after IP tamoxifen injections. (A) Body weights, 
(B) heart weights, (C) HW/BW ratios, (D) lung weights, (E) LuW/BW ratios, (F) liver weights and (G) 
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LiW/BW ratios of Tβ4shRNAflox/MerCreMer and control mice after 5 days tamoxifen (20 mg/kg daily) 
or control treatment and 3-4 weeks of rest. 
 
3.4.1 MerCreMer localisation following tamoxifen injections 
A separate batch of Tβ4shRNAflox/MerCreMer animals was sacrificed prematurely 3 days 
after completed injections and cardiac sections analysed for MerCreMer localisation. 
MerCreMer successfully translocated to nuclei of cardiomyocytes after tamoxifen but not 
after control injections (Figure 3.8). 
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Figure 3.8: MerCreMer localisation in the left ventricle of Tβ4shRNAflox/MerCreMer animals. Cardiac 
frozen sections stained with anti-Cre antibody following 5 days tamoxifen (20 mg/kg IP) or EtOH 
control injections and 3 days of rest. Green – anti-Cre, blue – DAPI. Scale bar 200 μm. n = 3 per 
group. 
 
3.4.2 Cardiac function and morphology 3-4 weeks following tamoxifen injections 
Following 3-4 weeks of rest, LV function of tamoxifen-treated Tβ4shRNAflox/MerCreMer 
(%EF 58.93 ± 1.40, %FS 26.47 ± 2.02) animals measured by ECHO was unchanged 
compared to control-treated Tβ4shRNAflox/MerCreMer (%EF 61.25 ± 2.86, %FS 28.73 ± 
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2.48) or tamoxifen-treated MerCreMer single-genotype (%EF 61.44 ± 6.16, %FS 29.56 ± 
3.94) animals (Figure 3.9). 
 
 
 
Figure 3.9: Cardiac function assessed by ECHO. Comparable LV function (EF, FS) at baseline was 
observed between all treatment groups. After 5 days of tamoxifen injections (20 mg/kg daily) and 3-4 
weeks (1M) of rest, cardiac function of Tβ4shRNAflox/MerCreMer animals was unaltered. 
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To investigate potential changes of cardiac morphology following the putative downregulation 
of Tβ4, cardiac sections of tamoxifen or EtOH-treated Tβ4shRNAflox/MerCreMer and control 
mice were analysed by Masson‟s trichrome staining. This revealed interstitial fibrosis in a 
number of Tβ4shRNAflox/MerCreMer mice (Figure 3.10). 
 
 
Figure 3.10: Masson‟s trichrome staining of cardiac sections. Overall morphology and fibrosis of the 
hearts of (A) control-treated Tβ4shRNAflox/MerCreMer and (B) tamoxifen-treated (20 mg/kg daily) 
Tβ4shRNAflox/MerCreMer 3-4 weeks following 5 days of injections. Tamoxifen-treated mice disply 
mild interstitial fibrosis. Scale bar 100 μm. n > 3 per group. 
 
The incidence of fibrosis was not seen in relation to putative Tβ4 downregulation, since it 
was also observed in tamoxifen-treated αMHC/MerCreMer mice lacking the floxed 
transgene. Since paraffinised tissue was only available of a subgroup of animals, this 
unexpected phenotype was analysed in a larger population of Tβ4shRNAflox/MerCreMer, 
αMHC/MerCreMer and wt mice. 
 
 
3.4.3 Cardiac physiology and function of Tβ4shRNAflox/MerCreMer animals 6 
weeks following tamoxifen treatment 
Following the discovery of fibrosis in some tamoxifen-treated MerCreMer positive animals, a 
larger cohort was injected for 5 days with 20 mg/kg tamoxifen daily. To investigate the full 
extent of fibrosis and its longer term effect on cardiac function, animals were rested for 6 
weeks before analysis by ECHO and histology. Body weights of treated animals were normal 
as for the previous study groups and the HW/BW ratio showed no increase in heart mass 
indicative of a cardiac hypertrophy (Figure 3.11). 
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Figure 3.11: Physiological parameters following tamoxifen injections and 6 weeks of rest. (A) Body 
weights and (B) HW/BW ratios of animals subjected to 5 days of IP tamoxifen treatment (20 mg/kg 
daily). 
 
However, after the prolonged resting phase of 6 weeks, a significant decrease in LV EF and 
FS was observed in tamoxifen-treated Tβ4shRNAflox/MerCreMer animals (%EF 55.90 ± 
6.29, %FS 25.35 ± 3.57) compared to control-treated mice (%EF 62.36 ± 2.76, %FS 29.49 ±  
1.93, Figure 3.12). In addition, the tamoxifen-treated MerCreMer control group also showed 
depressed cardiac function (%EF 55.52 ± 6.58, %FS 24.86 ± 3.93). 
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Figure 3.12: ECHO results after IP tamoxifen injections and 6 weeks rest. LV EF and FS of 
Tβ4shRNAflox/MerCreMer and MerCreMer animals following 5 days of tamoxifen (20 mg/kg daily) or 
control (EtOH) injections. 
 
This depression of LV function and the associated fibrotic cardiac phenotype of MerCreMer 
control mice prompted more detailed investigations described in Chapter 4. 
 
3.4.4 Assessment of Thymosin β4 knockdown following tamoxifen injections 
Tβ4 knockdown efficiency following the 5 day tamoxifen injection protocol was assessed by 
rtPCR and Western blotting. Cardiac Tβ4 mRNA and protein levels were unaltered after 6 
weeks of rest (Figure 3.13). 
 
  Chapter 3 
 
117 
 
Figure 3.13: rtPCR and Western Blot for Tβ4 following 5 days of tamoxifen injections (20 mg/kg daily). 
(A) Levels of Tβ4 mRNA were not changed in Tβ4shRNAflox/MerCreMer mouse hearts compared to 
control-treated Tβ4shRNAflox/MerCreMer animals after 6 weeks of rest. (B) Tβ4 Western blotting 
shows bands at the corresponding height and an abundance of aspecific bands. No changes are 
detectable between groups. Lanes 1-4 Tβ4shRNAflox/MerCreMer 5 days tamoxifen (20 mg/kg daily), 
5-6 EtOH control-treated Tβ4shRNAflox/MerCreMer, 7-8 mouse thymus controls and lane 9 normal wt 
heart. 
 
Immunofluorescence staining on cardiac sections of tamoxifen-treated 
Tβ4shRNAflox/MerCreMer mice revealed no differences in Tβ4 expression in the heart 
compared to controls (not shown). However, a strong signal was observed in cells lining the 
blood vessels (Figure 3.14). 
 
 
Figure 3.14: Immunofluorescence staining for Tβ4 on cardiac frozen sections. (A) Tβ4 was detected 
at basal levels in the left-ventricular myocardium. (B-C) Blood vessels of Tβ4shRNAflox/MerCreMer 
mice show a stronger signal. Sections shown are from EtOH control-treated 
Tβ4shRNAflox/MerCreMer. Scale bar 100 µm. 
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3.5 Thymosin β4 knockdown in vitro 
Since a knockdown of Tβ4 was not observed in vivo and Tβ4 immunofluorescence data 
suggested that other cardiac cell populations such as endothelial or smooth muscle cells 
express higher levels of Tβ4 than cardiomyocytes, alternative approaches to reduce the 
amount of contaminating cell types were considered. A more selective investigation of Tβ4 
knockdown was performed in vitro using neonatal cardiomyocytes (NCM) of 
Tβ4shRNAflox/MerCreMer mice. 
 
3.5.1 Neonatal cardiomyocyte culture 
The isolation procedure of mouse neonatal NCM removes endothelial cells, most fibroblasts 
and other contaminating cell types from the cell preparation. The aim of this experiment was 
to treat a purified culture with tamoxifen in vitro to obtain a more specific result of Tβ4 levels 
in cardiomyocytes. In the absence of a better reference, the initial range of suitable non-toxic 
tamoxifen concentrations for treatment in vitro was adopted from experiments involving 
MCF7 breast cancer cells, which showed that tamoxifen was effective at concentrations of 2 
μM and 6 μM while 10 μM tamoxifen resulted in cell death within 48h (Furr and Jordan 1984). 
In the present setup, concentrations of 8 μM, 4 μM and 2 μM were found to be toxic for NCM 
cultures. After careful titration 200 nM tamoxifen were found to be the most suitable 
concentration. 
To control for potential direct or indirect effects of tamoxifen-induced MerCreMer protein on 
Tβ4 expression (see Chapter 4), MerCreMer single-genotype NCM and fibroblast cultures 
were treated with 200 nm tamoxifen or equivalent EtOH control preparations. Tamoxifen-
induced MerCreMer did not affect Tβ4 mRNA levels which remained unchanged in 
αMHC/MerCreMer derived NCM and fibroblasts upon treatment (Figure 3.15 A). 
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Figure 3.15: Tβ4 mRNA levels after tamoxifen treatment of neonatal cardiomyocytes in vitro 
measured by rtPCR. (A) Tβ4 mRNA levels in NCM and neonatal cardiac fibroblasts derived from 
MerCreMer single-transgenic littermates were analysed after tamoxifen treatment. (B) Tβ4 mRNA 
levels in Tβ4shRNAflox/MerCreMer NCM and fibroblasts after tamoxifen treatment. 
 
However, Tβ4 mRNA was found to be significantly lower in αMHC/MerCreMer NCM 
compared to cardiac EtOH treated αMHC/MerCreMer fibroblasts. The loss of a tamoxifen-
treated MerCreMer fibroblast sample meant that a sufficient number of samples was not 
available to include this group in the statistical analysis (n = 2). Tamoxifen treatment of 
Tβ4shRNAflox/MerCreMer NCM and fibroblasts resulted in a similar expression pattern, with 
higher Tβ4 mRNA levels in neonatal cardiac fibroblasts compared to tamoxifen-treated NCM 
and no significant knockdown of Tβ4 in NCM (Figure 3.15 B). Control-treated 
Tβ4shRNAflox/MerCreMer showed no significant change compared to fibroblast controls. 
 
 
3.6 Ex-vivo investigation of thymosin β4 knockdown in adult cardiomyocyte 
preparations isolated by Langendorff perfusion 
One limitation of NCM cultures in terms of purity is the presence of cardiac fibroblasts. Even 
with relatively low starting counts following a good purification, the high proliferative potential 
of fibroblasts meant that a substantial contamination of up to estimated 10% was frequently 
observed at the end of each experiment. Eliminating all fibroblasts from the culture by 
prolonged pre-plating resulted in poor NCM cultures indicating the dependency of NCM on 
fibroblast-mediated conditioning of the culture likely by secretion of factors or extracellular 
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matrix. Since fibroblasts were shown to express higher concentrations of Tβ4 mRNA than 
cardiomyocytes (Figure 3.15) the dilution of a putative knockdown (albeit small) and 
consequently the failure to reach a statistically significant result was conceivable. An 
additional confounding factor could comprise of the culture conditions which could have 
potentially induced changes in Tβ4 mRNA expression. With the aim to limit these influences 
and to avoid dilution of the knockdown by Tβ4-expression of other cell types, adult 
cardiomyocytes were isolated from animals after 5 days tamoxifen injections (20 mg/kg). 
Since a separate line of experiments had established the formation of cardiac fibrosis and 
dysfunction in αMHC/MerCreMer animals following the 5 day injection protocol (see Chapter 
4), a single injection protocol of 40 mg/kg tamoxifen was additionally tested in this study. The 
reduced total tamoxifen concentration was aimed at lowering the impact of the treatment on 
cardiomyocytes by limiting the time of MerCreMer in the nucleus. In order to determine the 
success of nuclear localisation of MerCreMer after a single tamoxifen injection (40 mg/kg), 
immunohistochemistry was performed on frozen sections of tamoxifen and control-treated 
Tβ4shRNAflox/MerCreMer mice three days after treatment. A single injection (40 mg/kg) was 
sufficient to induce nuclear localisation of MerCreMer although to a lesser degree than the 5 
day injection protocol of 20 mg/kg daily (compare Figure 3.8 and Figure 3.16). 
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Figure 3.16: Immunofluorescence staining for Cre recombinase on left-ventricular cardiac tissue. 
Nuclear translocation of MerCreMer was shown in Tβ4shRNAflox/MerCreMer mice after 1d tamoxifen 
injection (40 mg/kg) but not after EtOH control injection. Green – anti-Cre, blue – DAPI. Scale bar 50 
μm. 
 
Following 5d/1d of tamoxifen injections and 1½ and 2½ months of rest respectively, hearts 
were harvested, Langendorff-perfused and adult cardiomyocytes enzymatically extracted 
from the tissue. Preparations typically yielded between 40% and 80% viable cardiac 
myocytes (Figure 3.17). 
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Figure 3.17: Morphology of adult cardiomyocytes isolated by Langendorff perfusion. (A) 10x 
magnification, (B) 20x magnification of adult cardiomyocytes in a Petri dish. * dead cardiomyocyte, # 
living and beating adult cardiomyocyte. 
 
mRNA was extracted from the isolated NCM and rtPCR analysis revealed that Tβ4 mRNA 
expression was unaltered compared to controls following 5 days of injections (20 mg/kg 
daily) and 1½ months of rest (Figure 3.18). In consequence, animals injected for 1 day (40 
mg/kg) were maintained for 2 ½ months prior to analysis. Nevertheless, as for the 5-day-
injected groups, this did not result in knockdown of Tβ4 mRNA. 
 
 
Figure 3.18: Determination of Tβ4 mRNA levels in adult cardiomyocytes by real-time PCR. Tβ4 
mRNA levels were unaltered in adult cardiomyocytes from Tβ4shRNA/MerCreMer mice after 5d 
tamoxifen injections IP (20 mg/kg daily) and 1½ months of rest or 1d injection (40 mg/kg) and 2½ 
month of rest. Controls (Ctrl) consisted of a tamoxifen-treated, heterogeneous population of 2 
Tβ4shRNA and 3 MerCreMer litter mates (5d) and 5 tamoxifen treated wt litter mates (1d) 
respectively. 
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3.7 Discussion 
shRNA-mediated knockdown of Tβ4 was evaluated after tamoxifen delivery in the diet, by IP 
injections, in vitro and ex vivo. In the following section strengths and limitations of each 
approach will be discussed and the overall suitability of a shRNA-mediated adult knockdown 
of cardiac Tβ4 evaluated. 
 
3.7.1 Tβ4 knockdown in vivo 
Oral tamoxifen delivery: Delivering tamoxifen in the diet has caused unexpected changes in 
physiology and animal behaviour. The weight loss observed in mice on tamoxifen diet is 
likely a consequence of diet refusal since animals were age-matched and body mass was 
comparable at baseline across all groups (Figure 3.4 A, Figure 3.5 B). With reference to 
data presented in Chapter 4, it is however notable that the strongest decrease in body weight 
occurred in mice carrying the MerCreMer transgene potentially indicating a contribution of 
Cre. The observed reduction in liver weight can be explained by increased glucogenesis and 
concomitant depletion of hepatic intracellular glucose stores resulting in decreased 
hepatocyte size in response to fasting (Figure 3.4 F, Sokolovic et al. 2008). Relative lung 
weights in untreated Tβ4shRNAflox/MerCreMer mice were significantly lower compared to 
tamoxifen-treated Tβ4shRNAflox/MerCreMer mice, but since overall lung weights were 
similar across all groups this can be attributed to the physiological body weight gain in 
untreated mice, which was absent in the treated populations (Figure 3.4 D, E). Despite the 
fact that cardiac function was not chronically altered and normalised after 14 days of rest on 
normal diet oral delivery of tamoxifen via the diet proved to affect overall animal health and 
physiology to a degree that could certainly influence overall experimental outcomes (Figure 
3.3). Since Cre localisation to nuclei of cardiomyocytes was only patchy and faint (Figure 
3.2) and since no decrease in Tβ4 mRNA levels was observed (Figure 3.6), concerns 
regarding the successful delivery of sufficient tamoxifen arose. In summary, refusal to ingest 
sufficient amounts of chow, indicated by total weight and liver weight loss, would explain the 
physiological and behavioural changes, as well as the failed knockdown of Tβ4. In addition, 
compensatory drinking indicated by excessive urination would have flushed out tamoxifen, 
thus further reducing tamoxifen levels in the body. To precisely control tamoxifen delivery 
and to avoid weight loss and the associated phenotypic changes, the IP injection protocol 
was adopted (Sohal et al. 2001). 
IP tamoxifen injections: In addition to expected transitory cardiac dysfunction in MerCreMer-
positive animals, cardiac interstitial fibrosis was discovered not only in tamoxifen-injected 
Tβ4shRNAflox/MerCreMer mice but also in tamoxifen-injected αMHC/MerCreMer animals 
(Figure 3.10, Buerger et al. 2006). Since these effects were not observed in control-treated 
Tβ4shRNAflox/MerCreMer mice, a causal relationship of tamoxifen-primed Cre or tamoxifen 
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alone was further investigated, as described in Chapter 4. Despite the longer resting period 
which allowed for more time of shRNA expression and its action, a decrease in Tβ4 levels 
was not observed. The observation of higher levels of Tβ4 in blood vessel-associated cells 
by immunofluorescence compared to overall cardiac expression prompted the adoption of an 
in vitro approach using NCM. 
 
3.7.2 Tβ4 knockdown in vitro 
During NCM culture setup, pre-plating removes most fibroblasts adhering to the plastic of the 
cell culture dish and smaller cell types are excluded by sequential low speed centrifugation 
and medium changes. The resulting cultures contain low counts of fibroblasts and high 
concentrations of NCM. Near complete removal of fibroblasts from the culture by repeated 
pre-plating was observed to cause CM distress potentially caused by their dependence on 
basal levels of fibroblast-secreted factors (data not shown). Consequently, low levels of 
fibroblasts were allowed. Treating NCM with tamoxifen in vitro proved difficult due to the 
absence of protocols suitable for NCM in the literature. Concentrations used for other cell 
types proved to be cytotoxic for NCM and had to be lowered to sub-lethal levels. After finding 
changes in cardiac function in response to tamoxifen-primed MerCreMer in the in vivo 
knockdown study, the effects of tamoxifen-treating αMHC/MerCreMer NCM were evaluated. 
Tamoxifen treatment of Tβ4shRNAflox/MerCreMer NCM in vitro also showed no significant 
knockdown of Tβ4 mRNA (Figure 3.15 B). The only other significant population of cells in 
the culture were cardiac fibroblasts in which a higher Tβ4 mRNA expression was observed in 
comparison with NCM. 
 
3.7.3 Assessment ex-vivo 
The observation that fibroblasts express higher levels of Tβ4 compared to cardiomyocytes 
showed that more accurately defined experimental parameters were required to investigate 
the effects of adult loss of Tβ4 in cardiomyocytes. The use of highly purified adult 
cardiomyocytes cultures from Tβ4shRNAflox/MerCreMer mice following tamoxifen-treatment 
in vivo was considered to be a suitable additional approach since it removes contaminating 
cell types. Although FACS sorting and marker analysis by rtPCR were not performed, the 
isolation conditions were specifically designed for cardiomyocytes and final visual inspection 
did not reveal any living cell populations other than cardiomyocytes. RNA was isolated 
immediately following the isolation procedure, however as for the previous approaches, ex 
vivo investigation of adult cardiomyocytes did not show a knockdown of Tβ4 (Figure 3.18). 
While failure to observe Tβ4 knockdown in any of the applied systems was unexpected and 
detrimental for the further conduct of this study, certain consideration need to be taken into 
account regarding each approach before judging the overall outcome. 
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3.7.4 Limitations in vivo 
Despite the finding of fibrosis in tamoxifen-treated αMHC/MerCreMer mice (see also Chapter 
4) there is uncertainty whether the amount of tamoxifen was sufficient to induce MerCreMer 
over a long enough period to activate shRNA expression. Although, MerCreMer was 
observed in nuclei following IP injections, others have reported that 5 days of 20 mg/kg 
tamoxifen IP is not sufficient to achieve significant reduction of their target gene (Koitabashi 
et al. 2009). Good recombination was reported at a dose of 80 mg/kg for 5 days but in this 
study resulted in 60% mortality after 7 days which would not have been acceptable in the UK 
following the Animals (Scientific Procedures) Act 1986. Furthermore, the side-effects in the 
surviving mice would have substantially influenced experimental outcomes. To distinguish 
between failed recombination and failed shRNA activity a direct investigation of genomic 
DNA by sequencing and analysis of Tβ4shRNA by Northern blotting respectively could have 
been performed and this should be considered for future shRNA-based depletion 
experiments (Hoess et al. 1982; Koscianska et al. 2011). An additional caveat constitutes the 
possibility that tamoxifen treatment alone modulates Tβ4 expression. Recent reports have 
shown that tamoxifen can change approximately 10.9% of the transcriptome after 4 days of 
tamoxifen injections although at a higher dose of 40 mg/kg daily (Hougen et al. 2010). 
However, since no difference was detectable between tamoxifen-treated 
Tβ4shRNAflox/MerCreMer animals and EtOH control-treated Tβ4shRNAflox/MerCreMer 
mice, this was ruled out as a possible explanation for the failure to observe a knockdown. 
“Leaky” MerCreMer, i.e. its nuclear activity in the absence of tamoxifen, was reported in vitro 
and can result in failure to obtain changes in reference to the already affected baseline 
measurement (Buelow and Scharenberg 2008). However, this requires very high expression 
of MerCreMer. Furthermore, the authors suggest that a small cell size is important since their 
study investigated the relatively small DT-40B lymphocyte line. In addition, levels of non-
tamoxifen primed nuclear MerCreMer would have been very low since nuclei of control-
treated animals did not stain positive for Cre during IF (Figure 3.1). 
While it is difficult to determine how much MerCreMer is expressed in our system and 
whether this is considered to be low enough to ensure tight regulation of Cre activity, 
cardiomyocytes are significantly larger than lymphocytes. That Tβ4 mRNA levels were 
comparable between treated Tβ4shRNAflox/MerCreMer mice and MerCreMer littermates 
indicated that uninduced nuclear Cre activity does not account for the failed knockdown. 
While adjusted tamoxifen delivery approaches in terms of composition, route, concentration 
and timing are issues to be considered (see Chapter 4), a main limitation of this work has 
been the absence of a reliable expression profile of Tβ4 in the adult heart. While there is 
some evidence that cardiomyocytes express higher levels of Tβ4 than the overall heart, I 
observed that vascular cells and fibroblasts are likely to contribute more significantly to the 
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cardiac Tβ4 pool than cardiomyocytes (Su et al. 2004). Since total cardiac RNA was 
investigated in vivo, this effect could have diluted the expected knockdown. In addition, 
macrophages, lymphocytes, and granulocytes were shown to express significant amounts of 
Tβ4 (Xu et al. 1982; Gondo et al. 1987; Hannappel et al. 1989). While every effort was made 
to remove residual blood from the tissue before freezing, even low amounts of contaminating 
blood cells could have caused significant interference. For future investigations, careful 
expression profiling by in situ hybridisation should be performed in the respective model in 
advance to identify domains and cell types of high Tβ4 expression. While levels in 
cardiomyocytes might be low, Tβ4 is a peptide with diverse functions and the role of basal 
Tβ4 expression and its importance for cardiac function especially after injury remain 
important questions to be answered. 
 
3.7.5 Limitations in vitro 
While experimentation in vitro had the described advantage of reducing contaminating cell 
populations a problem of the neonatal cell culture experiment was the genetic heterogeneity 
of the NCM. Whole litters of Tβ4shRNAflox/MerCreMer and αMHC/MerCreMer breedings 
were used for each NCM preparation, since genotyping individual embryos in advance was 
not feasible. Consequently, the cell population consisted predominantly of 
Tβ4shRNAflox/MerCreMer cells but also contained MerCreMer and Tβ4shRNAflox single-
transgenic cardiomyocytes. This would have reduced the overall degree of knockdown 
observed within each pooled sample, especially if the level of knockdown was not high to 
start with. In addition, a general limitation of any cell culture experiment is the use of 
undefined serum. Growth factors and other molecules induce changes in cultured primary 
cells making them less comparable to cells in vivo. This also applies to the isolation of adult 
cardiomyocytes by Langendorff apparatus. 
 
3.7.6 General considerations 
It is indeed conceivable that the isolation conditions stimulated a survival signalling in 
cardiomyocytes involving upregulation of Tβ4 (Bock-Marquette et al. 2004). Such an 
endogenous upregulation of Tβ4 as occurs in response to cardiac insult in zebrafish, mouse 
and pig heart could have been a source of substantial interference affecting all described in 
vitro experiments (Lien et al. 2006; Smart et al. 2007; Shah et al. 2011). In vivo, harvesting 
the heart for RNA extraction involved resection, weighing and dissected prior to freezing 
indicating that this limitation could extend to this part of study. To circumvent this potential 
caveat, freeze-clamping of beating hearts before cardiac resection and immediate storage in 
liquid N2 would have been necessary. However, this would have limited the use of each heart 
to RNA analysis and would have doubled the amount of animals needed if other experiments 
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such as protein analysis and histology were to be performed as well. A final consideration 
should be given to the fact that standard mouse chow is soy-based and as such contains 
relatively high levels of phytoestrogens (Konhilas and Leinwand 2007). While the affinity of 
Mer for oestrogen is 1,000 times lower than for tamoxifen it is conceivable that in some 
settings this could result in unwanted MerCreMer activation (Zhang et al. 1996). However, as 
described previously, similar levels of Tβ4 were observed in Tβ4shRNAflox/MerCreMer mice 
and single-genotype controls this can be discounted as a possible explanation. 
Surprisingly, a very recent report showed that global knockout of Tβ4 is not embryonic lethal 
and does not result in abnormal cardiac function or morphology (Banerjee et al. 2012). In 
general, global knockout mice can in some instances compensate for an early loss of 
function throughout their embryonic development by compensatory upregulation of 
functionally redundant or protective genes hence buffering the phenotype which would occur 
in an acute loss of function. However, Banerjee et al. included data from a conditional Tβ4 
knockout which showed no abnormalities following this sudden ablation of Tβ4 during 
development. In the light of these new findings, it is evident that shRNA-mediated 
downregulation of Tβ4 as attempted here, is now obsolete since it is indirect, too complex 
and does not produce a significant cardiac phenotype. Conditional knockouts are more 
effective at depleting the target gene and do not suffer potential shRNA related pitfalls of 
limited knockdown efficiency and off target effects. 
It is conceivable that the strong cardiac phenotype and embryonic lethality observed in 
Tβ4shRNAflox/Nkx2.5-Cre mice is the result of shRNA off-target effects or related to Cre 
toxicity (Chapter 4) or a combination of both (Smart et al. 2007). Regardless of these 
potential shortcomings of this developmental study, the beneficial effects of Tβ4 during 
wound healing and recovery have been well documented and it will remain an interesting 
candidate peptide for future gene or cell based therapy (Malinda et al. 1999; Philp et al. 
2003; Bock-Marquette et al. 2004; Hinkel et al. 2008; Zhang et al. 2009). Besides its well 
characterised relationship with actin, only a limited number of Tβ4-interacting proteins have 
been identified (Safer et al. 1991; Didry et al. 2012). These include PINCH and ILK to 
facilitate complex formation with Akt1/2 (Fan et al. 2009), DNase helicase subunit II Ku80 
(Bednarek et al. 2008), indirect or direct interaction with hMLH1 (Brieger et al. 2007) and 
more recently extracellular receptor F1-F0 ATP synthase (Freeman et al. 2011). However, 
how Tβ4 regulates the abundance of diverse functions described in the literature can 
currently not be explained mechanistically. Especially in the heart the absence of known 
binding partners necessitates future proteomic research into Tβ4-interacting proteins. An 
effective and popular approach to achieve this is the use of a tagged recombinant fusion 
proteins used to pulldown binding partners followed by 2D electrophoresis and mass 
spectrometry, as outlined in Chapter 5. 
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3.7.7 Summary 
In summary, the presented work showed that Tβ4 is expressed at higher levels in fibroblasts 
and potentially other cardiac cell types compared to cardiomyocytes. shRNA-mediated 
downregulation using a cardiomyocyte-specific tamoxifen-sensitive Cre driver is an overly 
complex approach of gene regulation since it requires excessive controlling and contains 
risks related to shRNA expression or functional failure. Furthermore, a recent publication has 
performed total ablation of Tβ4 during development using a conditional knockout and 
observed no defects under physiological conditions. For future investigations into the function 
of Tβ4-depleted hearts during stress or injury, this model should be favoured over shRNA-
based approaches. 
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Chapter 4 -  Cardiac Fibrosis in Tamoxifen-treated 
αMHC/MerCreMer Mice 
 
4.1 Introduction 
Histological analyses of Chapter 3 showed interstitial cardiac fibrosis in the majority 
MerCreMer-positive mice (~60%) treated with tamoxifen for 5 days (20 mg/kg). 
αMHC/MerCreMer mice have become the most prominent tool of inducible cardiac gene 
regulation and a chronic defect such as fibrosis caused by the system itself would have 
significant implications for the interpretability of research past and present. This chapter 
describes the fibrotic phenotype discovered in tamoxifen-treated mice harbouring the 
MerCreMer transgene. The circumstances surrounding the appearance of the phenotype 
including the correlation between fibrosis and the abundance of MerCreMer in the genome 
were investigated in Tβ4shRNAflox/MerCreMer mice. The extent of the phenotype and 
molecular changes that contribute to it are characterised in the original αMHC/MerCreMer 
strain and the role of tamoxifen dose evaluated in this context. 
 
 
4.2 Cardiac morphology of Tβ4shRNAflox/MerCreMer animals following 
tamoxifen treatment 
Changes in cardiac function are often reflected in altered macroscopic or microscopic 
morphology of the heart. To investigate the cause of the observed decreased cardiac 
performance measured by ECHO, changes in cardiac morphology were analysed (Chapter 
3, Figure 3.12). To assess the structure of Tβ4shRNAflox/MerCreMer hearts after tamoxifen-
mediated induction of MerCreMer, paraffinised cardiac sections were stained by Masson‟s 
trichrome technique to visualise changes in extracellular matrix (ECM) expression and 
cellular architecture of the organ. After 5 days tamoxifen injections (20 mg/kg daily) and 3-4 
weeks of rest, patchy interstitial and perivascular fibrosis was observed predominantly in the 
left ventricle, but also in the right ventricle and septum (Figure 4.1). 
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Figure 4.1: Masson‟s trichrome staining on cardiac sections following 5 days of tamoxifen injections 
and 3-4 weeks of rest. (A) Normal LV morphology observed in EtOH-treated 
Tβ4shRNAflox/MerCreMer mice. (B-E) Interstitial fibrosis observed in tamoxifen-treated 
Tβ4shRNAflox/MerCreMer mice and (F-I) tamoxifen-treated MerCreMer littermates. (J) Septum of 
tamoxifen-treated Tβ4shRNAflox/MerCreMer mouse. (K) RV observed in EtOH-treated and (L) in 
tamoxifen-treated Tβ4shRNAflox/MerCreMer mice. Scale bar 100 μm. 
 
Fibrosis was accompanied by an infiltration of small cells in the proximity of blood vessels, 
which may relate to a strong inflammatory response. A larger study group was setup to 
specifically assess the distribution of fibrosis among mice of the different transgenic 
backgrounds used in this study. Animals were rested for 6-7 weeks after treatment to allow 
more time for the manifestation of the phenotype. To implicate tamoxifen in the disease 
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process, tamoxifen-treated wt and Tβ4shRNAflox animals as well as EtOH-treated 
Tβ4shRNAflox/MerCreMer mice were also included in this experiment. An incomplete 
penetrance of the fibrotic phenotype was observed, with only ~60% of tamoxifen-treated 
MerCreMer-positive mice affected (16/27, Figure 4.2, Table 4.1). 
 
 
Figure 4.2: Masson‟s trichrome stain of cardiac sections of Tβ4shRNAflox/MerCreMer animals and 
controls following tamoxifen or control injections and 6-7 weeks of rest. (A) Normal cardiac 
morphology as observed in EtOH control treated Tβ4shRNAflox/MerCreMer mice and tamoxifen-
treated Tβ4shRNAflox and wt animals. (B, C) Tβ4shRNAflox/MerCreMer animals and (D-F) 
Tβ4shRNAflox
-/-
/MerCreMer animals display cardiac fibrosis after 5 days of daily tamoxifen injections 
(20 mg/kg). All images display LV tissue. Scale bars 100 μm. 
 
Based on observations by Buerger and co-workers showing that high cellular levels of Cre 
driven by the αMHC promoter (αMHC/Cre) caused dilated cardiomyopathy, heart failure and 
death in mice in a copy number-dependent fashion, a potential correlation of the phenotype 
with MerCreMer gene copy number was investigated (Buerger et al. 2006). Since, 
αMHC/MerCreMer transgenic animals were generated by non-targeted insertion, detection of 
homo-/heterozygosity by means of normal genotyping PCR was not possible. Hence, a gene 
copy analysis was performed by rtPCR (Table 4.1). 
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Table 4.1: Cre gene copy number analysis. Genotype and correlating gene copy score indicating 
heterozygosity/low Cre (0.86 – 1.35), homozygosity/high Cre (1.80 – 2.62) and absence of a Cre 
transgene (~0). Presence and absence of cardiac fibrosis following tamoxifen injections for 5 days at 
20mg/kg daily are indicated by + and – respectively. 
Genotype Gene copy 
score 
Cardiac 
fibrosis 
Cardiac 
fibrosis per 
group 
Group 
classification 
Tβ4shRNAflox/MerCreMer 0,97 +* 
9/14 Low Cre 
 1,05 + 
 1,08 + 
 1,09 + 
 0,95 + 
 1,01 + 
 0,93 + 
 1,04 + 
 0,96 + 
 0,86 - 
 0,96 - 
 0,99 - 
 1,05 - 
 1,35 - 
MerCreMer 0,92 + 
3/5 Low Cre 
 0,98 + 
 1,19 + 
 0,92 - 
 0,93 - 
 1,00 # - 
Tβ4shRNAflox/MerCreMer 1,80 +* 
2/5 High Cre 
 1,98 + 
 2,23 - 
 2,44 - 
 2,62 - 
MerCreMer 2,18 +* 
3/3 High Cre  2,31 + 
 2,43 + 
Tβ4shRNAflox and wt 0,00 - 
0/5 Cre negative 
 0,00 - 
 0,00 - 
 0,00 - 
 0,04 - 
# Reference sample, * Severe cardiac fibrosis 
 
No correlation between cardiac fibrosis or its severity and gene copy number could be 
observed since both MerCreMer homo- and heterozygous mice of any background were 
affected by fibrosis. Tβ4shRNAflox and wt littermate controls had the expected gene copy 
score of 0 and served as negative controls in this experiment. 
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4.3 Abnormal cardiac function and morphology in αMHC/MerCreMer mice 
following tamoxifen treatment 
Tβ4shRNAflox/MerCreMer animals used in Chapter 3 were of a mixed 129Ola/C57Bl/6J 
background. To address the possibility of strain-specific effects of MerCreMer expression, 8 
week old heterozygous αMHC/MerCreMer mice of the original C57Bl/6J background were 
examined at 4-5 weeks following standard tamoxifen treatment (5 days, 20 mg/kg daily). A 
significant depression of cardiac function (EF% 51.04 ± 2.10, FS% 23.40 ± 2.00) compared 
to wt mice (EF% 62.55 ± 3.00, FS% 29.35 ± 2.17), untreated αMHC/MerCreMer mice of 
various ages (8w EF% 60.21 ± 3.64, FS% 28.36 ± 1.44, 7-8M EF% 59.27 ± 1.34, FS% 27.07 
± 1.35) and tamoxifen treated Cre-negative (MerCreMer-/-) littermates (EF% 59.31 ± 2.50, 
FS% 27.55 ± 2.37) was observed by ECHO (Figure 4.3). 
 
 
Figure 4.3: Cardiac function of αMHC/MerCreMer measured by ECHO. Animals were injected with 
tamoxifen for 1 day (40 mg/kg) or 5 days (20 mg/kg daily) and rested for 4-5 weeks. Left-ventricular 
ejection fraction measured in 2D-mode was significantly reduced after 5 days tamoxifen injections in 
αMHC/MerCreMer mice compared to wt or untreated littermates (*** p < 0.001). Injecting a single dose 
of tamoxifen (40 mg/kg) had no effect on function. Left-ventricular fractional shortening was 
significantly reduced in the 5 days-injected group compared to all other groups (* p < 0.05). Data is 
expressed as ± SD. 
 
Since the original study was conducted in Tβ4shRNAflox/MerCreMer mice at 3-4 month of 
age, aged αMHC/MerCreMer mice were included in the analysis to rule out any age related 
occurrence of fibrosis as a consequence of chronic cytoplasmic levels of MerCreMer protein. 
Given that Hougen and co-workers reported that a single tamoxifen injection of 40 mg/kg is 
sufficient to induce recombination without impacting cardiac function, an additional 
αMHC/MerCreMer group using the 1 day injection protocol was assessed (Hougen et al. 
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2010). A single injection of tamoxifen (40 mg/kg) showed no detectable negative effect on 
cardiac function in the ECHO traces (EF% 60.14 ± 2.92, FS% 27.16 ± 1.62). 
Histological analyses revealed that following the 5 day injection protocol, all samples of 
MerCreMer-positive animals displayed interstitial and perivascular cardiac fibrosis (5/5, 
Figure 4.4). As previously described for Tβ4shRNAflox/MerCreMer animals (Figure 4.2), 
increased ECM expression and replacement of cardiomyocytes with fibroblasts were 
observed in LV, RV and interventricular septum in this group. The single injection protocol 
did not result in any microscopic changes of heart morphology. 
 
 
Figure 4.4: Masson‟s trichrome staining of cardiac sections of αMHC/MerCreMer animals after 
tamoxifen injections and 4-5 weeks of rest. (A-E) Interstitial and perivascular fibrosis in the LV of 
following 5 days of injections (20 mg/kg). (F) LV morphology after a single injection of tamoxifen (40 
mg/kg). Scale bar 100 μm. 
 
Gross cardiac morphology was normal with no thinning or thickening of myocardium in the 
affected group. This is in line with the ECHO data showing normal LV inner diameters (LVID) 
during diastole and systole (Figure 4.5). Untreated αMHC/MerCreMer animals of all ages (8 
weeks, 7-8 months) were unaffected. 
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Figure 4.5: Left-ventricular inner diameters analysed by ECHO. Left-ventricular inner diameters of 
untreated αMHC/MerCreMer animals of various ages and tamoxifen-treated animals at 8 weeks of age 
were measured during diastole (LVIDd) and systole (LVIDs). 
 
Following 1 day (40 mg/kg) or 5 days (20 mg/kg) tamoxifen treatment, normal BW, HW/BW 
and LuW/BW ratios and a healthy liver weight were observed in αMHC/MerCreMer and 
C57BL/6J mice compared to untreated αMHC/MerCreMer animals (Figure 4.6).  
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Figure 4.6: Physiological parameters of αMHC/MerCreMer mice measured after tamoxifen or control 
injections and 4-5 weeks of rest. (A) Body weight, (B) heart weight, (C) heart-weight-to-body-weight 
(HW/BW) ratio, (D) lung weight, (E) lung-weight-to-body-weight (LuW/BW) ratio and (F) liver weights 
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of αMHC/MerCreMer and C57BL/6J mice after 1d or 5d tamoxifen treatment (40 mg/kg, 20 mg/kg 
daily). 
 
In summary, detailed analyses including histology and functional assessment showed that 
despite the fibrosis, dilated cardiomyopathy, hypertrophy or advanced heart failure were not 
present after 4-5 weeks of rest in animals treated with a single tamoxifen injection. 
 
 
4.4 Mechanism of MerCreMer-induced fibrotic phenotype 
To investigate the immediate response of the heart to 5 days tamoxifen exposure, animals 
were sacrificed 3 days after completing the treatment. At time of explant, the hearts of 
tamoxifen treated αMHC/MerCreMer animals showed clear signs of an inflammatory 
reaction, such as swelling and a deep red discoloration. Histology revealed cell infiltrates in 
the affected ventricles (Figure 4.7). 
 
 
Figure 4.7: Cardiac sections of tamoxifen treated αMHC/MerCreMer mice 3 days after tamoxifen 
treatment. (A, B) Haematoxylin/Eosin staining showing cell infiltration, cardiomyocyte loss and 
beginning tissue replacement after 5 days of tamoxifen injections (20 mg/kg daily). (C, D) Normal 
cardiac morphology in unaffected areas of the same hearts. Scale bar 50 μm. 
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To further understand the mechanisms involved in the observed phenotype, rtPCR analysis 
for mediators of inflammation was performed. Pro-inflammatory cytokines IL-1β, IL-6, TNFα, 
IFNγ and Ccl2 were significantly upregulated in tamoxifen-treated αMHC/MerCreMer mice 
compared to controls (Figure 4.8). 
 
 
Figure 4.8: Cytokine expression analysis in tamoxifen treated αMHC/MerCreMer animals. rtPCR 
analysis at 3 days following 5d tamoxifen injections (20 mg/kg daily). αMHC/MerCreMer mice 
presented significant upregulation of pro-inflammatory IL-1b, IL-6, TNFα, IFNγ and Ccl 2 mRNA. n = 7, 
4, 4, 4 from left to right on the graph. 
 
In addition, the expression of anti-inflammatory markers IL-10 and TGFβ1 was increased in 
this group (Figure 4.9). 
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Figure 4.9: rtPCR cytokine expression analysis in tamoxifen treated αMHC/MerCreMer animals. Anti-
inflammatory cytokines TGFβ1 and IL-10 are significantly upregulated 3 days after completion of 5 
days tamoxifen (20 mg/kg daily). n = 7, 4, 4, 4 from left to right on the graph. 
 
While functional and morphological analyses had not indicated cardiac hypertrophy or failure 
following 5 days tamoxifen treatment (20 mg/kg), ANF, BNP and Col3A1, hallmarks of 
cardiac remodelling, were expressed at significantly higher levels compared to controls 
(Figure 4.10, McMullen and Jennings 2007; Felkin et al. 2009). 
 
 
Figure 4.10: rtPCR for markers of cardiac remodelling 3 days after completion of 5 days tamoxifen (20 
mg/kg daily). αMHC/MerCreMer mice express elevated levels of ANF, BNP and Col3a1. n = 7, 4, 4, 4 
from left to right on the graph. 
 
The extensive inflammatory response observed after treating αMHC/MerCreMer for 5 days 
(20 mg/kg daily) was not observed after a single injection of tamoxifen (40 mg/kg) and IFNγ 
expression was the same across all groups (Figure 4.11). However, TNFα was significantly 
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upregulated compared to all controls and levels of IL-1β, IL-6 and Ccl2 where elevated 
compared to untreated animals but not compared to tamoxifen-treated control mice. 
 
Figure 4.11: rt-PCR for pro-inflammatory makers in the heart of αMHC/MerCreMer. Following a single 
(1d) tamoxifen injection (40 mg/kg) differential expression of IL-1β, IL-6, TNFα and Ccl2 was detected. 
n = 7, 4, 4, 4 from left to right on the graph. 
 
Unlike after 5 days of tamoxifen treatment (20 mg/kg), mRNA levels of IL-10 and TGFβ1 
were not upregulated 3 days following the single-injection protocol (40 mg/kg, Figure 4.12). 
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Figure 4.12: rtPCR analysis of anti-inflammatory markers following a single injection of tamoxifen (40 
mg/kg). No difference in IL-10 and TGFβ1 mRNA levels were detected. n = 7, 4, 4, 4 from left to right 
on the graph. 
 
While histological analysis of 1 day-treated αMHC/MerCreMer hearts had not revealed any 
morphological changes, markers of cardiac remodelling were upregulated in response to this 
reduced total tamoxifen dose and treatment period (Figure 4.13). 
 
 
Figure 4.13: rtPCR analysis of markers of cardiac remodelling following a single injection of tamoxifen 
(40 mg/kg). Upregulation of ANF, BNP and Col3a1 mRNA levels was detected following treatment. n = 
7, 4, 4, 4 from left to right on the graph. 
 
To evaluate the role of apoptosis in the pathological phenotype, proteins involved in 
apoptotic signalling were investigated by Western blotting 3 days following tamoxifen 
treatment (Figure 4.14). 
 
  Chapter 4 
 
142 
 
Figure 4.14: Western blots for markers of apoptosis. Cytochrome c and Bcl2 proteins are upregulated 
in αMHC/MerCreMer mice 3 days following 5 days of tamoxifen injections (20 mg/kg daily). Levels 
after one day of tamoxifen (40 mg/kg) are comparable to those in control-treated αMHC/MerCreMer 
mice. 
 
This showed an upregulation of both cytochrome c and Bcl-2 in animals treated for 5 days 
(20 mg/kg daily), but not after a single injection of tamoxifen (40 mg/kg). Cleaved caspase 3 
was not observed after tamoxifen treatment (Figure 4.15). 
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Figure 4.15: Western blot analysis for caspase 3. αMHC/MerCreMer mouse heart protein extracts 
were analysed for caspase-3 cleavage 3 days following tamoxifen treatment. No cleaved caspase 3 
was observed in any group. Uncleaved pro-caspase-3 was detected at 35 kDa and ~40 kDa 
respectively. The upper band (#) is decreased in both tamoxifen treated groups. The lower band (§) is 
shows upregulation of this isoform after 5 days of tamoxifen exposure (20 mg/kg daily) but not after 1 
day (40 mg/kg) of treatment. 
 
However, a changed expression pattern was observed between two bands that appear to be 
different isoforms or differentially modified versions of pro-caspase-3 at 35 kDa and 40 kDa. 
Bax was not differentially regulated following tamoxifen treatment (Figure 4.16). 
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Figure 4.16: Western blotting analysis of Bax expression in αMHC/MerCreMer mice. Cardiac protein 
extracts were analysed 3 days following 5 days of tamoxifen (20 mg/kg daily), a single injection of 
tamoxifen (40 mg/kg) or control treatment. 
 
Levels of apoptotic regulator Bax were not significantly changed between groups, but high 
variation within the 5 day-treated group was observed. 
 
 
4.5 Discussion 
The presented data shows that episodic tamoxifen-primed nuclear Cre recombinase 
accumulation in adult mouse hearts causes irreversible damage to the myocardium, reflected 
in decreased left-ventricular function. Since a single injection of tamoxifen (40 mg/kg) did not 
result in cardiac fibrosis, the observed phenotype is dose dependent and is caused by either 
the nuclear levels of MerCreMer protein or its duration in the nucleus, or a combination of 
both. While my results show that the single injection protocol is sufficient to induce nuclear 
localisation of MerCreMer in αMHC/MerCreMer cardiomyocytes, the nuclear signal was less 
pronounced compared to that after 5 days of injections (20 mg/kg), raising questions whether 
sufficient recombination is achieved by low tamoxifen exposure. That cytoplasmic 
MerCreMer in itself is not toxic was further supported by the observation of normal cardiac 
function and morphology in aged untreated animals (data not shown). Tamoxifen alone was 
also shown to have no effect in any MerCreMer-negative background. The toxicity of nuclear 
Cre could potentially stem from promiscuous aspecific genomic recombination at cryptic loxP 
sites on the genome (Loonstra et al. 2001; Semprini et al. 2007). This could lead to 
chromosomal aberration following DNA fragmentation and could be responsible for cell death 
and subsequent replacement of cardiac myocytes by fibroblasts resulting in the observed 
phenotypes. The observed cell infiltration and upregulation of various cytokines involved in 
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acute inflammation (IL-1β, IL-6, TNFα, IFNγ and Ccl2) in the tamoxifen treated 
αMHC/MerCreMer group, are a further indicators of the negative impact of excessive active 
MerCreMer in cardiac tissue (Figure 4.7, Figure 4.9). Although this response could be 
secondary to excessive tissue damage or necrosis, it is a further factor potentially 
compromising interpretation experimental outcomes, such as inflammation and cell death, 
which are frequently assessed in cardiac regeneration research studies. This also applies for 
markers of cardiac hypertrophy (ANF, BNP, Col3a1), frequently used as indicators of 
hypertrophy in cardiac-specific conditional knockout mice. Elevated pro-hypertrophic markers 
in tamoxifen-treated αMHC/MerCreMer mice have been reported previously, although higher 
doses of tamoxifen were used in these studies (40 mg/kg daily for 5 days, 200 mg total) 
(Andersson et al. 2010). The fact that IL-10 and TGFβ mRNA levels were increased after 3 
days is potentially attributable to a negative feedback response and indicating the end of the 
acute inflammatory phase following MerCreMer-mediated insult (Figure 4.9). A single 
injection of tamoxifen (40 mg/kg) resulted in a more heterogenic outcome. While pro-
inflammatory TNFα was increased in the treated group, changes in IL-1β, IL-6 and Ccl2 were 
only statistically significant in comparison to the untreated αMHC/MerCreMer control group. 
mRNA levels of IFNγ were unchanged (Figure 4.11). While anti-inflammatory cytokines (IL-
10 and TGFβ1) were not elevated potentially due to the absence of a preceding inflammatory 
reaction, markers of cardiac remodelling (ANF, BNP and Col3a1) were shown to be 
increased, although to a lesser degree compared to the 5 days injection protocol (Figure 
4.12, Figure 4.13). This indicated that while the single injection protocol was generally better 
tolerated, it still affected some parameters important for the assessment of cardiac health. To 
investigate the implication of apoptotic signalling in the observed phenotype, typical markers 
of programmed cell death were investigated by Western blotting. Increased cytochrome c 
expression indicated upregulated apoptosis, 3 days after 5 tamoxifen injections (20 mg/kg 
daily). The observation of elevated anti-apoptotic Bcl2, however, suggested that the resting 
period of 3 days was long enough to remove most damaged cells and the surviving tissue 
was counteracting sustained programmed cell death. This was supported by the fact that one 
of the key indicators of apoptosis, cleaved caspase-3, was not detected at this time point. 
Cleaved caspase-3 is rapidly activated and peaks around 30 h after insult in some tissues 
(Tyas et al. 2000; Ray et al. 2008). While there is no direct evidence for loss of an apoptotic 
signalling in the first 3 days following the treatment, the absence of cleaved caspase-3 could 
indicate excessively damaged cells have already completely undergone apoptosis in the 
damaged areas of the heart. In addition, pro-apoptotic Bax, a central regulator of all apoptotic 
pathways, was not expressed at increased levels 3 days after completed treatment, further 
supporting that apoptosis is either complete or the putative cell death follows a different 
mechanism such as necrosis (Wei et al. 2001). 
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Overall, the present findings are consistent with a recent parallel report, describing the 
chronic detrimental impact of MerCreMer and tamoxifen administration on cardiac physiology 
(Lexow et al. manuscript submitted, Kuhn et al. manuscript submitted). 
 
4.5.1 αMHC/MerCreMer in the literature 
Since αMHC/MerCreMer mice have been used in numerous cardiac research studies to 
date, I conducted a survey of the literature to determine previous reports of Cre mediated 
toxicity in the heart. A significant number of recent publications showed the use of this strain 
in conditional gene targeting without including tamoxifen treated αMHC/MerCreMer single-
genotype experimental controls (Table 4.2). 
 
Table 4.2: Publications using αMHC/MerCreMer mice in experiments without inclusion of tamoxifen-
treated αMHC/MerCreMer controls (list not exhaustive). 
Author Journal Year Age of 
animals 
Injection protocol Reference 
Birnbaum et 
al. 
Basic Res Cardiol 2011 ? 20 mg/kg * day
-1
, 7d (Birnbaum et al. 
2011) 
Agarwal et 
al. 
Circ Res 2010 6w 40 mg/kg * day
-1
, 5d (Agarwal et al. 2010) 
Ruan et al. J Mol Cell Cardiol 2010 10-12w 20 mg/kg * day
-1
, 7d (Ruan et al. 2009) 
Stokke et al. Cardiovasc Res 2010 10w 40
#
 mg/kg * day
-1
, 1d (Stokke et al. 2010) 
Andersson 
et al. 
J Mol Cell Cardiol 2009 8-10w 40
#
 mg/kg * day
-1
, 4d (Andersson et al. 
2009) 
Wang et al. PNAS 2009 ? 100 mg/kg * day
-1
, 5d (Wang et al. 2009) 
Martins et al. Circulation 2008 3/8w 20 mg/kg * day
-1
, 5d (Martins et al. 2008) 
Nakai et al. Nat Med 2007 8w 80 mg/kg * day
-1
, 7d (Nakai et al. 2007) 
Noh et al. Am J Physiol 
Endocrinol Metab 
2006 8-9w 20 mg/kg * day
-1
, 2w (Noh et al. 2006) 
Zhou et al. Am J Physiol 
Heart Circ Physiol 
2006 3-4M 20 mg/kg * day
-1
, 2w (Zhou et al. 2007) 
Parlakian et 
al. 
Circulation 2005 2M 20 mg/kg * day
-1
, 4d (Parlakian et al. 
2005) 
M - month, w - week, d - day, 
#
 - estimated 
 
Noh et al., Martins et al., Parlakian et al., Agarwal et al., Ruan et al., Andersson et al., Nakai 
et al., and Zhou et al. measured cardiac function by ECHO at different time points and 
reported varying degrees of impairment of cardiac function. Since tamoxifen-treated 
αMHC/MerCreMer controls were omitted, it is impossible to judge the contributions of the 
respective knockout and Cre-toxicity respectively to the reported functional (ECHO), 
histological (fibrosis) and molecular (ANF upregulation) phenotype. It is worth noting that 
many of these studies used far more extensive treatment regimen compared to that used in 
this project with some having used up to five times the tamoxifen dose or having extended 
the treatment to over 2 weeks. Among these publications, Noh et al., Wang et al., Martins et 
al. and Parlakian et al. observed cardiac fibrosis which they attributed to their conditional 
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knockout phenotype (Parlakian et al. 2005; Noh et al. 2006; Martins et al. 2008; Wang et al. 
2009). Furthermore, Martins et al., Andersson et al. and Nakai et al. claim that their 
respective conditional knockouts (dicer, serca2a, atg5) result in increased ANF expression 
(Nakai et al. 2007; Martins et al. 2008; Andersson et al. 2009). Nakai et al. and Ruan et al. 
also performed TUNEL assays to investigate cell death in vivo and in Langendorff perfused 
hearts (Ruan et al. 2009). 
In the light of my results, the findings derived from these studies could have potentially been 
confounded by a Cre-mediated cardiomyopathy. We are grateful for the input of the authors 
Faqian Li, Vickas Patel, Garret Fitzgerald, Ira Goldberg, Mathis Stokke and Zhenlin Li who 
were open to discuss their use of αMHC/MerCreMer mice and the resulting data in personal 
communications. This confirmed that indeed in many cases, an unspecified number of 
control mice had been monitored during preliminary experiments, but were excluded from the 
main experiments that were later published due to the apparent absence of any remarkable 
phenotype. It is conceivable that the number of animals used during the setup phase was 
small and affected animals were not identified due to a low number being affected in the 
corresponding genetic background or discarded as irrelevant outliers. 
Differences in genetic background are indeed likely a contributing factor to the observed 
variation in phenotypic penetrance. This is supported by the fact that we observed fibrosis in 
60% of Tβ4shRNAflox/MerCreMer mice (129Ola/C57Bl/6J) and in 100% of 
αMHC/MerCreMer mice (C57Bl/6J), following tamoxifen treatment. This should be noted 
when considering that the majority of reports involving the αMHC/MerCreMer strain 
incorporated appropriate controls and some performed histological analyses, but did not 
report the detrimental phenotype observed here. For instance, studies by Xiong et al. and Di 
et al. measured fibrosis in tamoxifen treated αMHC/MerCreMer control mice, but did not 
report a fibrotic or otherwise adverse phenotype (Xiong et al. 2007; Di et al. 2010). Mice used 
in these studies were of CD1/Balbc/C57Bl/6 and C57Bl/6 backgrounds respectively. Since 
the phenotype appears less pronounced in certain genetic backgrounds, it is also 
conceivable that the fibrotic phenotype was missed where only a small number of animals 
were investigated. Regarding functional assessments by ECHO, it is evident that several 
measurements and a sufficiently large study group are required to identify significant 
outcomes when investigating small changes, as in the case of Cre-mediated cardiac 
damage. 
 
4.5.2 Potential solutions to the problem of inducible Cre-mediated toxicity 
Optimising the mode of tamoxifen administration: Temporary effects of tamoxifen exposure 
and nuclear MerCreMer accumulation on cardiac function have been well documented and 
methods have been proposed to reduce a transient cardiomyopathy (Hougen et al. 2010; 
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Hall et al. 2011). In addition to genetic background, the specific details of the injection 
protocol and the form of tamoxifen used may constitute parameters contributing to diverse 
outcomes. For instance Kiermayer et al. reported that oral tamoxifen citrate appears to be 
equally effective in terms of recombination and potentially safer compared to tamoxifen or its 
active metabolite 4-hydroxytamoxifen, while at the same time reducing stress and adverse 
effects associated with injections (Kiermayer et al. 2007). However, as the present study 
underlines, oral delivery is sensitive to diet refusal by the animals and can consequently 
result in insufficient recombination, weight loss and starvation-related phenotypes (see 
Chapter 3, Andersson et al. 2009). 
These findings are in line with previous reports showing that administration of tamoxifen 
citrate pellets resulted in 10% weight loss regardless of genotype after 4 days as well as 
suboptimal recombination (< 50%) after 7 days (Andersson et al. 2010). Consequently, 
despite causing some stress to the animals, injecting tamoxifen citrate might  be a good 
approach (Touvron et al. 2012 manuscript submitted). Regardless, there are a number of 
supportive arguments for delivery in the diet. It was demonstrated that tamoxifen absorption 
via the gut is as effective as via peritoneal cavity and changing the constitution of the chow 
could address diet refusal issues (Seibler et al. 2003). Indeed, Andersson et al. showed good 
acceptance of the chow and optimal recombination after feeding in the animals with self-
made tamoxifen cakes (Andersson 2010). Others have shown that a mix of tamoxifen and 
soft chow over 7 days showed no mortality during oral delivery at concentrations (80 mg/kg) 
that were lethal during IP injections (Koitabashi et al. 2009). This is attributable to the fact 
that the LD50 of tamoxifen via the diet is 15-fold higher compared to IP injections (Seibler et 
al. 2003). The protocol proposed by Andersson et al. describes crushing standard chow and 
mixing it with drinking water and tamoxifen (Sigma T5648) at 0.5 mg/g (mass of dry chow, 
(Andersson et al. 2010). After drying, these pellets were administered for 4 days, which 
proved to be as effective as 2 days of tamoxifen in oil at 40 mg/kg via IP injections in terms of 
recombination. The oral delivery of raloxifene as a substitute for tamoxifen was also shown to 
be effective and to cause less short term cardiac side effects (Koitabashi et al. 2009). The 
potentially most potent composition is 4-hydroxytamoxifen which is now rarely used in adult 
studies. It remains however in use for genetic/lineage tracing. To achieve this, pregnant 
females are injected with 0.5 mg 4-hydroxytamoxifen daily over 14 days (Porrello et al. 
2011). 
It is evident that inducible genetic manipulations have become indispensable with hundreds 
of new Cre drivers currently generated as part of a large European consortium 
(EUCOMMTOOLS) and thousands of crosses to floxed alleles that are bound to follow from 
international initiatives (www.knockoutmouse.org, Skarnes et al. 2011). Conditional knockout 
approaches and cell lineage tracing have become to rely almost exclusively on the Cre/loxP 
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system, leaving two possible options to address the presented concern which will be 
discussed in detail below: 1) Elucidating mechanisms of Cre toxicity and defining the balance 
between satisfactory site-specific recombination in the various systems while carefully 
monitoring the effects of nuclear Cre or MerCreMer by use of meaningful controls and 2) 
Development and use of previously less popular alternatives available for gene targeting. 
1) Optimisation Cre recombination: As indicated, it is not feasible to abandon MerCreMer-
based systems immediately, given their current importance for developmental and 
regeneration research. Any experimentation involving the MerCreMer system, however, 
requires careful titration of tamoxifen to obtain maximal recombination with minimal side 
effects. Every step of this process should be controlled. Tamoxifen-primed MerCreMer 
localisation can be assessed by immunofluorescence (see Chapter 3) but ideally the ultimate 
outcome, i.e. gene activation or ablation must be assessed. The lowest possible tamoxifen 
dose to achieve a satisfying result must be established prior to experimentation. This 
approach was already successfully adopted by a recent study (Touvron et al. 2012). Most 
importantly, however, experimental design should take the toxic effects of nuclear Cre into 
consideration and controls should be included accordingly. In the light of the present findings, 
these controls are more relevant than tamoxifen-treated flox/flox single-genotype littermate 
controls, which to my knowledge have never been reported to produce any significant 
phenotype unless the construct itself was leaky. Leakiness of the construct, however, should 
be identified during generation of the respective floxed strain before establishing crosses with 
a Cre-driver strain. 
2) Alternative means of gene targeting: Long term, there are number of approaches to 
manipulate gene expression that should be considered as alternatives to the Cre/loxP 
system. For example, the use of tetracycline-responsive promoters to externally activate 
gene expression has been used in vitro for decades and could constitute an alternative for 
certain experiments. The Tet-Off system which has found wide application in murine models 
relies on the presence of the tetracycline derivative doxycycline which binds a TetR/VP16 
fusion protein (Gossen and Bujard 1992; Marongiu et al. 2012). This so-called tetracycline-
responsive transcriptional activator (tTA) normally induces expression of transgenes by 
binding Tet operator (TetO) sequences, which activates the associated promoter. Upon 
doxycycline interaction the protein tTa is no longer bound to TetO and transcription is halted. 
The Tet-On system has an inverse working mechanism since tetracycline relieves 
transcriptional repression by binding the reverse tetracycline-responsive transcriptional 
activator (rtTA) fusion protein (Gossen et al. 1995). This is subsequently removed from TetO 
to allow target gene expression. There is some evidence that Tet-Off is superior to Tet-On in 
regulating gene expression following viral vector mediated delivery in mice (Mizuguchi and 
Hayakawa 2002). The reversibility of the Tet-mediated gene regulation is one of the key 
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strengths of this technique. Ironically however, this could pose a considerable disadvantage 
for long term in vivo experimentation. While recombinase-based techniques remove target 
sequences permanently there is a requirement for continuous doxycycline treatment in Tet-
based experiments (Lai et al. 2012). Maintaining the necessary levels of this antibiotic could 
have side effects in vivo and requires meticulous controlling. In regenerative medicine, Tet 
was shown to be a well controllable regulator of gene overexpression in a pre-clinical animal 
model of MI (Lai et al. 2012). While the application of Tet in lineage tracing appears feasible, 
its future application for conditional gene downregulation is questionable. This is due to its 
incapacity to irreversibly remove DNA sequences, as discussed. 
Despite being discovered almost simultaneously with Cre, another alternative molecule 
called FLP recombinase or flippase has not yet found wider application. Due to its ability of 
sequence specific DNA recombination, FLP has however received recent recognition for its 
use in cell lineage tracing experiments together with Cre in so called dual fate-mapping 
approaches (Schlake and Bode 1994; Engleka et al. 2012). Being a cleavage-dependent 
DNA ligase, FLPs mode of function is mechanistically similar to that of Cre. It is however of 
yeast origin (Saccharomyces cerevisiae) and has site specificity for FLP recombination target 
(frt) consisting of three 13 bp symmetry elements and surrounding the 8 bp core (Zhu and 
Sadowski 1995). Its yeast origin initially constituted the disadvantage that the native FLP had 
a temperature optimum at 30 °C (Buchholz et al. 1996). Using genetic engineering it has 
since been further developed into FLPe which shifted the effective working temperature to 37 
°C (Buchholz et al. 1998). To date the most suitable FLP variant for use in mammalian 
systems is Flpo which shows recombination efficiencies comparable to Cre, with excellent 
expression characteristics and optimal activity at 37 °C (Raymond and Soriano 2007). The frt 
target site is more complex than the loxp site which consists of only two 13 bp repeats and 
the 8 bp core (Lee and Sadowski 2003). While this potentially implicates higher specificity of 
FLP-mediated recombination and subsequently a diminished risk of aspecific cleavage, 
caution should be exerted when using FLP since it has not been studied as extensively as 
Cre and similar problems in terms of concentration-dependent promiscuity of recombination 
could yet be uncovered. In the light of the current discourse surrounding Cre-mediated 
cytotoxicity, controls should be set up in a comparable fashion and data analysed with due 
vigilance. 
The latest addition to the group of site-specific tyrosine recombinases developed for use in 
the mouse is Dre recombinase (Sauer and McDermott 2004; Anastassiadis et al. 2009). Dre 
targets rox sites, 32 bp sequence not recognised by Cre or FLP. Dre side-effects in mice 
have not yet been described. However, as for FLP the absence of adverse data is largely 
attributable to the fact that so far it has not found wide application, unlike Cre, which on its 
own or in fusion with Mer domains has been expressed in mice for more than a decade. 
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4.5.3 Summary 
In summary, several conclusions can be drawn from the present study and literature survey. 
First of all, high levels of tamoxifen-induced MerCreMer can cause substantial cardiac 
phenotypes with short- and long-term effects. Secondly, the genetic background is most 
likely a determining factor of penetrance of the tamoxifen-induced MerCreMer phenotype. 
Thirdly, delivery methods have varying effectiveness in terms of tamoxifen bioavailability and 
will consequently affect concentration and duration of MerCreMer in the nucleus. The most 
appropriate delivery method for each model must be evaluated prior to extensive 
experimentation and the optimal dose of tamoxifen adjusted to the lowest concentration 
required for achieving sufficient recombination, as performed by Touvron et al. (Touvron et 
al. 2012). Given its potential to cause a substantial phenotype with regards to 
macrostructure, function and on the molecular level, the present findings support the call for 
inclusion of tamoxifen-treated MerCreMer single-genotype animals, particularly in 
experiments involving myocardial specific MerCreMer transgenes (reviewed in Anastassiadis 
et al. 2010). Since I showed that the observed phenotype is not related to cytoplasmic 
MerCreMer or the presence of a floxed transgene, tamoxifen-treated αMHC/MerCreMer 
animals should be chosen over flox/flox mice as negative controls where time and resources 
prohibit the inclusion of all control groups. Alternatively, FLP/frt and Dre/rox systems may 
provide suitable replacements for Cre recombinase in the future but have yet to be 
sufficiently developed and evaluated to seriously challenge the omnipresent Cre/loxp system. 
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Chapter 5 -  Work in Progress: Alternative Approaches to 
Investigate the Role of Thymosin β4 in Cardiomyocytes 
 
5.1 Introduction 
Traditionally the main role of Tβ4 was considered to be binding of monomeric G-actin (Safer 
et al. 1991; Didry et al. 2012). This stabilises intracellular actin pools which serve as supplies 
for F-actin assembly for cytoskeletal rearrangement. However, Tβ4 has various intracellular 
and extracellular functions other than actin binding. Given its many diverse functions, the 
number of Tβ4-interacting proteins that have been identified over the decades seems 
surprisingly small. In endothelial cells, Tβ4 interacts directly with PINCH and ILK to facilitate 
complex formation with Akt1/2 and also binds extracellular receptor F1-F0 ATP synthase 
(Fan et al. 2009; Freeman et al. 2011). Also in endothelial cells, DNase helicase subunit II 
Ku80 was identified as a nuclear receptor for Tβ4 (Bednarek et al. 2008). In cancer cells, Tβ4 
indirectly or directly interacts with hMLH1, a molecule involved in DNA mismatch repair 
(Brieger et al. 2007). Since previous research has focused on specific cell types in vitro, the 
scope of this part of the project was the identification of proteins interacting with Tβ4 
specifically in the heart. To address this goal, the aim was to produce a tagged, recombinant 
Tβ4 fusion peptide to pull out interacting partners from total cardiac lysates or from protein 
preparations of cardiac subpopulations. 
Historically, working with the Tβ4 peptide has been known to bear some technical 
challenges. For example, during filtration the behaviour of Tβ4 is anomalous. It appears 4-
fold greater during gel filtration and during ultrafiltration is retained by a 10 kDa MWCO pore 
size despite having a theoretical molecular weight of 4.9 kDa (Haritos et al. 1989; Huff and 
Hannappel 1997). But even recent research has suffered from limited specificity of current 
Tβ4 antibodies and this poses a significant obstacle in Tβ4 research (from discussions with 
collaborators and other researchers, see also Chapter 3). 
In the following study, two different expression systems namely prokaryotic and mammalian 
cells were used to produce a recombinant Tβ4 peptide that is fused to 6 histidine repeats 
(His6) required for purification of the fusion peptide and a viral V5 epitope for improved 
detection. A similar proteomic procedure has been well described previously by Bednarek 
and co-workers in 2008 (Bednarek et al. 2008). 
 
 
5.2 Proteomics – Identification of Tβ4-interacting proteins 
Tβ4 cDNA was amplified from mouse cDNA using Pfx proofreading polymerase. Following 
electrophoresis, a single band of the predicted molecular weight was identified (Figure 5.1). 
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Figure 5.1: 2% Agarose gel showing the PCR product of Tβ4 amplification. (1) PCR product using Pfx 
proofreading polymerase. (2) Positive control from standard Taq pol amplification of Tβ4. 1 kb DNA 
ladder was used as molecular weight marker (Invitrogen, Carlsbad, CA, USA). 
 
Tβ4 cDNA was cloned into the pcDNA3.1 expression vector also containing the C-terminal 
V5-His6 tag coding sequence (see Chapter 2: Methodology). Tβ4-V5-His6, LacZ-V5-His6 
plasmids and empty vector controls were transformed into E. coli. The success of 
transformation was controlled by monitoring LacZ protein expression on X-gal plates showing 
blue colonies for LacZ-V5-His6 but not control transformed cells (Figure 5.2). 
 
 
Figure 5.2: Transformation and protein expression control using β-galactosidase activity assay. (A) 
Colourless bacterial colonies transformed with the empty vector (B) LacZ-transformed bacteria 
metabolising X-gal shown by blue colouration of colonies. 
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Individual colonies of all three transformations were selected, expanded in liquid culture and 
DNA extracted. Correct insertion of Tβ4 sequence in the plasmid was confirmed by MfeI 
endonuclease restriction digest and subsequent Agarose gel electrophoresis (Figure 5.3). 
 
 
Figure 5.3: 2% Agarose gel of MfeI-digested vectors. Lane (1) linearised lacZ control plasmid, (2) 
linearised empty plasmid, (3) vector with inverted Tβ4 sequence, (4) vector with correctly insert Tβ4 
sequence, (5) vector with inverted Tβ4 sequence, (6) vector with correctly insert Tβ4 sequence, (7) 
undigested control plasmid. 
 
Two clones containing the vector with correct orientation of the Tβ4 sequence were 
identified. Lanes 4 and 6 show the corresponding band of 891 bp (and 4767 bp). Examples 
of inverted Tβ4 sequences can be seen in lanes 3 and 5 showing a band corresponding to 
826 bp (and 4832 bp). Positive clones were sequenced using Imperial College Genomics 
Laboratory core facility and used for Tβ4-V5-His6 protein production. In a separate 
experiment, plasmid DNA derived from sequence controlled clones was used to transiently 
transfect HeLa cells using Lipofectamine. Total protein was isolated from E. coli and HeLa 
cells and 100 µL of each sample used for precipitation of Tβ4-V5-His6 and controls using 
protein A/G slurry and anti-V5 monoclonal antibodies. Precipitated protein was separated by 
SDS PAGE and evaluated by Western blotting (Figure 5.4). 
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Figure 5.4: Western blot detection of V5 epitopes. (A) Immunoprecipitation of Tβ4-V5-His6 and control 
peptides generated in E. coli. (B) Original unprocessed protein extract from E. coli. (C) Protein extracts 
from Tβ4-5-His6 and LacZ-V5-His6 HeLa cell lysates. 
 
Band of the corresponding molecular weights of Tβ4-V5-His6 at ~11 kDa (5 kDa + 6 kDa) and 
for LacZ-V5-His6 at 122 kDa (116 kDa + 6 kDa) were identified. Two distinct bands at 25 kDa 
and 50 kDa stem from the denatured small and heavy chain of the IgG. For co-IP with 
subsequent mass spectrometry analysis, high purity recombinant protein is required. Protein 
extracts were therefore purified using ProBond His-affinity columns (Invitrogen, Carlsbad, 
CA, USA, # 45-0055). Although the recombinant protein had been identified in both E. coli 
and HeLa systems, expression in bacteria was selected over the mammalian system due to 
ease of handling and lower cost. 
 
 
5.3 Pitfalls of recombinant protein production for proteomics 
After His-affinity column purification, no clear band for Tβ4-V5-His6 was detected in any 
fraction by coomassie staining (Figure 5.5). 
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Figure 5.5: Fractions eluted after ProBond Ni
2+
-affinity column purification. Protein lysates from E. coli 
were used. Arabic numerals indicate fractions (T – Tβ4-V5-His6, L – LacZ-V5-His6). 
 
Although bands were found at low molecular weights potentially corresponding to the Tβ4 
fusion protein, these bands were also detected in LacZ control preparations. To rule out the 
possibility of accidental wash out of the recombinant proteins, wash supernatants were 
investigated but did not show clear bands indicative of a robust overexpression. The 
experiment was repeated including a solubilisation step to address the possibility of inclusion 
body formation frequently occurring during bacterial overexpression, but no significant 
expression was observed (data not shown). 
To investigate if HeLa cells were more suitable in producing sufficient protein amounts for 
His-affinity purification, a stable Tβ4-V5-His6 cell line was generated. Stable transfection of 
HeLa cells did not produce a clear band on a coomassie gel after protein isolation and His-
affinity purification (Figure 5.6). 
 
 
Figure 5.6: Coomassie stained gel of HeLa protein lysates after stable transfection and Ni
2+
column 
purification. Eluted fractions: 1T-4T. Lysate = Unpurified cell lysate. NEB wide range pre-stained 
protein marker was used (New England Biolabs, Ipswich, MA, USA, # P7708V). 
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To investigate whether the recombinant protein was potentially secreted into the cell culture 
medium, supernatants were concentrated using 30 kDa and 3 kDa MWCO columns. Tβ4 
passes 30 kDa MWCO pore sized filters but is retained by membranes with MWCO <10kDa 
(Huff and Hannappel 1997). As for previous attempts, no clear band for the Tβ4-V5-His6 was 
identified in medium preparations (Figure 5.7). 
 
 
Figure 5.7: Medium from Tβ4-V5-His6 transfected HeLa cells cultured under serum-free conditions. 
(1-2) Unpurified medium, (3-4) Concentrated medium MWCO 30 kDa, (5) concentrated medium with a 
MWCO of 3 kDa. Novex sharp (Invitrogen, Carlsbad, CA, USA) was used as molecular weight marker. 
 
During this concentration approach the formation of dissoluble aggregates was observed. 
Re-diluting the purified and concentrated medium also showed irregular behaviour during 
electrophoresis, potentially indicating that it is not a concentration-dependent mechanism. 
Furthermore, Western blot analysis using anti-V5 antibodies to investigate basal levels of 
Tβ4-V5-His6 in the medium was negative suggesting that it is not secreted even at low 
concentrations (not shown). Several modifications to the lysis protocol and isolation 
procedure as well as the inclusion of imidazole gradients to increase selectivity of His-affinity 
column interaction were attempted. Imidazole was added to the binding buffer at 5 mM, at 5 - 
10 mM during washes and in a gradient from 10 - 500 during elution. While not solving the 
problem, it added complexity to the problem, since imidazole absorbs light making 
spectrophotometric protein quantification impossible. Subsequent Western blotting analysis 
using V5 antibodies on the unquantified fractions from the imidazole-assisted isolation only 
detected a Tβ4-V5-His6 positive control from previous experiments but recombinant protein in 
the purified fractions (not shown). 
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5.4 Discussion 
The aim of this chapter was to generate a polyhistidin and V5-epitope tagged recombinant 
protein to identify for the first time Tβ4 interacting proteins in the heart by co-
immunoprecipitaion with subsequent mass spectrometry analysis. Problems resulting in poor 
purity and low levels of recombinant Tβ4-V5-His6 were encountered and approaches to 
overcome these are discussed here. 
Generally solubility problems during recombinant protein expression can stem from 
interactions of hydrophobic residues resulting in aggregates that require strong detergents or 
high concentrations of denaturants such as urea to re-dissolve proteins. However, Tβ4 is 
highly water-soluble and up to 100 mg/L Tβ4 can be dissolved in water (reviewed in 
Hannappel 2010). Given these hydrophilic properties and its disorganised structure in water, 
aggregation of the core peptide due to hydrophobic interactions is unlikely. In addition, the 
problems of low protein yield were also observed for LacZ-V5-His6. To determine whether 
His6 or V5 epitope interactions are underlying the putative protein aggregation, expression of 
the Tβ4 core without the tags could serve as a negative control for future experiments. 
Generally, bacteria can form inclusion bodies, intracellular aggregates mediated by 
heatshock proteins normally in response to thermal stress in order to compartmentalise 
poorly folded proteins (reviewed in Villaverde 2003). This is a frequently observed problem in 
bacterial overexpression settings. A commercially available kit was used to dissolve putative 
inclusion bodies but this did not significantly improve the outcome. Additionally, the observed 
failure to purify significant amounts of recombinant Tβ4-V5-His6 could stem from low 
expression. This is supported by the lack of a clear band on coomassie stained gels, which 
are normally observed for robust overexpression (Figure 5.5, Figure 5.6). While the 
presence of the recombinant as well as LacZ-V5-His6 was confirmed by Western blotting, this 
is a very sensitive technique able to detect very small amounts of protein. Secretion of the 
fusion peptide was ruled out as a possible explanation since the fusion peptide was not 
detected in the cell culture medium (Figure 5.7). 
The failure to express significant amounts of recombinant protein in the stable HeLa cell line 
is most likely attributable to a loss of overexpression. This can happen as a result of gene 
silencing, but in this case is most likely attributable to the competitive disadvantage of highly 
expressing cells within the heterogeneous culture. To avoid this loss of expression, larger 
batches of cells could be transiently transfected to achieve a higher yield of recombinant 
protein. However, the high costs of Lipofectamine are prohibitive for this large scale transient 
transfection approach. A financially more feasible and much more elegant approach would 
be to select strongly expressing single clones of a freshly established stable cell line and 
expand these in culture. Strong monoclonal cultures could be selected for subsequent 
protein production. 
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In the bacterial system, inducible expression could be used to maximise recombinant protein 
yield while reducing the risk of gene silencing and protein aggregation. Commercially 
available options are vectors containing IPTG inducible tac promoters (GE Healthcare 
[Internet], Little Chalfont, UK, GST Gene Fusion System Handbook 10/2010, ©2009-2010, 
Cited 02/07/2012, Available from: 
https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/131480726
2343/litdoc18115758AB_20110831220904.pdf). These vectors allow optimisation of protein 
expression in bacteria by monitoring bacterial growth using photospectrometry and induction 
of protein expression during the exponential growth phase. The time point of harvest can be 
adjusted to ensure that sufficient protein has been produced without formation of dissoluble 
aggregates due to overloading of the bacterial cells. Furthermore reducing the culture 
temperature to 20 °C can reduce the formation of inclusion bodies. 
Increasing the abundance of soluble protein could potentially address the problem of poor 
protein purification. Insufficient binding of residues of the Ni2+-column allows for contaminants 
to attach to unoccupied binding sites and are subsequently eluted together with the 
recombinant protein resulting in multiple bands, as observed in this work (Figure 5.5). 
Consequently, it would be more feasible to optimise expression levels first and then address 
any prevailing purification issues. 
 
5.4.1 Summary 
Given the low yield and dissatisfying purity it was not possible at this stage to continue to 2D 
gel electrophoresis and mass-spectrometry to identify Tβ4-interacting proteins. Ultimately the 
unexpected complexity in terms of time and financial resources could justify outsourcing the 
whole production of the recombinant protein to an experienced company. Recombinant 
biotynilated Tβ4 peptides suitable for co-immunoprecipitation experiments are now 
commercially available (Freeman et al. 2011, Celtek Peptides, Nashville, TN, USA). 
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Chapter 6 -  Work in Progress: Transmission Electron Microscope 
Analysis αMHC/IGF-1Ea Transgenic Hearts and the Role of IGF-1Ea 
in Cardiac Autophagy 
 
6.1 Introduction 
Along with Tβ4, insulin-like growth factor 1 (IGF-1) is another molecule that holds great 
potential for future therapeutic application to treat human heart disease. IGF-1 increases 
expression of antioxidant enzymes in blood vessels and inversely IGF-1 deficiency renders 
the blood vessels more prone to obesity-related vascular disease (Csiszar et al. 2008; 
Ungvari et al. 2010; Bailey-Downs et al. 2012). Overall IGF-1 is artheroprotective and 
promotes endothelial repair (reviewed in Higashi et al. 2010). In humans, promoter 
polymorphisms lowering the levels of IGF-1 decrease life expectancy after MI and low levels 
of circulating IGF-1 increase the risk of heart failure in elderly without previous MI (Vasan et 
al. 2003; Bleumink et al. 2004; Bleumink et al. 2005). 
Several isoforms and pro-peptides have been identified including the locally acting IGF-1Ea 
isoform (reviewed in Musaro et al. 2001; Barton 2006). Muscle specific overexpression of 
IGF-1Ea in mice increases the number of myogenic progenitors, promotes healing after 
muscle injury and reduces muscle loss in cachexia and ageing (Musaro et al. 2001; Musaro 
et al. 2004). IGF-1Ea overexpression in the mouse heart decreases the inflammatory 
reaction and reduces scar formation following experimental MI which results in overall 
cardiac functional improvements compared to wt littermates (Santini et al. 2007). While 
macro- and microscopically these hearts have been well studied, a comprehensive analysis 
of their subcellular structure had not previously been performed. The following chapter 
details a transmission electron microscope (TEM) analysis of αMHC/IGF-1Ea hearts and 
focuses on newly discovered intracellular structures with potential implications in protein 
homeostasis and autophagy. 
 
 
6.2 Large electron-dense structures in αMHC/IGF-1Ea cardiomyocytes 
Normal 3-4 month old male αMHC/IGF-1Ea and FVB control mice were sacrificed and left-
ventricular tissue prepared for microstructural investigation by TEM. Gross appearance of the 
myocardium was comparable between transgenic and wt animals. In αMHC/IGF-1Ea 
cardiomyocytes, previously not described large electron-dense structures were observed in 
in areas of high mitochondrial density (Figure 6.1). 
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Figure 6.1: Electron micrographs of cardiac section from αMHC/IGF-1Ea transgenic mice. (A, B) 
Large electron-dense structures (arrows) were observed in the cytoplasm of cardiomyocytes. (C) 
Cardiomyocytes of wt littermates presented normal subcellular morphology. Scale bars A, B = 1μm, C 
= 2 μm. 
 
The structures were mostly round or oval in shape and had smooth or slightly irregular 
outlines. In a few areas the structures were observed to be larger than the cell nucleus. The 
structures were not detectable in skeletal muscle (data not shown). A literature survey did not 
reveal any previous data on similar sized electron-dense structures in cardiomyocytes. The 
timing of the appearance of the structures in cardiac tissue was investigated by studying the 
hearts of juvenile mice. Six week old αMHC/IGF-1Ea mice presented normal intracellular 
morphology and the described electron-dense bodies were not observed (Figure 6.2). 
 
 
Figure 6.2: Electron micrographs of cardiac sections from 6 week old αMHC/IGF-1Ea mice. (A, B) 
Representative micrographs showing normal subcellular morphology of cardiomyocytes. (N – nucleus) 
Scale bar 1 μm. 
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Since IGF-1Ea expression is controlled by the strong αMHC promoter in these transgenic 
cardiomyocytes, the possibility that extensive protein overexpression results in overloaded 
intracellular degradation mechanisms such as proteasomal or autophagy pathways was 
considered. The accumulation of the final product of incomplete degradation of highly cross-
linked proteins debris can lead to pathological aggregation in the form of lipofuscin (reviewed 
in Terman and Brunk 2004). Since lipofuscin accumulation can be aggravated over time and 
is found predominantly in aged post-mitotic tissues and since brain and heart are known to 
accumulate non-dissolvable, misfolded protein in mammals, we investigated whether 
lipofuscin aggregates were present in aged mice and whether they shared morphological 
resemblance with the observed electron-dense structures (Benavides et al. 2002). Electron-
dense structures were identified in cardiac specimen from 2 year-old αMHC/IGF-1Ea mice 
but not wt mice and were of comparable size and abundance to those observed in 3-4 month 
old mice (Figure 6.3). 
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Figure 6.3: Electron micrographs of cardiac sections from 2 year old αMHC/IGF-1Ea mice. (A-D) 
Transmission electron micrographs showed electron-dense structures in similar size, abundance and 
morphology compared to those observed in 3-4 month old animals. Scale bars A, D = 2 μm, B, C = 1 
μm. 
 
In addition, lipofuscin granules, which were morphologically clearly distinguishable from the 
electron-dense structures and significantly smaller in size, were observed in aged 
cardiomyocytes of αMHC/IGF-1Ea and wt mice (Figure 6.4). 
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Figure 6.4: Electron micrographs of cardiac sections from 2 year old αMHC/IGF-1Ea and wt mice. (A, 
B) Lipofuscin granules (arrows) were observed in αMHC/IGF-1Ea and (C, D) wt cardiomyocytes. 
Scale bar 1 μm. 
 
Processed cardiac tissue samples were transferred to our colleague Bart Wagner, Chief 
Biomedical Scientist at Northern General Hospital Sheffield to obtain an additional expert 
opinion. While no consensus was reached regarding the nature and origin of the structures, 
high quality images were obtained, clearly showing a membrane delineating the structures 
(Figure 6.5). 
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Figure 6.5: Transmission electron micrographs of cardiac sections from 3 month old αMHC/IGF-1Ea 
mice. (A-C) Electron-dense structures appear delineated by phospholipid bilayer (Images of panels A 
and B courtesy of Bart Wagner). Scale bars A = 2 μm, B, 200 nm, C = 1 μm. 
 
Since the electron-dense structures did not appear to be any larger or more abundant in 2 
year old mice compared to our previous findings, they were considered either remnants of an 
event occurring before the age of 3-4 months or were constantly turned over thus stabilising 
their size and abundance. Turnover of large intracellular structures mainly involves pathways 
that depend on lysosomal enzymes (Luzio et al. 2007). Since a lysosomal or endosomal 
origin would be in line with the phospholipid bilayer surrounding the structures, cardiac 
sections were analysed for lysosomal marker LAMP1 by immunogold labelling (Figure 6.6). 
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Figure 6.6: Immunogold staining of cardiac sections of αMHC/IGF-1Ea mice for LAMP1. (A-C) 
Electron micrographs showing LAMP1-negative electron-dense bodies in cardiomyocytes. (D) Liver 
tissue serving as positive control. Scale bars A, B, C = 100 nm, D = 500 nm. 
 
The electron-dense structures were negative for LAMP1 and the positive control (liver tissue) 
showed only a small number of LAMP1-positive foci. Since the liver is considered a place of 
significant lysosomal activity, antibody specificity was questioned and a second lysosomal 
marker, cathepsin D, was used for further analysis (Erickson et al. 1981; Skop et al. 2012). 
While the electron-dense structures themselves did not stain positively for cathepsin D, 
positive signals were detected in vacuoles in the direct proximity of the structures (Figure 
6.7). 
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Figure 6.7: Immunogold staining for cathepsin D on cardiac sections of 3-4 month old αMHC/IGF-1Ea 
mice. (A-D) Vacuoles positive for cathepsin D (arrows) were discovered in the proximity of the 
electron-dense structures (EDS). Scale bars A, D = 100 nm, B, C = 500 nm. 
 
This could indicate an intracellular attempt to dissolve the structures or could provide clues 
for a mechanism regulating their size. Since large organelles are degraded by a mechanism 
referred to as macroautophagy (or short autophagy), we investigated whether this pathway 
was involved in the formation or regulation of the structures. 
 
 
6.3 The role of IGF-1Ea in cardiac autophagy 
IGF-1 was previously shown to be involved in autophagy, the removal of old defective 
organelles and misfolded or excess proteins (reviewed in Klionsky and Emr 2000). Since the 
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electron-dense structures bear morphological resemblance to exceptionally large 
autophagosomes or autophagolysosomes, an analysis of markers of autophagy was carried 
out. The most prominent marker of autophagosomes is microtubule-associated protein 1 light 
chain 3 (LC3) and its isoforms (reviewed in Mizushima 2004). Consequently the presence of 
LC3 was analysed by immunogold labelling (Figure 6.8). 
 
 
Figure 6.8: LC3 immunogold labelling of αMHC/IGF-1Ea cardiac sections. (A, B) Intracellular, large 
electron-dense structures (EDS) are negative for autophagosomal marker LC3. Scale bars A = 500 
nm, B = 200 nm. 
 
The electron-dense structures where negative for LC3. Since processing cardiac samples for 
TEM is extremely laborious, further investigations into differentially regulated markers of 
autophagy were performed by Western blotting and by PCR array using cardiac samples of 
3-4 month old mice. Pro-autophagic protein Beclin-1 and LC3B II, the active form of the 
LC3B isoform, were not differentially regulated following IGF-1Ea overexpression (Liang et 
al. 1999, Figure 6.9). 
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Figure 6.9: Western blot for markers of autophagy in adult mice. Cardiac protein extracts of 3 month 
old αMHC/IGF-1Ea and wt mice were analysed for Beclin-1 and LC3B. Beclin-1 was not differentially 
regulated. Active LC3B II was not quantifiable due low presence of the cleaved form but did not 
appear to be differentially regulated. Beclin-1 data expressed as standard deviation of the mean. 
 
Since the analysis of these classical markers by immunogold and immunoblotting had not 
indicated a change in signalling, the broader approach of using a PCR array was considered 
to further elucidate the potential implication of autophagy signalling in the formation of 
electron-dense structures in αMHC/IGF-1Ea transgenic hearts. 
 
 
6.3.1 Autophagy PCR array results 
A more detailed analysis of the role of IGF-1Ea overexpression on autophagy signalling in 
the heart was performed using a PCR array covering 83 genes involved in autophagy (for full 
description see Chapter 2). Highly purified RNA extracts of 3 month old mouse hearts of wt 
and αMHC/IGF-1Ea mice were used. 7 genes were identified to be differentially regulated in 
αMHC/IGF-1Ea mice compared to wt (Table 6.1). 
 
Table 6.1: Autophagy PCR array results. Statistically significant changes in gene expression are 
highlighted by bold fonts Experiments were performed in triplicate and analysed using the 
SABiosciences RT2 Profiler PCR Array Data Analysis version 3.5 online service (SABiosciences 
QIAGEN [Internet], Crawley, RT2 Profiler PCR Array Data Analysis version 3.5, ©2000-2010, Cited 
24/06/2012, Available at: http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 
Symbol Gene Name Fold Change p-value 
Akt1 Thymoma viral proto-oncogene 1 1.0384 0.858282 
Ambra1 Autophagy/beclin 1 regulator 1 1.0631 0.331051 
App Amyloid beta (A4) precursor protein 1.0694 0.338062 
Arsa Arylsulfatase A 1.0512 0.743929 
Atg10 Autophagy-related 10 (yeast) 0.9961 0.932497 
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Atg12 Autophagy-related 12 (yeast) 1.1321 0.359769 
Atg16l1 Autophagy-related 16-like 1 (yeast) 1.0218 0.680907 
Atg16l2 Autophagy related 16 like 2 (S. cerevisiae) 0.8472 0.335553 
Atg3 Autophagy-related 3 (yeast) 1.0701 0.40901 
Atg4a Autophagy-related 4A (yeast) 1.067 0.597124 
Atg4b Autophagy-related 4B (yeast) 1.0129 0.878001 
Atg4c Autophagy-related 4C (yeast) 1.0847 0.374467 
Atg4d Autophagy-related 4D (yeast) 1.1132 0.512934 
Atg5 Autophagy-related 5 (yeast) 1.0256 0.827225 
Atg7 Autophagy-related 7 (yeast) 1.0358 0.798985 
Atg9a Autophagy-related 9A (yeast) 0.9363 0.670983 
Atg9b 
ATG9 autophagy related 9 homolog B (S. 
cerevisiae) 1.0283 0.59055 
Bad BCL2-associated agonist of cell death 0.9568 0.269167 
Bak1 BCL2-antagonist/killer 1 1.0515 0.616988 
Bax Bcl2-associated X protein 0.9496 0.636052 
Bcl2 B-cell leukemia/lymphoma 2 0.8775 0.059786 
Bcl2l1 Bcl2-like 1 1.3685 0.059459 
Becn1 Beclin 1, autophagy related 1.0059 0.920936 
Bid BH3 interacting domain death agonist 1.2974 0.172133 
Bnip3 BCL2/adenovirus E1B interacting protein 3 0.8609 0.136066 
Casp3 Caspase 3 0.978 0.837968 
Casp8 Caspase 8 1.053 0.728667 
Cdkn1b Cyclin-dependent kinase inhibitor 1B 1.031 0.858326 
Cdkn2a Cyclin-dependent kinase inhibitor 2A 0.7753 0.78705 
Cln3 
Ceroid lipofuscinosis, neuronal 3, juvenile 
(Battenin) 0.8176 0.026159 
Ctsb Cathepsin B 1.0235 0.702501 
Ctss Cathepsin S 1.2077 0.117806 
Cxcr4 Chemokine (C-X-C motif) receptor 4 0.6981 0.000787 
Dapk1 Death associated protein kinase 1 1.0568 0.988436 
Dram1 DNA-damage regulated autophagy modulator 1 1.4384 0.0169 
Eif2ak3 
Eukaryotic translation initiation factor 2 alpha kinase 
3 1.0188 0.840751 
Eif4g1 Eukaryotic translation initiation factor 4, gamma 1 1.0096 0.896417 
Esr1 Estrogen receptor 1 α 1.592 0.024487 
Fadd Fas (TNFRSF6)-associated via death domain 0.9062 0.496774 
Fas Fas (TNF receptor superfamily member 6 0.8941 0.656449 
Gaa Glucosidase, alpha, acid 0.9628 0.499632 
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Gabarap 
Gamma-aminobutyric acid receptor associated 
protein 0.9328 0.272841 
Gabarapl1 
Gamma-aminobutyric acid (GABA) A receptor-
associated protein-like 1 0.9693 0.501304 
Gabarapl2 
Gamma-aminobutyric acid (GABA) A receptor-
associated protein-like 2 0.9621 0.611293 
Hdac1 Histone deacetylase 1 1.3491 0.464767 
Hgs HGF-regulated tyrosine kinase substrate 0.8736 0.410567 
Hsp90aa1 
Heat shock protein 90, alpha (cytosolic), class A 
member 1 1.0234 0.88025 
Hspa8 Heat shock protein 8 1.0208 0.721579 
Htt Huntingtin 0.9655 0.691381 
Ifna2 Interferon alpha 2 1.0451 0.820517 
Ifna4 Interferon alpha 4 0.9736 0.917096 
Ifng Interferon gamma 1.7311 0.366353 
Igf1 Insulin-like growth factor 1 1.3225 0.034521 
Ins2 Insulin II 1.3045 0.436792 
Irgm1 Immunity-related GTPase family M member 1 1.1224 0.531918 
Map1lc3a Microtubule-associated protein 1 light chain 3 alpha 0.9765 0.786952 
Map1lc3b Microtubule-associated protein 1 light chain 3 beta 0.9728 0.626954 
Mapk14 Mitogen-activated protein kinase 14 1.0692 0.512479 
Mapk8 Mitogen-activated protein kinase 8 1.0951 0.441882 
Nfkb1 
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1, p105 0.9969 0.935844 
Pik3c3 Phosphoinositide-3-kinase, class 3 0.9717 0.777134 
Pik3cg 
Phosphoinositide-3-kinase, catalytic, gamma 
polypeptide 1.1736 0.483422 
Pik3r4 
Phosphatidylinositol 3 kinase, regulatory subunit, 
polypeptide 4, p150 0.9813 0.745914 
Prkaa1 
Protein kinase, AMP-activated, alpha 1 catalytic 
subunit 1.0265 0.766799 
Prkaa2 
Protein kinase, AMP-activated, alpha 2 catalytic 
subunit 1.0381 0.716181 
Pten Phosphatase and tensin homolog 1.1721 0.171834 
Rab24 RAB24, member RAS oncogene family 0.9833 0.630217 
Rb1 Retinoblastoma 1 0.9933 0.879346 
Rgs19 Regulator of G-protein signaling 19 1.0185 0.79704 
Rps6kb1 Ribosomal protein S6 kinase, polypeptide 1 0.8669 0.349614 
Snca Synuclein, alpha (α-synuclein) 2.9428 0.007024 
Sqstm1 Sequestosome 1 1.0339 0.570836 
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Tgfb1 Transforming growth factor, beta 1 0.9093 0.131689 
Tgm2 Transglutaminase 2, C polypeptide 1.0585 0.525486 
Fam176a Family with sequence similarity 176, member A 0.8814 0.449408 
Tmem74 Transmembrane protein 74 1.148 0.480341 
Dram2 VDNA-damage regulated autophagy modulator 2 0.9764 0.499394 
Tnf Tumor necrosis factor 0.8022 0.437152 
Tnfsf10 
Tumor necrosis factor (ligand) superfamily, member 
10 0.9444 0.561366 
Trp53 Transformation related protein 53 (p53) 0.8982 0.018938 
Trp73 Transformation related protein 73 1.0435 0.634059 
Ulk1 Unc-51 like kinase 1 (C. elegans) 0.8947 0.36501 
Ulk2 Unc-51 like kinase 2 (C. elegans) 1.0682 0.373641 
Uvrag UV radiation resistance associated gene 1.2278 0.154676 
 
Expression data was derived using 4 of the 5 available reference genes: Gusb, Hprt, 
Hsp90ab1, Gapdh. The fifth control Actb was excluded since it appeared to be affected by 
IGF-1Ea overexpression. Due to the relatively low increase of IGF-1 expression on the array, 
a separate rtPCR using Taqman® reagents was performed to confirm overexpression of the 
rat IGF-1 isoform (Figure 6.10). 
 
 
Figure 6.10: Real-time PCR for IGF-1 in cardiac samples using Taqman® reagents. FVB wt (n = 3) 
and αMHC/IGF-1Ea (n = 4) cDNA was analysed using a rat IGF-1 probe. Data is presented as 
standard deviation of the mean. 
 
As expected from previous work, IGF-1 was significantly upregulated around 300 fold in mice 
overexpressing cardiac IGF-1Ea. From the panel of differentially regulated genes, α-
synuclein and battenin were selected for validation on the protein level. α-synuclein and 
battenin are known to play a role in intracellular amyloid/Lewy body formation and 
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lipofuscinosis respectively (reviewed in Lerner et al. 1995; Quinn et al. 2012). Elevated α-
synuclein expression was confirmed on the protein level by Western blotting, showing a ~10-
fold increase (Figure 6.11). 
 
 
Figure 6.11: Western blot for α-synuclein using cardiac extracts from 3 month old wt and αMHC/IGF-
1Ea mice. α-tubulin was used for normalisation and a brain sample served as positive control. Data 
presented as standard deviation of the mean. 
 
Since α-synuclein immunofluorescence did not show a clear signal indicative of its presence 
in the large intracellular vacuoles in preliminary experiments, a detailed immunogold analysis 
for α-synuclein was not performed (data not shown). Despite a minor but significant 
downregulation on the mRNA level, battenin protein was not significantly downregulated in 
cardiac samples of αMHC/IGF-1Ea mice (Figure 6.12). 
 
 
 
Figure 6.12: Western blot for battenin using cardiac protein samples of 3 month old wt and 
αMHC/IGF-1Ea mice. Bands normalised against α-tubulin. No statistical evaluation was possible due 
to high background and presence of an aspecific doublet. 
 
The battenin Western blot showed high background staining and a potentially aspecific band 
at similar molecular weight which was prohibitive for quantification by ImageJ. Battenin 
bands appear to be slightly stronger in αMHC/IGF-1Ea but the α-tubulin revealed that also 
slightly larger amounts were loaded. 
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To further elucidate whether abnormal aggregation of protein destined for degradation may 
contribute to the formation of the large electron-dense structures, ubiquitination was 
investigated by Western blotting (Figure 6.13). 
 
 
Figure 6.13: Western blot for ubiquitin using cardiac protein extracts of 3 month old wt and 
αMHC/IGF-1Ea mice. α-tubulin was used as control. 
 
The overall level of ubiquitination appeared to be comparable between αMHC/IGF-1Ea and 
wt mice. Since not a single band but overall signal intensity was investigated, standard 
quantification using ImageJ was not possible. 
 
The initial hypothesis was that IGF-1Ea could be mechanistically involved in the formation of 
the large vesicles or indirectly promote their formation by overloading protein production, 
storage or degradation mechanisms or even by depleting nutrients pushing the cells towards 
autophagy. Given the negative evidence for a role in autophagy, I considered that IGF-1Ea 
overexpression could lead to aggregation of this protein. To assess if IGF-1Ea was present 
within the structures, IGF-1 immunogold analysis was performed. This revealed that the 
electron-dense structures contained an abundance of IGF-1 protein (Figure 6.14). 
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Figure 6.14: Immunogold staining for IGF-1 on cardiac section of 3 month αMHC/IGF-1Ea mice. (A-C) 
Transmission electron graphs showing positive signal for IGF-1 in electron-dense structures. (D) 
Negative control after incubation with secondary antibody only (EDS– Electron-dense structure, N – 
Nucleus). Scale bars A, D = 1 μm, B, C = 0.5 μm. 
 
In addition to the presented data, paraffin sections of αMHC/IGF-1Ea or wt hearts were 
analysed for the presence of amyloid plaque (by congo red stain) and for iron deposits (by 
Pearl‟s Prussian blue), but neither were shown to aggregate in the myocardium (data not 
shown). 
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6.4 Discussion 
This chapter describes the discovery of large electron-dense structures in the hearts of 
αMHC/IGF-1Ea transgenic mice. The fact that they arise between 6 weeks and 3 months of 
age and did not increase in size and abundance thereafter could be indicative of a 
compensatory adaption to high IGF-1Ea levels. The arrest in growth/formation is not caused 
by promoter silencing since high expression of IGF-1 mRNA was detected (Figure 6.10). I 
investigated whether the structures could be lipofuscin, highly oxidised and cross-linked 
protein and organelle debris that cannot be removed by standard pathways, such as 
ubiquitin-proteasome degradation and autophagy (Powell et al. 2005). This was based on the 
knowledge that despite promoting preservation of bone and muscle tissue during ageing, 
elevated serum IGF-1 has indeed been linked increased oxidative stress/ROS production in 
skeletal muscle and IGF-1 treatment increased ROS production in adipose cells (Fukuoka et 
al. 2010; Elis et al. 2011). An intracellular mechanism to suppress ROS formation is the 
removal of defective mitochondria by autophagy (Gu et al. 2004). In the presence of IGF-1, 
however, autophagic degradation of mitochondria is reduced and this mechanism increases 
ROS-mediated protein crosslinking potentially resulting in their accumulation in the electron-
dense structures. At the same time, knockdown of IGF-1 was shown to result in decreased 
oxidative stress tolerance in the liver and IGF-1 supplementation increases resistance to 
oxidative stress-induced apoptosis potentially explaining the absence of an adverse 
phenotype in αMHC/IGF-1Ea mice (Gu et al. 2004; Bailey-Downs et al. 2012). The local IGF-
1Ea isoform in particular was found to reduce oxidative stress in cardiomyocytes via the 
protective molecule SirT1 (Alcendor et al. 2007; Vinciguerra et al. 2010). While it is 
conceivable that ROS plays a role in the formation of the structures, the distinct 
morphological difference between lipofuscin found in aged animals compared to the 
observed structures and disproved the lipofuscin hypothesis. Furthermore, increased 
lipofuscin formation is generally accompanied by a dramatic increase in ubiquitinated 
proteins, which was not observed in αMHC/IGF-1Ea mice (Figure 6.13, Powell et al. 2005). 
Given their morphological resemblance to large autophagosomes, further investigations 
focused on whether the electron-dense structures could resemble intermediates or arrested 
late stage components of autophagy signalling (Figure 6.4). 
 
6.4.1 Autophagy in αMHC/IGF-1Ea hearts 
Despite being much larger size, the structures resembled autophagosomes or later 
autophagolysosomes and I investigated this hypothesis given the implications of IGF-1 in 
autophagy regulation. Autophagy is a vital process that next to turnover of old organelles and 
proteins is mainly required to provide nutrition during starvation or following events that 
require large amounts of nutrients in a short period of time. While autophagy is critical to 
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overcome acute poor nutrient supply, excessive macroautophagy results in so called 
autophagic cell death and thus contributes to cardiomyocyte loss during human heart failure 
(reviewed in Kostin et al. 2003; Tsujimoto and Shimizu 2005). Ablation of autophagy on the 
other hand accelerates heart failure and increases mortality among patients indicating that 
pro and anti-autophagic stimuli have to be carefully balanced in a healthy cell (Tannous et al. 
2008). IGF-1 is protecting the heart by preventing excessive autophagy and is reportedly 
balancing autophagy and apoptosis (Gu et al. 2004; Troncoso et al. 2012). It is thus not 
surprising to see apoptotic master regulator p53 downregulated on the autophagy PCR array 
(Table 6.1). In the rat, skeletal muscle protein production is reduced following major burn 
injury and hypercatalytic responses degrading protein and glucose are initiated (Clark et al. 
1984; Fang et al. 1995). While this is normally accompanied by decreased protein 
production, IGF-1 supplementation was shown to increase protein production and prevent 
protein degradation in this model (Fang et al. 1997; Fang et al. 1998). 
The role of IGF-1 to reduce the catabolic response to injury was further consolidated in the 
same burn injury model indicating that IGF-1 prevents lysosomal activity and the ubiquitin-
proteasome pathway (Fang et al. 2002). If these findings could be extended to the IGF-1Ea 
propeptide, this would strongly support the hypothesis that the structures, though of unknown 
origin, could be accumulating due to reduced lysosomal activity. As such, it would have been 
interesting to investigate if overall protein content is increased in αMHC/IGF-1Ea 
cardiomyocytes, but limited time restricted further experimentation in this direction. Evidence 
in vitro showed that long-term IGF-1 exposure reduces autophagy and as a result increases 
the amount of depolarised mitochondria (Bitto et al. 2010). Conversely, mice with reduced 
IGF-1 activity due to hypomorphic IGF-1 alleles showed increased autophagy shown by 
elevated levels of LC3 in the tissue. 
Mechanistically, IGF-1 reduces autophagy via Akt signalling in vascular endothelial cells 
indicated by decreased abundance of Beclin-1 and LC3-positive vacuolated cells (Jia et al. 
2006). This occurs in synergy with mTOR activation which has been implicated in autophagy 
suppression in yeast and mammals (Noda and Ohsumi 1998; Cutler et al. 1999; Sobolewska 
et al. 2009). This was confirmed in neonatal rat cardiomyocytes in which IGF-1 mediated 
inhibition of autophagy is achieved via the Akt/mTOR and AMPK/mTOR signalling axes 
(Troncoso et al. 2012). In relation to the electron-dense vesicles observed in αMHC/IGF-1Ea 
mice, it is noteworthy that experiments by Jia and colleagues showed that the overall number 
of vacuoles positive for autophagic markers was decreased in response to IGF-1 treatment 
(Jia et al. 2006). In line with the previously reported improved function of αMHC/IGF-1Ea 
hearts after injury, IGF-1 was also shown to rescue mitochondrial metabolism and to inhibit 
excessive autophagy in the heart thereby mitigating nutrient-related insult, as occurs during 
ischaemia (Santini et al. 2007; Troncoso et al. 2012). 
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In the current work, autophagy marker beclin-1 was not differentially regulated in the hearts 
of αMHC/IGF-1Ea mice and neither increased conversion of LC3BI into LC3BII, nor 
localisation of LC3 to the electron-dense structures was observed (Figure 6.9). However, 
beclin-1 is an early marker of autophagy involved in membrane nucleation and LC3 
dissociates from the outer membrane after fusion of the autophagosome with the lysosome 
and is subsequently degraded on the inner membrane (Liang et al. 1999; Ropolo et al. 2007, 
Kabeya et al. 2000). Hence, neither would be expected to be present in late stage 
autophagolysosomes To determine if the electron-dense structures could resemble large 
arrested autophagolysosomes, the expression of a wider panel of genes involved in 
autophagy was analysed. 
 
6.4.2 α-synuclein and battenin – Markers of neurological disease 
Robust overexpression of IGF-1Ea was confirmed by rtPCR (Figure 6.10). Apart from IGF-1, 
six further genes were found to be differentially regulated on the autophagy PCR array 
(Table 6.1). Out of these, α-synuclein (Snca) and battenin (Cln3) were selected due to their 
implication in storage diseases of post-mitotic tissues. 
α-synuclein is a natively unfolded protein and lacks a defined structure but can assume a 
more organised shape if bound to other proteins (Weinreb et al. 1996). While the function of 
α-synuclein is poorly characterised, it is recognised for its pathological accumulation in so 
called Lewy bodies in brain cells during Parkinson‟s disease (Spillantini et al. 1997). An 
Ala30Pro point mutation has been identified to contribute to this pathology (Kruger et al. 
1998). Since proline is involved in secondary protein structure acquisition this could lead to 
aberrant folding making the protein prone to aggregation. Along point mutations α-synuclein 
accumulation is frequently caused by triplications of the α-synuclein gene (Kruger et al. 1998; 
Singleton et al. 2003). This indicates neuronal storage disease can be caused by α-synuclein 
in a qualitative and quantitative manner. 
α-synuclein is found predominantly cytosolic but is present in mitochondria as well (Shavali et 
al. 2008). Mitochondria are affected in Parkinson‟s disease displaying a swollen and rounded 
morphology in brain tissues (Trimmer et al. 2000). Since α-synuclein was upregulated both 
on mRNA and protein levels, a retrospective analysis of the TEM data was performed. This 
revealed that mitochondria appeared slightly enlarged in αMHC/IGF-1Ea hearts compared to 
wt but retained an otherwise normal structure (data not shown). It remains unclear whether 
there is a connection between this observation and elevated α-synuclein levels. With regards 
to the presence of the electron-dense structures, it is noteworthy that α-synuclein 
predisposes cells to proteasomal dysfunction (Sun et al. 2005). Furthermore, α-synuclein and 
Akt were shown to directly interact to regulate IGF-1 (Chung et al. 2011). α-synuclein 
translational regulation is controlled in part by intracellular iron and the expression of ferritins, 
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proteins that convert Fe(II) into Fe(III), is in turn regulated by IGF-1 signalling in nematodes, 
indicating further possible links between the two molecules (Lawson et al. 1989; Ackerman 
and Gems 2012; Febbraro et al. 2012). However, iron deposition was not observed in the 
electron-dense structures or in αMHC/IGF-1Ea cardiac tissue in general. While α-synuclein 
was increased on both mRNA and protein level, a direct link with IGF-1Ea overexpression 
and the electron-dense structures was not established. It is furthermore remarkable that 
despite the presence of the large structures and elevated α-synuclein, cardiac function was 
normal in these mice compared to wt and even superior under pathological conditions 
(Santini et al. 2007). This could be explained by the ability of IGF isoforms to rescue α-
synuclein toxicity (Kao 2009). This analysis potentially indicates that the increase in α-
synuclein is an effect not directly related to IGF-1Ea function, but could rather be a 
secondary response mechanism, which does not result in a pathologic phenotype on the 
organ level due to the protective effects of IGF-1Ea counteracting its toxicity. 
The second marker selected from the PCR array for further analysis was battenin, which was 
reduced in αMHC/IGF-1Ea hearts (Table 6.1). Battenin, or CLN3, has been researched in 
the context of a lipofuscinosis called Batten disease, which is caused by reduction of battenin 
expression due to genetic mutations (Lerner et al. 1995). It is a multipass transmembrane 
protein found on lysosomes and endosomes and plays a role in late endosomal/lysosomal 
membrane transport (reviewed in Phillips et al. 2005; Uusi-Rauva et al. 2012). Low IGF-1 
levels in cerebrospinal fluid have previously been associated with neuropathology in infantile 
CLN1 disease due to its role in regulating apoptosis via PI3K signalling and an ex-vivo 
canine model of related CLN8 NCF showed that IGF-1 was improving outgrowth of neurons 
(Dunn et al. 1994; Riikonen et al. 2000; Katz et al. 2005). However, an analysis of 
cerebrospinal fluid showed that levels of IGF-1 are normal in CLN3-type neuronal ceroid 
lipofuscinosis/Battens disease in humans and sheep (Kay et al. 2009). While the role of 
battenin in juvenile lipofuscinosis and the associated reduction of autophagy and 
accumulation of storage vesicles have been well documented, the present study was unable 
to link the large intracellular vesicles to reduction in battenin. The downregulation on the 
mRNA levels on the autophagy PCR array was not confirmed on the protein level. (Cao et al. 
2006). 
It is important to highlight that the majority of published work on IGF-1 has involved the 
analysis of fully processed IGF-1 protein and did not consider the unique action of propeptide 
precursors such as IGF-1Ea. On a case-by-case basis the signalling pathways of IGF-1 and 
IGF-1Ea differ significantly and the full spectrum mechanisms regulated by either form 
remains to be elucidated (Grounds 2002; Santini et al. 2007). In the presented work, neither 
changes in LC3B conversion or beclin-1 levels nor in the expression of classical markers of 
autophagy were observed. This is in line with previous work showing that mTOR is not 
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differentially regulated αMHC/IGF-1Ea mouse hearts and potentially indicates that there is no 
direct involvement of IGF-1Ea in the regulation of autophagy (Santini et al. 2007). Finally, the 
possibility that the structures could be the product of an overloaded protein degradation 
mechanism was considered since ribosomal subunit S6 activity is induced in αMHC/IGF-1Ea 
hearts under physiological conditions. When investigating overall ubiquitination of proteins in 
αMHC/IGF-1Ea hearts, we observed no increase compared to wt under physiological 
conditions it possible that a change would be observed following cardiac MI (Figure 6.13). 
To understand whether the electron-dense vesicles relate to an abnormal IGF-1Ea 
accumulation simply as a consequence of overexpression we compared electron 
micrographs of αMHC/IGF-1Ea to those of Fstl1 overexpressing mice of our collaborator 
Enrique Lara-Pezzi. Comparable structures were not identified indicating that overexpression 
of proteins per se does not result in the formation of the observed electron-dense structures 
in cardiomyocytes. This could indicate either a direct role of IGF-1Ea in the formation of 
these structures or that the specific biochemical attributes of IGF-1Ea render it more prone to 
aggregation compared to other overexpressed proteins. 
 
6.4.3 Summary 
The current work describes the morphology and timing of appearance of large, IGF-1-
containing, electron-dense structures in cardiomyocytes of αMHC/IGF-1Ea mice, but does 
not come to a final conclusion as to the origin of the structures and whether they comprise a 
pathological aggregation, are beneficial as storage vesicles or prime the cells to respond to 
starvation or other challenges. While storage diseases have been researched predominantly 
in diseases of the nervous system, they are not exclusively confined to this environment but 
found in post-mitotic tissues in general (Nakano and Gotoh 1992; Zhou et al. 2006). An 
exploratory characterisation of the biochemical properties was performed and showed an 
involvement of lysosomes, but not of the autophagy pathway. To further characterise the 
vesicles, the remaining positive hits of the autophagy PCR array could be validated, but 
these are not strong classical markers and it is therefore not feasible to continue this line of 
investigation. Further analyses by molecular biology and histology techniques are neither 
cost nor time effective and broader analytical techniques should be considered. Laser 
dissection and subsequent digestion and mass spectrometry analysis could provide 
information on the composition of the structures which could then be followed up by 
appropriate, more educated experimental approaches. 
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Final Conclusion 
 
The original aim of this thesis was the investigation of a knock-down of Tβ4 in adult mouse 
hearts. This was based on the previous finding that shRNA-mediated cardiac-specific 
depletion of Tβ4 resulted in a severe, embryonic lethal cardiac phenotype in mouse embryos. 
My work has demonstrated that shRNA-mediated knockdown of Tβ4 in cardiomyocytes using 
a tamoxifen-sensitive Cre driver strain does not result in a measurable reduction of Tβ4 in 
vivo, in vitro or in isolated adult cardiomyocytes. In addition, recent results from another 
laboratory have indicated that complete Tβ4 knockout as well as adult cardiac-specific 
conditional knockout do not result in any significant cardiac phenotype. These findings show 
that even if a sufficient knock-down of Tβ4 mRNA would have been achieved, this would not 
have resulted in a significant phenotype at least under physiological conditions and implies 
that the previously observed embryonic phenotype is likely attributable to off-target effects of 
the shRNA rather than reduction of Tβ4. While Tβ4 depletion in adult mouse hearts proved 
unsuccessful and in the light of more recent data redundant, I uncovered an important 
perturbation in tamoxifen-treated αMHC/MerCreMer mice. Treatment using standard 
protocols not only resulted in a transient cardiomyopathy but also in a previously not 
described chronic fibrotic phenotype altering cardiac function. This was furthermore 
characterised to stimulate inflammatory processes and to elevate expression of pathological 
hypertrophy markers, both of which are frequently used as readouts in cardiac regeneration 
experiments. Overall these findings raised concerns about the use of appropriate controls in 
a number of recent publications in the field and emphasises the importance of using 
appropriate controls for complex genetic manipulations. 
The proteomic investigation to further study Tβ4-interacting proteins was hampered by 
technical difficulties and resulted in the conclusion that dedicated proteomic support services 
should be used where local infrastructure, resources and time are limited. 
In αMHC/IGF-1Ea mice, I characterised novel electron-dense structures the nature of which 
was not conclusively resolved at the end of this study. While they appeared morphologically 
similar to autophagolysosomes a detailed marker analysis did not reveal any implication of 
autophagy in their formation. However, the fact that they were co-localising with lysosomes 
could imply a role in turnover of intracellular macromolecules but this will need to be 
addressed by more focused research in this direction. 
Given the urgency to develop novel approaches to treat cardiac disease, the research into 
novel molecules and their mechanisms is critical but should be performed to the highest 
standards. Critical reflection and diligence should be exercised to ascertain that the most 
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robust data is obtained. While being essentially good scientific practice and preserving vital 
resources this is also crucial to avoid unnecessary use of animals in laboratory research. 
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